1 | (-)-3-(4-Aminophenyl)-2-methoxypropionic acid | - | - | - | - | 1件: 97 97 💬 |
2 | (1-3)-beta-D-Glucan (BDG) assay (Fungitell) | - | - | - | - | 1件: 107 107 💬 |
3 | (1-3)-ß-D-Glucan (BDG) assay (Fungitell) | - | - | - | - | 1件: 107 107 💬 |
4 | (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide | - | - | - | - | 1件: 11 11 💬 |
5 | (2)-epigallocatechin-3-gallate (EGCG) | 2件: Epigallocatechin Epigallocatechin, Epigallocatechin gallate | - | - | - | 1件: 8 8 💬 |
6 | (2-chloro-5-[11C]methoxy-N-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide) | - | - | - | - | 1件: 6 6 💬 |
7 | (3beta, 5beta, 25R)-spirostan-3-ol | - | - | - | - | 1件: 6 6 💬 |
8 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1- | - | - | - | - | 1件: 46 46 💬 |
9 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile, | - | - | - | - | 1件: 46 46 💬 |
10 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1- | - | - | - | - | 1件: 46 46 💬 |
11 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1-piperidinepropanenitrile, | - | - | - | - | 1件: 46 46 💬 |
12 | (3R,4R)-4-metil-3-(metil-1H-pirrolo [2,3-d]pirimidin-4-ilamino)-beta-oxo-1- | - | - | - | - | 1件: 46 46 💬 |
13 | (3R,4R)-4-metil-3-(metil-1H-pirrolo [2,3-d]pirimidin-4-ilamino)-ß-oxo-1- | - | - | - | - | 1件: 46 46 💬 |
14 | (3ß, 5ß, 25R)-spirostan-3-ol | - | - | - | - | 1件: 6 6 💬 |
15 | (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile | - | - | - | - | 1件: 231 231 💬 |
16 | (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4’- | - | - | - | - | 1件: 79 79 💬 |
17 | (6R)-4, 5, 6, 7 - tetrahydro-N6-propyl-2,6-benzothiazolidiamine dihydrochloride monohydrate | - | - | - | - | 1件: 2 2 💬 |
18 | (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol | - | - | - | - | 1件: 6 6 💬 |
19 | (7R,8R,9R)-2.3-Dimethyl-8-hydroxy-7(2-methoxyethoxy)- 9-phenyl-7.8.9.10-tetrahydro-imidazo-[1.2-h].[1.7].- naphthyridine | - | - | - | - | 1件: 301 301 💬 |
20 | (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime | - | - | - | - | 1件: 161 161 💬 |
21 | (minus)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate | - | - | - | - | 1件: 6 6 💬 |
22 | (R) 3-(5-Dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1- methylethyl) benzamide | - | - | - | - | 1件: 13 13 💬 |
23 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 75 75 💬 |
24 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 75 75 💬 |
25 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4YL)SULFONYL)4,4A,5,6,7,8HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN4AYL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 75 75 💬 |
26 | (R)-3-(1-oxo-propoxy)-4-(N,N,N-trimethyl amonium chloride)-butanoic acid | 2件: Butyric Acid Butyric Acid, Chloride ion | - | - | - | 1件: 97 97 💬 |
27 | (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 58 58 💬 |
28 | (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1METHYL-1H-PYRAZOLE-4-CARBOXAMIDE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 58 58 💬 |
29 | (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1METHYL-1HPYRAZOLE-4-CARBOXAMIDE | - | - | - | - | 1件: 58 58 💬 |
30 | (R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4- yl)pyridine-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate | 1件: Piperazine Piperazine | 1件: Piperazine
Piperazine
💬 | - | - | 1件: 272 272 💬 |
31 | (R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4- yl)pyridine-2yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate | 1件: Piperazine Piperazine | 1件: Piperazine
Piperazine
💬 | - | - | 1件: 272 272 💬 |
32 | (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol | - | - | - | - | 1件: 6 6 💬 |
33 | (S)-(+)-2-(4-(3-fluorobenzyl)oxybenzyl)aminopropanamide methanesulfonate | - | - | - | - | 1件: 6 6 💬 |
34 | (S)-(-)-3-(4-Aminophenyl)-2-methoxypropionic Acid | - | - | - | - | 1件: 97 97 💬 |
35 | (S)-2-(4,6-dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropanoic acid | - | - | - | - | 1件: 86 86 💬 |
36 | (S)-2-amino-6-(2-hydroxypropanoyl)-7,8-dihydropteridin-4(3H)-one | - | - | - | - | 1件: 240 240 💬 |
37 | (S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2- YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM | - | - | - | - | 1件: 86 86 💬 |
38 | (S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2-YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM | - | - | - | - | 1件: 86 86 💬 |
39 | (S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazo | - | - | - | - | 1件: 284 284 💬 |
40 | (S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide | 3件: Hydroxide ion Hydroxide ion, Magnesium, Magnesium hydroxide | 1件: Magnesium hydroxide
Magnesium hydroxide
💬 | - | - | 1件: 284 284 💬 |
41 | (S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-m | - | - | - | - | 1件: 284 284 💬 |
42 | (S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide | 3件: Hydroxide ion Hydroxide ion, Magnesium, Magnesium hydroxide | 1件: Magnesium hydroxide
Magnesium hydroxide
💬 | - | - | 1件: 284 284 💬 |
43 | (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5- yl)-2-isopropoxybenzonitrile hydrochloride | - | - | - | - | 1件: 97 97 💬 |
44 | (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxyben | - | - | - | - | 1件: 97 97 💬 |
45 | (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile hydrochloride | - | - | - | - | 1件: 97 97 💬 |
46 | * D.3.4 Solution for infusion in pre-filled syringe | - | - | - | - | 1件: 97 97 💬 |
47 | * D.3.4 Solution for injection in pre-filled syringe | - | - | - | - | 1件: 97 97 💬 |
48 | * D.3.4 Solution for injection/infusion in pre-filled syringe | - | - | - | - | 1件: 97 97 💬 |
49 | * D.3.6.2.1 - valore : Every 4 weeks dosing of 200 mg | - | - | - | - | 1件: 41 41 💬 |
50 | * D.3.6.2.1 - valore :Every 4 weeks dosing of 400 mg | - | - | - | - | 1件: 41 41 💬 |
51 | 0,5 mg Fingolimod | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
52 | 0,5 mg Prevenar i.m. | - | - | - | - | 1件: 51 51 💬 |
53 | 0,5 mg seasonal influenza vaccine i.m. | - | - | - | - | 1件: 51 51 💬 |
54 | 0.005% Lacripep | - | - | - | - | 1件: 53 53 💬 |
55 | 0.01% Lacripep | - | - | - | - | 1件: 53 53 💬 |
56 | 0.02% Fm, SH | - | - | - | - | 1件: 53 53 💬 |
57 | 0.02% Fm, SH, 0.05% CsA | - | - | - | - | 1件: 53 53 💬 |
58 | 0.02% Fm, SH, AS | - | - | - | - | 1件: 53 53 💬 |
59 | 0.04 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
60 | 0.05%cyclosporin eye drop | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 38 38 💬 |
61 | 0.08 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
62 | 0.3 mg tropicamide | 1件: Tropicamide Tropicamide | 1件: Tropicamide
Tropicamide
💬 | 5件: CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
63 | 0.5 mg budesonide effervescent tablet for orodispersible use | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
64 | 0.5 mg RPC1063 | - | - | - | - | 2件: 13 13, 97 💬 |
65 | 0.5% marcaine | - | - | - | - | 1件: 70 70 💬 |
66 | 0.5mg RPC1063 | - | - | - | - | 1件: 13 13 💬 |
67 | 009-0 | - | - | - | - | 1件: 6 6 💬 |
68 | 009-3 | - | - | - | - | 1件: 6 6 💬 |
69 | 009-5 | - | - | - | - | 1件: 6 6 💬 |
70 | 0109-0012A 100 mg/ml | - | - | - | - | 1件: 46 46 💬 |
71 | 0109-0012A 25 mg/ml | - | - | - | - | 1件: 46 46 💬 |
72 | 0109-0012A 50 mg/ml | - | - | - | - | 1件: 46 46 💬 |
73 | 0114-0006B | - | - | - | - | 2件: 46 46, 96 💬 |
74 | 1 mg budesonide effervescent tablet for orodispersible use | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
75 | 1 mg QD to 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
76 | 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
77 | 1 ml 0.9 % NaCl | - | - | - | - | 1件: 46 46 💬 |
78 | 1) Inosine 5'-monophosphate | 1件: Inosine Inosine | 1件: Inosine
Inosine
💬 | - | - | 1件: 17 17 💬 |
79 | 1,2-Dihexadecanoyl-sn-Glycero-3-Phospho-(1-raac-glycerol) | 1件: Glycerin Glycerin | 1件: Glycerin
Glycerin
💬 | - | - | 1件: 79 79 💬 |
80 | 1,5 (Butylimino)-1,5-dideoxy-D-glucitol | 1件: Sorbitol Sorbitol | 1件: Sorbitol solution
Sorbitol solution
💬 | - | - | 1件: 299 299 💬 |
81 | 1,5-anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[7,8-dihydro-3- (trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]c | - | - | - | - | 1件: 46 46 💬 |
82 | 1-(2,3,4-Trimethoxybenzyl)piperazine dihydrochloride | 1件: Piperazine Piperazine | 1件: Piperazine
Piperazine
💬 | - | - | 1件: 58 58 💬 |
83 | 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one | - | - | - | - | 1件: 17 17 💬 |
84 | 1-(6-BENZOTHIAZOLYLSULFONYL)-5-CHLORO-1H-INDOLE-2-BUTANOIC ACID | 2件: Butyric Acid Butyric Acid, Indole | - | - | - | 1件: 51 51 💬 |
85 | 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline carboxylic acid | - | - | - | - | 1件: 299 299 💬 |
86 | 1-{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone | - | - | - | - | 1件: 13 13 💬 |
87 | 1.0 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
88 | 1.0 mg rasagiline mesylate | 1件: Rasagiline Rasagiline | 2件: Rasagiline
Rasagiline
,
Rasagiline tartrate
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
89 | 1.0 mg RPC103 | - | - | - | - | 1件: 97 97 💬 |
90 | 1.0 mg RPC1063 | - | - | - | - | 1件: 97 97 💬 |
91 | 1.0 MIU IL-2 per day | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 1件: 2 2 💬 |
92 | 1.0mg RPC1063 | - | - | - | - | 1件: 13 13 💬 |
93 | 10% Nitroglycerine in Propylene Glycol, USP | 2件: Nitroglycerin Nitroglycerin, Propylene glycol | 2件: Propylene glycol
Propylene glycol
,
Nitroglycerin
💬 | - | - | 1件: 51 51 💬 |
94 | 100 mg ELX (VX-445) / 50 mg TEZ / 75 mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
95 | 100 mg ELX /50 mg TEZ /75 mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
96 | 100 mg ELX/50 mg TEZ /75 mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
97 | 100 mg ELX/50 mg TEZ/75 mg IVA fixed dose combination | - | - | - | - | 1件: 299 299 💬 |
98 | 100 mg VX-445 /50 mg TEZ/75 mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
99 | 100 mg VX-445/50 mg TEZ /75 mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
100 | 100-mg ELX (VX-445) / 50-mg TEZ / 75-mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
101 | 100-mg ELX (VX-455) / 50-mg TEZ / 75-mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
102 | 100-mg ELX / 50-mg TEZ / 75 -mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
103 | 100-mg VX-445 / 50-mg TEZ / 75- mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
104 | 100-mg VX-445 / 50-mg TEZ / 75-mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
105 | 100-mg VX-445 /50-mg TEZ/75-mg | - | - | - | - | 1件: 299 299 💬 |
106 | 100-mg VX-445/50-mg TEZ/75-mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
107 | 100g ELX / 50mg TEZ / 75mg IVA | - | - | - | - | 1件: 299 299 💬 |
108 | 100mg ELX/50mg TEZ /75mg IVA | - | - | - | - | 1件: 299 299 💬 |
109 | 100mg VX-445/50mg TEZ /75mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
110 | 118-42-3 | - | - | - | - | 1件: 46 46 💬 |
111 | 13-15mg/kg/d Ursodeoxycholic | - | - | - | - | 1件: 93 93 💬 |
112 | 1393641-34-3 | - | - | - | - | 1件: 13 13 💬 |
113 | 14C]-RPC1063 Solution (0.1 mg/mL) for Oral Administration | - | - | - | - | 3件: 13 13, 96, 97 💬 |
114 | 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
115 | 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
116 | 15-0 H20 | - | - | - | - | 2件: 6 6, 19 💬 |
117 | 16,5% Cutaquig | - | - | - | - | 1件: 65 65 💬 |
118 | 1643368-58-4 | - | - | - | - | 2件: 53 53, 160 💬 |
119 | 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione | - | - | - | - | 1件: 41 41 💬 |
120 | 17beta-hydroxy-11beta-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one | - | - | - | - | 1件: 75 75 💬 |
121 | 17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one | - | - | - | - | 1件: 75 75 💬 |
122 | 18-22mg/kg/d Ursodeoxycholic | - | - | - | - | 1件: 93 93 💬 |
123 | 18F]-(E)-N-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane | - | - | - | - | 1件: 6 6 💬 |
124 | 1[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- | - | - | - | - | 1件: 6 6 💬 |
125 | 1[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea | - | - | - | - | 1件: 6 6 💬 |
126 | 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- | - | - | - | - | 1件: 6 6 💬 |
127 | 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea | - | - | - | - | 1件: 6 6 💬 |
128 | 1mg budesonide effervescent tablet for orodispersible use | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
129 | 2 x 10 mg Natura-alpha capsules | - | - | - | - | 1件: 97 97 💬 |
130 | 2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid | 1件: Diflunisal Diflunisal | 1件: Diflunisal
Diflunisal
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 28 28 💬 |
131 | 2,3-dihydroxybutanedioic acid | - | - | - | - | 1件: 299 299 💬 |
132 | 2,5-Dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide | - | - | - | - | 1件: 6 6 💬 |
133 | 2-(((2E)-3-(3-methoxy-4-(2-propyn-1-yloxy)phenyl)-1-oxo-2-propen-1-yl)amino)benzoic acid | 1件: Benzoic acid Benzoic acid | 1件: Benzoic acid
Benzoic acid
💬 | - | - | 1件: 51 51 💬 |
134 | 2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate ester | 1件: Famciclovir Famciclovir | 1件: Famciclovir
Famciclovir
💬 | - | - | 1件: 13 13 💬 |
135 | 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylat | - | - | - | - | 1件: 28 28 💬 |
136 | 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylate | - | - | - | - | 1件: 28 28 💬 |
137 | 2-(4-[5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy)-N-(methylsulfonyl)actamide | - | - | - | - | 1件: 86 86 💬 |
138 | 2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE | - | - | - | - | 2件: 6 6, 162 💬 |
139 | 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl) acetamide | 1件: Acetamide Acetamide | - | - | - | 1件: 86 86 💬 |
140 | 2-{7-[1,1-dimethyl-3-(4-sulfobutyl)-benz[e]indolin-2-ylidene]-1,3,5-heptatrienyl}-1,1-dimethyl-3-(sulfobutyl)-1H-benz[e]-indolium hydroxide,inner salt | 1件: Hydroxide ion Hydroxide ion | - | - | - | 1件: 46 46 💬 |
141 | 2.0 MIU IL-2 per day | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 1件: 2 2 💬 |
142 | 20 mg BID of PF-02545920 | - | - | - | - | 1件: 8 8 💬 |
143 | 200 mg BIA 6-512 | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
144 | 207-3120 | - | - | - | - | 1件: 6 6 💬 |
145 | 20mg/0.5ml GA | - | - | - | - | 1件: 13 13 💬 |
146 | 20mg/0.5ml glatiramer acetate | 2件: Acetate Acetate, Glatiramer | - | - | - | 1件: 13 13 💬 |
147 | 225mg SHP647 (PF-00547659) | - | - | - | - | 1件: 97 97 💬 |
148 | 29180.00.00, 34681.00.00, 34681.01.00, 34681.02.00 | - | - | - | - | 1件: 113 113 💬 |
149 | 2mg budesonide effervescent tablet for orodispersible use | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
150 | 3 mg QD to 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
151 | 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
152 | 3-(3,4-Dihydroxyphenyl)-L-alanine | 1件: Alanine Alanine | 1件: Alanine
Alanine
💬 | - | - | 1件: 6 6 💬 |
153 | 3-(3-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)PROPOXY)-4-FLUOROBENZOIC ACID | 1件: Pyrazole Pyrazole | - | - | - | 1件: 28 28 💬 |
154 | 3-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- | - | - | - | - | 1件: 93 93 💬 |
155 | 3-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl]methyl}amino)pentanedioic acid | - | - | - | - | 1件: 93 93 💬 |
156 | 3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt | - | - | - | - | 2件: 51 51, 85 💬 |
157 | 3-hydroxy-2-methyl-4H-pyrane-4-one iron (III) complex (3:1), Ferric (3-hydroxy-2-methyl-4-pyrone), Tris-maltol-iron (III), Tri=maltol-iron (III) | 1件: Tromethamine Tromethamine | 1件: Tromethamine
Tromethamine
💬 | - | - | 2件: 96 96, 97 💬 |
158 | 3-methyl-1-phenyl-4, 5-dihydro-1H-pyrazol-5-one. | 1件: Pyrazole Pyrazole | - | - | - | 1件: 2 2 💬 |
159 | 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-oic acid | - | - | - | - | 1件: 93 93 💬 |
160 | 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-oic acid | - | - | - | - | 1件: 93 93 💬 |
161 | 4 cholesten-3-one, oxime | - | - | - | - | 1件: 2 2 💬 |
162 | 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-benzamide, methane sulphonic acid salt. AB1010base | 1件: Methane Methane | - | - | - | 1件: 2 2 💬 |
163 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)- 1H-pyrazol-1-yl] benzenesulfonamide | 1件: Pyrazole Pyrazole | - | - | - | 1件: 46 46 💬 |
164 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide | 1件: Pyrazole Pyrazole | - | - | - | 1件: 46 46 💬 |
165 | 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione | - | - | - | - | 1件: 5 5 💬 |
166 | 4-Benzyl-2-naphthalen-1-yl-1,2,4- thiadiazolidine-3,5-dione | - | - | - | - | 1件: 113 113 💬 |
167 | 4-benzyl-2-naphthalen-1-yl-1,2,4-thiadiazolidine-3,5-dione | - | - | - | - | 1件: 113 113 💬 |
168 | 4-cholesten-3-one, oxime | - | - | - | - | 2件: 2 2, 3 💬 |
169 | 4-cholesten-3-one,oxime | - | - | - | - | 1件: 3 3 💬 |
170 | 4-{[(1R,2s,3S,5s,7s)-5-Hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide monohydrobromide | - | - | - | - | 1件: 46 46 💬 |
171 | 4.5 mg Naltrexone | 1件: Naltrexone Naltrexone | 1件: Naltrexone
Naltrexone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 💬 |
172 | 40 MG- SOLUZIONE INIETTABILE IN SIRINGHE PRE-RIEMPITE- USO SOTTOCUTANEO- SIRINGA PRERIEMPITA (0,4ML)- 2 SIRINGHE PRE-RIEMPITE + 2 TAMPONI IMBEVUTI DI ALCOOL | - | - | - | - | 1件: 107 107 💬 |
173 | 400 mg BIA 5-1058 | 1件: BIA BIA | - | - | - | 1件: 86 86 💬 |
174 | 4D-310 | - | - | - | - | 1件: 19 19 💬 |
175 | 5% lidocaine/5 mg/ml 0.02% estradiol compound cream | 2件: Estradiol Estradiol, Lidocaine | 3件: Estradiol
Estradiol
,
Lidocaine
,
Lidocaine hydrochloride monohydrate
💬 | 7件: ESR1 ESR1, ESR2, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 13件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Breast cancer, Chemical carcinogenesis - receptor activation, Dopaminergic synapse, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Taste transduction, Thyroid hormone signaling pathway 💬 | 1件: 226 226 💬 |
176 | 5-[4-[2-(5-(1-hydroxyethyl)-2- pyridinyl)ethoxy]benzyl]-2,4- thiazolidinedione hydrochloride | 1件: 2,4-thiazolidinedione 2,4-thiazolidinedione | - | - | - | 1件: 20 20 💬 |
177 | 5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride | 1件: 2,4-thiazolidinedione 2,4-thiazolidinedione | - | - | - | 1件: 20 20 💬 |
178 | 5-[[4-[2-[5-(1-HYDROXYETHYL)-2-PYRIDINYL]ETHOXY]PHENYL]METHYL]-2,4-THIAZOLIDINEDIONE HYDROCHLORIDE | 1件: 2,4-thiazolidinedione 2,4-thiazolidinedione | - | - | - | 1件: 20 20 💬 |
179 | 5-amino salicylic acid (5-ASA) | 2件: Mesalazine Mesalazine, Salicylic acid | 2件: Salicylic acid
Salicylic acid
,
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
180 | 5-Aminosalicylic acid (5-ASA) | 2件: Aminosalicylic acid Aminosalicylic acid, Mesalazine | 2件: Aminosalicylic acid
Aminosalicylic acid
,
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
181 | 5-ASA (5-Aminosalicylate) | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
182 | 5-Chlor-6'-methyl- 3-[4-(methylsulfonyl)phenyl]- 2,3'-bipyridin | 1件: Chlorine Chlorine | - | - | - | 2件: 46 46, 271 💬 |
183 | 5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium | - | - | - | - | 1件: 8 8 💬 |
184 | 50 mg ELX/25 mg TEZ/37.5 mg IVA | - | - | - | - | 1件: 299 299 💬 |
185 | 50 mg ELX/25 mg TEZ/37.5 mg IVA fixed dose combination | - | - | - | - | 1件: 299 299 💬 |
186 | 500 0500 0 | - | - | - | - | 1件: 19 19 💬 |
187 | 52069.00.01 | - | - | - | - | 1件: 13 13 💬 |
188 | 549-0261/F02-01 | - | - | - | - | 2件: 96 96, 97 💬 |
189 | 552-02 | - | - | - | - | 2件: 53 53, 299 💬 |
190 | 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine | - | - | - | - | 1件: 38 38 💬 |
191 | 6-(nitrooxy)hexyl(2Z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate | - | - | - | - | 1件: 46 46 💬 |
192 | 6-[(methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-purine | - | - | - | - | 1件: 96 96 💬 |
193 | 6-[2-(3,4-diethoxyphenyl)thiazol-4-yl] pyridine-2-carboxylic acid | - | - | - | - | 1件: 97 97 💬 |
194 | 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one | - | - | - | - | 1件: 2 2 💬 |
195 | 6036937.00.01 | - | - | - | - | 1件: 6 6 💬 |
196 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
197 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o, obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
198 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
199 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o, obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
200 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
201 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o , obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
202 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
203 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o , obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
204 | 7 mg QD to 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
205 | 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
206 | 70930.00.00 | - | - | - | - | 1件: 46 46 💬 |
207 | 750 mg metformin and 7.5 g L-citrulline daily p.o. | 2件: Citrulline Citrulline, Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 113 113 💬 |
208 | 75mg SHP647 (PF-00547659) | - | - | - | - | 1件: 97 97 💬 |
209 | 9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo[2,3-b] quinoxaline | - | - | - | - | 1件: 46 46 💬 |
210 | 98-92-0 | - | - | - | - | 1件: 107 107 💬 |
211 | 99mTc-3PRGD2 | - | - | - | - | 1件: 46 46 💬 |
212 | : 2-{4-[(5,6-difenilpirazin-2-yl)(isopropil)amino]butoxi}-N- | - | - | - | - | 1件: 86 86 💬 |
213 | : immunoglobulina umana normale 10% per somministrazione endovenosa | - | - | - | - | 1件: 14 14 💬 |
214 | ?-3 polyunsaturated fatty acid | - | - | - | - | 1件: 96 96 💬 |
215 | [11C]-GSK2256098 500 MBq | 1件: GSK2256098 GSK2256098 | - | - | - | 1件: 86 86 💬 |
216 | [123I] 5-IA | - | - | - | - | 1件: 6 6 💬 |
217 | [124I]IB PF 06687234 | - | - | - | - | 2件: 96 96, 97 💬 |
218 | [18F]P17-059 | - | - | - | - | 1件: 6 6 💬 |
219 | [18F]UCB-2897 | - | - | - | - | 1件: 6 6 💬 |
220 | [21CFR640.30] Plasma from 18 - 25 year old volunteer donors | - | - | - | - | 1件: 6 6 💬 |
221 | A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) | - | - | - | - | 1件: 60 60 💬 |
222 | A-glucosidasi acida umana ricombinante coniugata con multiple copie di bis-mannosio-6- fosfato-tetra-mannosio glicano sintetico (NEOGAA) | 1件: Avalglucosidase alfa Avalglucosidase alfa | 1件: Avalglucosidase alfa
Avalglucosidase alfa
💬 | 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 💬 |
223 | A4250-015 | - | - | - | - | 1件: 297 297 💬 |
224 | AAV2/5-hPDE6B | - | - | - | - | 1件: 90 90 💬 |
225 | AAV2/5-hRKp.RPGR | - | - | - | - | 1件: 90 90 💬 |
226 | AAV2/5-RPGR | - | - | - | - | 1件: 90 90 💬 |
227 | AAV2CUhCLN2 (3x10^12 particle units) | - | - | - | - | 1件: 19 19 💬 |
228 | AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies | - | - | - | - | 1件: 19 19 💬 |
229 | Abacavir 300mg twice daily | 1件: Abacavir Abacavir | 1件: Abacavir
Abacavir
💬 | - | - | 1件: 265 265 💬 |
230 | ABBV-006 | - | - | - | - | 1件: 97 97 💬 |
231 | ABBV-066 | - | - | - | - | 2件: 96 96, 97 💬 |
232 | ABBV-0805 | - | - | - | - | 1件: 6 6 💬 |
233 | ABBV-105, A-1519938.0 | - | - | - | - | 1件: 46 46 💬 |
234 | ABBV-3067 | - | - | - | - | 1件: 299 299 💬 |
235 | ABBV-323 | - | - | - | - | 2件: 53 53, 97 💬 |
236 | ABBV-323 Dose A | - | - | - | - | 1件: 97 97 💬 |
237 | ABBV-323 Dose B | - | - | - | - | 1件: 97 97 💬 |
238 | ABBV-3373 | - | - | - | - | 1件: 46 46 💬 |
239 | ABBV-576 | - | - | - | - | 1件: 299 299 💬 |
240 | ABC/DTG/3TC STR - Tablet | - | - | - | - | 1件: 256 256 💬 |
241 | Abetimus sodium (LJP 394) | 1件: Abetimus Abetimus | - | - | - | 1件: 49 49 💬 |
242 | Abituzumab 500 mg | 1件: Abituzumab Abituzumab | - | - | - | 1件: 51 51 💬 |
243 | ABP 501 | - | - | - | - | 1件: 46 46 💬 |
244 | ABT 494 3mg | - | - | - | - | 2件: 46 46, 96 💬 |
245 | ABT-494 30mg | - | - | - | - | 1件: 46 46 💬 |
246 | ABT-555 | - | - | - | - | 1件: 13 13 💬 |
247 | ABX464 50mg | - | - | - | - | 2件: 46 46, 97 💬 |
248 | ABY-035 | - | - | - | - | 1件: 271 271 💬 |
249 | Accelerated 30 minutes-infusion | - | - | - | - | 2件: 96 96, 97 💬 |
250 | Accordion Pill ¿ Carbidopa/Levodopa 50/400 mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
251 | Accordion Pill ¿ Carbidopa/Levodopa 50/500 mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
252 | Accordion Pill? Carbidopa/Levodopa 50/400 mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
253 | Accordion Pill? Carbidopa/Levodopa 50/500 mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
254 | Accordion Pill™ Carbidopa/Levodopa 50/400 mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
255 | Accordion Pill™ Carbidopa/Levodopa 50/500 mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
256 | ACE-011 | - | - | - | - | 1件: 86 86 💬 |
257 | ACE-011 / MK - 7962 | - | - | - | - | 1件: 86 86 💬 |
258 | ACE-011 / MK-7962 | - | - | - | - | 1件: 86 86 💬 |
259 | ACE-011/ MK-7962 | - | - | - | - | 1件: 86 86 💬 |
260 | ACE-031 (Extension of cohort 1 from core study, A031-03) | - | - | - | - | 1件: 113 113 💬 |
261 | ACE-031 (Extension of cohort 2 from core study, A031-03) | - | - | - | - | 1件: 113 113 💬 |
262 | ACE-031 (Extension of cohort 3 from core study, A031-03) | - | - | - | - | 1件: 113 113 💬 |
263 | ACE-031 0.5 mg/kg q4wk | - | - | - | - | 1件: 113 113 💬 |
264 | ACE-031 1.0 mg/kg q2wk | - | - | - | - | 1件: 113 113 💬 |
265 | ACE-083 | - | - | - | - | 2件: 10 10, 113 💬 |
266 | ACER-002 (celiprolol) 200 mg BID | 1件: Celiprolol Celiprolol | 1件: Celiprolol
Celiprolol
💬 | 1件: ADRB1 ADRB1 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 168 168 💬 |
267 | Acetyl-L-carnitine 1000mg 2X per day for 3 months | 2件: Acetylcarnitine Acetylcarnitine, Levocarnitine | 1件: Levocarnitine
Levocarnitine
💬 | - | - | 1件: 298 298 💬 |
268 | ACH-0144471 | - | - | - | - | 2件: 62 62, 222 💬 |
269 | ACH-0144471 compresse | - | - | - | - | 1件: 222 222 💬 |
270 | ACH-0145228 | - | - | - | - | 1件: 62 62 💬 |
271 | ACIDE TRANEXAMIQUE MYLAN 0,5 g/ 5 mL, solution injectable | - | - | - | - | 1件: 299 299 💬 |
272 | Acido ursodessicolico | - | - | - | - | 1件: 93 93 💬 |
273 | Aclasta 5 mg Infusionslösung | 1件: Zoledronic acid Zoledronic acid | 2件: Zoledronic acid
Zoledronic acid
,
Zoledronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 💬 |
274 | Aclasta 5mg solution for infusion | - | - | - | - | 1件: 13 13 💬 |
275 | ACP-001 | - | - | - | - | 1件: 78 78 💬 |
276 | ACP-001 (TransCon hGH) | - | - | - | - | 1件: 78 78 💬 |
277 | ACP-011 | - | - | - | - | 1件: 78 78 💬 |
278 | ACR16 22.5 mg | - | - | - | - | 1件: 8 8 💬 |
279 | ACT - 064992 | - | - | - | - | 1件: 86 86 💬 |
280 | ACT-050089 | - | - | - | - | 1件: 86 86 💬 |
281 | ACT-050089 (Ro 61-0612) | - | - | - | - | 1件: 86 86 💬 |
282 | ACT-064992 | - | - | - | - | 5件: 51 51, 85, 86, 88, 210 💬 |
283 | ACT-064992 (macitentan) | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 85 85 💬 |
284 | ACT-064992 / JNJ-67896062 | - | - | - | - | 1件: 86 86 💬 |
285 | ACT-064992/ JNJ-67896062 | - | - | - | - | 1件: 86 86 💬 |
286 | ACT-064992D | - | - | - | - | 1件: 86 86 💬 |
287 | ACT-128800 Dose 3 | - | - | - | - | 1件: 13 13 💬 |
288 | ACT-293987 (NS-304) | - | - | - | - | 1件: 86 86 💬 |
289 | ACT-334441 | - | - | - | - | 1件: 49 49 💬 |
290 | ACT-385781A | - | - | - | - | 1件: 86 86 💬 |
291 | ACT-385781A (Actelion Epoprostenol) | 1件: Epoprostenol Epoprostenol | 1件: Epoprostenol
Epoprostenol
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
292 | ACT-HIB Polvere e solvente per soluzione iniettabile in siringa preriempita 0,5 ml | 1件: Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen | - | - | - | 2件: 61 61, 62 💬 |
293 | Acthar 80 unit injection | 1件: Corticotropin Corticotropin | 1件: Corticotropin
Corticotropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 66 66 💬 |
294 | ACTHAR Gel 40 units twice weekly | 1件: Corticotropin Corticotropin | 1件: Corticotropin
Corticotropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 84 84 💬 |
295 | ACTHAR Gel 80 units twice weekly. | 1件: Corticotropin Corticotropin | 1件: Corticotropin
Corticotropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 84 84 💬 |
296 | Acthar high dose (80 U) | 1件: Corticotropin Corticotropin | 1件: Corticotropin
Corticotropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 49 49 💬 |
297 | Acthar low dose (40 U) | 1件: Corticotropin Corticotropin | 1件: Corticotropin
Corticotropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 49 49 💬 |
298 | ACTHIB - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONCINO POLVERE+1 SIRINGA PRERIEMPITA SOLVENTE 0.5 ML | 1件: Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen | - | - | - | 2件: 62 62, 66 💬 |
299 | Active drug (BIIB014) at 10, 30, 100, or 300 mg once daily. | - | - | - | - | 1件: 6 6 💬 |
300 | Active Investigational Treatment ENT-01 | - | - | - | - | 1件: 6 6 💬 |
301 | Actonel 5mg Film Coated Tablets | 1件: Risedronic acid Risedronic acid | 1件: Risedronic acid
Risedronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 274 274 💬 |
302 | Actonel Once a Week 35 mg film-coated tablets | 1件: Risedronic acid Risedronic acid | 1件: Risedronic acid
Risedronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 274 274 💬 |
303 | Actonel Once a week 5mg film coated tablets | 1件: Risedronic acid Risedronic acid | 1件: Risedronic acid
Risedronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 113 113 💬 |
304 | Actonel/Optinate 5mg film-coated tablets | 1件: Risedronic acid Risedronic acid | 1件: Risedronic acid
Risedronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 274 274 💬 |
305 | Actos 30 mg | 1件: Pioglitazone Pioglitazone | 1件: Pioglitazone
Pioglitazone
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 2 2 💬 |
306 | Acylated and unacylated ghrelin dosages | 1件: Lenomorelin Lenomorelin | - | - | - | 3件: 193 193, 201, 202 💬 |
307 | ACZ885, 150mg/1.0ml | - | - | - | - | 2件: 266 266, 267 💬 |
308 | AD 452 4.5 mg Tablet | - | - | - | - | 1件: 46 46 💬 |
309 | Ad26.COV2-S.02 | - | - | - | - | 1件: 299 299 💬 |
310 | ADA Umbilical Cord Blood Cells | - | - | - | - | 1件: 65 65 💬 |
311 | Adalimumab (up to 9 months exposure) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
312 | Adalimumab - US licensed Humira | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
313 | Adalimumab, Solution for Injection 40 mg/ (0.8 ml) Pre-filled Syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
314 | Adderall XR | - | - | - | - | 1件: 13 13 💬 |
315 | Adderall XR 10 mg | - | - | - | - | 1件: 13 13 💬 |
316 | Adderall XR 5mg | - | - | - | - | 1件: 13 13 💬 |
317 | ADEMPAS - 0,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
318 | ADEMPAS - 1 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 💬 |
319 | ADEMPAS - 1,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 💬 |
320 | ADEMPAS - 2 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 💬 |
321 | ADEMPAS - 2,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 💬 |
322 | Adempas 0.125 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 299 299 💬 |
323 | Adempas 0.5 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 299 💬 |
324 | Adempas 0.5 mg Film Coated Tablet | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
325 | Adempas 1.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 299 💬 |
326 | Adempas 1.5 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
327 | Adempas 1.5 mg Film Coated Tablet | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
328 | Adempas 2.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 299 💬 |
329 | Adempas 2.5 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
330 | Adempas 2.5 mg Film Coated Tablet | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
331 | Adempas® 0.5 mg film-coated tablets | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
332 | Adempas® 1.0 mg film-coated tablets | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
333 | Adempas® 1.5 mg film-coated tablets | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
334 | Adempas® 2.0 mg film-coated tablets | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
335 | Adempas® 2.5 mg film-coated tablets | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
336 | Adempas¿ 0.5 mg compressa rivestita con film | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
337 | Adempas¿ 1.0 | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
338 | Adempas¿ 1.5 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
339 | Adempas¿ 2.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
340 | Adempas¿ 2.5 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
341 | Adeno-associated viral vector serotype 3B encoding shortened human ATP7B | - | - | - | - | 1件: 171 171 💬 |
342 | ADENO-ASSOCIATED VIRUS SEROTYPE 5 ENCODING A MICRORNA TARGETED TO HUMAN HUNTINGTIN GENE | - | - | - | - | 1件: 8 8 💬 |
343 | ADS-001 | - | - | - | - | 1件: 231 231 💬 |
344 | ADS-5102 | - | - | - | - | 2件: 6 6, 13 💬 |
345 | ADS-5102 (extended release amantadine HCl) | 1件: Amantadine Amantadine | 1件: Amantadine
Amantadine
💬 | 5件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 20件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
346 | ADS-5102, 137 mg | - | - | - | - | 1件: 13 13 💬 |
347 | ADS-5102, 274 mg | - | - | - | - | 1件: 13 13 💬 |
348 | Advagraf 0,5mg | 1件: Tacrolimus Tacrolimus | 2件: Tacrolimus
Tacrolimus
,
Tacrolimus
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
349 | Advagraf 5mg | 1件: Tacrolimus Tacrolimus | 2件: Tacrolimus
Tacrolimus
,
Tacrolimus
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
350 | ADVATE 500 IU powder and solvent for solution for injection | 1件: Antihemophilic factor, human recombinant Antihemophilic factor, human recombinant | - | - | - | 1件: 288 288 💬 |
351 | Adverse Reactions of Gammagard subcutaneously at Week 36 | - | - | - | - | 1件: 65 65 💬 |
352 | Adverse Reactions of Gammagard subdermally at Week 36 | - | - | - | - | 1件: 65 65 💬 |
353 | ADVM-043 | - | - | - | - | 1件: 231 231 💬 |
354 | Aerolised Liposomal Ciclosporin A 5mg | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 228 228 💬 |
355 | AEZS-130 (formerly ARD-07) | - | - | - | - | 1件: 78 78 💬 |
356 | Afimetoran (2.5mg) | 1件: Afimetoran Afimetoran | 1件: Afimetoran
Afimetoran
💬 | - | - | 1件: 49 49 💬 |
357 | Afinitor 5mg Tablets | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 2件: 89 89, 158 💬 |
358 | AGS-009 | - | - | - | - | 1件: 49 49 💬 |
359 | AK106-001616 | 1件: AK106-001616 AK106-001616 | - | - | - | 1件: 46 46 💬 |
360 | AKBM-3031 | - | - | - | - | 1件: 49 49 💬 |
361 | Aknemin 50 | - | - | - | - | 1件: 201 201 💬 |
362 | AKR-501, YM-477 | - | - | - | - | 1件: 63 63 💬 |
363 | Albumin (Human) 20%, United States Pharmacopeia (USP) | - | - | - | - | 1件: 231 231 💬 |
364 | Albumin (Human) 25%, United States Pharmacopeia (USP) | - | - | - | - | 2件: 13 13, 14 💬 |
365 | Albunorm® 5%, | - | - | - | - | 1件: 20 20 💬 |
366 | Albutein 5% | 1件: Albumin human Albumin human | 1件: Albumin human
Albumin human
💬 | - | - | 1件: 2 2 💬 |
367 | ALDURAZYME*INFUS 1FL 5ML 500U | 1件: Laronidase Laronidase | 1件: Laronidase
Laronidase
💬 | 1件: IDUA IDUA 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
368 | Alemtuzumab 0.2 mg | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 2件: 65 65, 164 💬 |
369 | Alemtuzumab 0.3 mg | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 2件: 65 65, 164 💬 |
370 | ALGLUCOSIDASI ALFA UMANA RICOMBINANTE | - | - | - | - | 1件: 256 256 💬 |
371 | ALK-001 | - | - | - | - | 1件: 301 301 💬 |
372 | ALK-001 (No generic name) | - | - | - | - | 1件: 301 301 💬 |
373 | All subjects will receive maraviroc 300mg orally twice a day for 6 weeks | 1件: Maraviroc Maraviroc | 1件: Maraviroc
Maraviroc
💬 | 1件: CCR5 CCR5 💬 | 11件: Chemokine signaling pathway Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Toxoplasmosis, Viral carcinogenesis, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬 | 1件: 84 84 💬 |
374 | All-P-ambo-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'-O->5'-O)-2'-deoxy-P-thioguanylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy-P-thioadenylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methylcytidine | - | - | - | - | 1件: 2 2 💬 |
375 | All-P-ambo-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'-O->5'-O)-2'-deoxy-P-thioguanylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy-Pthioadenylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy- | - | - | - | - | 1件: 2 2 💬 |
376 | Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
377 | Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
378 | Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
379 | Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
380 | Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells | - | - | - | - | 1件: 13 13 💬 |
381 | ALLOGENEIC MESENCHYMAL STROMAL CELLS DERIVED FROM THE UMBILICAL CORD | 1件: Human Umbilical Cord Mesenchymal Stem Cells Human Umbilical Cord Mesenchymal Stem Cells | - | - | - | 1件: 49 49 💬 |
382 | Allogeneic Umbilical Cord Mesenchymal Stem Cell and Adipose Secretome Implantation | - | - | - | - | 1件: 17 17 💬 |
383 | Allogeneic Umbilical Cord Mesenchymal Stem Cell Implantation | - | - | - | - | 1件: 17 17 💬 |
384 | Allogeneic umbilical cord mesenchymal stem cells | - | - | - | - | 1件: 13 13 💬 |
385 | Allogenic eASCs 5 milion cells/ml suspension for injection. Cx601 | - | - | - | - | 1件: 96 96 💬 |
386 | Allogenic eASCs 5 million cells/ml suspension for injection CX601 | - | - | - | - | 1件: 96 96 💬 |
387 | Allogenic eASCs 5 million cells/ml suspension for injection. CX601 | - | - | - | - | 1件: 96 96 💬 |
388 | Allogenic eASCs 5 million/ml suspension for injection. | - | - | - | - | 1件: 96 96 💬 |
389 | ALN-51547 | - | - | - | - | 1件: 28 28 💬 |
390 | Alphanate 1000 I.U. | 3件: Antihemophilic factor human Antihemophilic factor human, Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
391 | Alphanate 1500 I.U. | 3件: Antihemophilic factor human Antihemophilic factor human, Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
392 | ALPHANATE*INF 1F 250UI+F 5ML | 2件: Beroctocog alfa Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
393 | ALPHANATE*INF 1F 500UI+F 5ML | 2件: Beroctocog alfa Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
394 | ALRN-5281 0.015 mg/kg | - | - | - | - | 1件: 78 78 💬 |
395 | ALRN-5281 0.05 mg/kg | - | - | - | - | 1件: 78 78 💬 |
396 | ALRN-5281 0.15 mg/kg | - | - | - | - | 1件: 78 78 💬 |
397 | ALX-0061 | - | - | - | - | 2件: 46 46, 49 💬 |
398 | ALX-0061 150 mg/mL | - | - | - | - | 1件: 49 49 💬 |
399 | ALX-0061 Nanobody | - | - | - | - | 1件: 46 46 💬 |
400 | ALX-0081 | - | - | - | - | 1件: 64 64 💬 |
401 | ALX-009 | - | - | - | - | 1件: 299 299 💬 |
402 | ALX-0600 | - | - | - | - | 1件: 96 96 💬 |
403 | ALXN2040 (ACH-0144471) | - | - | - | - | 1件: 62 62 💬 |
404 | AM-01 | - | - | - | - | 1件: 51 51 💬 |
405 | Amantadine 300 mg | 1件: Amantadine Amantadine | 1件: Amantadine
Amantadine
💬 | 5件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 20件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
406 | AMB-05X | - | - | - | - | 1件: 85 85 💬 |
407 | Ambrisentan 5 mg | 1件: Ambrisentan Ambrisentan | 1件: Ambrisentan
Ambrisentan
💬 | 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 88 88 💬 |
408 | Ambrisentan 5 mg film-coated tablets | 1件: Ambrisentan Ambrisentan | 1件: Ambrisentan
Ambrisentan
💬 | 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
409 | Ambrisentan 5mg film-coated tablets [marketed product] | 1件: Ambrisentan Ambrisentan | 1件: Ambrisentan
Ambrisentan
💬 | 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
410 | AMG 357 | - | - | - | - | 1件: 46 46 💬 |
411 | AMG 531 | - | - | - | - | 1件: 63 63 💬 |
412 | AMG 557 | - | - | - | - | 1件: 49 49 💬 |
413 | AMG 557/MEDI5872 | - | - | - | - | 1件: 53 53 💬 |
414 | AMG 570 | - | - | - | - | 2件: 46 46, 49 💬 |
415 | AMG 592 | - | - | - | - | 3件: 46 46, 49, 97 💬 |
416 | AMG 827 350 MG | - | - | - | - | 1件: 96 96 💬 |
417 | Amiloride Hcl 5mg Tab | 1件: Amiloride Amiloride | 1件: Amiloride
Amiloride
💬 | 3件: SCNN1A SCNN1A, SCNN1B, SCNN1G 💬 | 2件: Aldosterone-regulated sodium reabsorption Aldosterone-regulated sodium reabsorption, Taste transduction 💬 | 1件: 67 67 💬 |
418 | ANA001XHCl (Syntagon) or VEXA-04 (Patheon) | - | - | - | - | 1件: 156 156 💬 |
419 | ANG-3070 | - | - | - | - | 1件: 85 85 💬 |
420 | Anifrolumab (MEDI-546) | 1件: Anifrolumab Anifrolumab | 1件: Anifrolumab
Anifrolumab
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 46 46 💬 |
421 | Anifrolumab 300 mg | 1件: Anifrolumab Anifrolumab | 1件: Anifrolumab
Anifrolumab
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 49 49 💬 |
422 | Anti-Beta Interferon (PF-06823859) | - | - | - | - | 1件: 50 50 💬 |
423 | Anti-IL-20 (109-0012) | 1件: Fletikumab Fletikumab | 1件: Fletikumab
Fletikumab
💬 | 1件: IL20 IL20 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
424 | Anti-IL-36R monoclonal antibody | - | - | - | - | 1件: 37 37 💬 |
425 | Anti-interleukin 5 (IL-5) humanized monoclonal | - | - | - | - | 2件: 44 44, 45 💬 |
426 | Anticorpo monoclonale anti GM-CSF umano | - | - | - | - | 1件: 46 46 💬 |
427 | Anticorpo monoclonale umano anti-Interleuchina-23 Immunoglobulina G2 (IgG2) | - | - | - | - | 1件: 96 96 💬 |
428 | Antiepileptic drug (1 to 3 only) | - | - | - | - | 1件: 158 158 💬 |
429 | Antivirale ad uso diretto | - | - | - | - | 1件: 107 107 💬 |
430 | Apomorphine 0.25% (2.5mg/ml) | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
431 | Apomorphine hydrochloride 4.0 mg inhalation powder, pre-dispensed | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
432 | Apomorphine hydrochloride 5.8 mg inhalation powder, pre-dispensed | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
433 | Apraclonidine Hcl 0.5% Oph Soln | 1件: Apraclonidine Apraclonidine | 1件: Apraclonidine
Apraclonidine
💬 | 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 11 11 💬 |
434 | Apremilast 30 mg | 1件: Apremilast Apremilast | 1件: Apremilast
Apremilast
💬 | 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 3件: 46 46, 56, 107 💬 |
435 | Apremilast 30mg | 1件: Apremilast Apremilast | 1件: Apremilast
Apremilast
💬 | 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 1件: 50 50 💬 |
436 | Apremilast tablet 30 mg BID | 1件: Apremilast Apremilast | 1件: Apremilast
Apremilast
💬 | 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 1件: 271 271 💬 |
437 | Apriso 0.375G ER CAP | - | - | - | - | 1件: 97 97 💬 |
438 | APRISO 375 mg extended-release capsules | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 97 97 💬 |
439 | APT-1011 - 3 mg | - | - | - | - | 1件: 98 98 💬 |
440 | APT-1011 3 mg HS | - | - | - | - | 1件: 98 98 💬 |
441 | Arbaclofen placarbil 30 mg BID | 2件: Arbaclofen Arbaclofen, Arbaclofen Placarbil | 2件: Arbaclofen placarbil
Arbaclofen placarbil
,
Arbaclofen
💬 | 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
442 | ARCT-032 | - | - | - | - | 1件: 299 299 💬 |
443 | ARD-3150 | - | - | - | - | 1件: 299 299 💬 |
444 | Aricept 5 mg | 1件: Donepezil Donepezil | 1件: Donepezil
Donepezil
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 13 13 💬 |
445 | Aricept 5 mg filmdragerade tabletter | 1件: Donepezil Donepezil | 1件: Donepezil
Donepezil
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 13 13 💬 |
446 | Aricept 5 mg-Filmtabletten | - | - | - | - | 1件: 6 6 💬 |
447 | ARICEPT 5*28 CPR 5 MG | 1件: Donepezil Donepezil | 1件: Donepezil
Donepezil
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 124 124 💬 |
448 | Aricept 5mg-Filmtabletten | - | - | - | - | 1件: 6 6 💬 |
449 | Arikayce™ 560 mg | 1件: Amikacin Amikacin | 1件: Amikacin
Amikacin
💬 | - | - | 1件: 299 299 💬 |
450 | ARO-ANG 3 Injection | - | - | - | - | 1件: 79 79 💬 |
451 | ARRY-371797 | - | - | - | - | 1件: 271 271 💬 |
452 | ARRY-371797, p38 inhibitor | - | - | - | - | 2件: 46 46, 271 💬 |
453 | ARZERRA - 100 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONE(VETRO) - 5 ML(20MG/ML) 3 FLACONI | 1件: Ofatumumab Ofatumumab | 1件: Ofatumumab
Ofatumumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
454 | ARZERRA - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 50 ML (20 MG/ML) 1 FLACONCINO + 2 KIT DI PROLUNGA | 1件: Ofatumumab Ofatumumab | 1件: Ofatumumab
Ofatumumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
455 | ASC42 5 mg | - | - | - | - | 1件: 93 93 💬 |
456 | Asendis 50 mg | - | - | - | - | 1件: 46 46 💬 |
457 | ASF-1096 Cream 0.25% | - | - | - | - | 1件: 49 49 💬 |
458 | ASF-1096 Cream 0.5% | - | - | - | - | 1件: 49 49 💬 |
459 | ASF-1096 Cream 1.0% | - | - | - | - | 1件: 49 49 💬 |
460 | ASP015K hydrobromide, AS1940150-BR, JKT-201A, 4-{[(1R,2s,3S,5s,7s)-5-Hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide monohydrobromide | - | - | - | - | 1件: 46 46 💬 |
461 | AT-GTX-501 | - | - | - | - | 1件: 19 19 💬 |
462 | ATI-450 50mg oral tablet BID | - | - | - | - | 1件: 46 46 💬 |
463 | ATN-103 30 mg q4wks | - | - | - | - | 1件: 46 46 💬 |
464 | ATYR1923 1.0 mg/kg | 1件: ATYR1923 ATYR1923 | - | - | - | 1件: 84 84 💬 |
465 | ATYR1923 3.0 mg/kg | 1件: ATYR1923 ATYR1923 | - | - | - | 1件: 84 84 💬 |
466 | ATYR1923 5.0 mg/kg | 1件: ATYR1923 ATYR1923 | - | - | - | 1件: 84 84 💬 |
467 | AUBAGIO - 14 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BISTER (ALU/ALU) PERFORATO MONODOSE - 10 X 1 COMPRESSA | 1件: Teriflunomide Teriflunomide | 1件: Teriflunomide
Teriflunomide
💬 | 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
468 | AUBAGIO - 14 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) - 28 COMPRESSE | 1件: Teriflunomide Teriflunomide | 1件: Teriflunomide
Teriflunomide
💬 | 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
469 | Autologous (self) mononuclear cells derived from umbilical cord blood | - | - | - | - | 1件: 211 211 💬 |
470 | Autologous adult bone marrow mononuclear cells (BM-MNC) unexpanded | - | - | - | - | 1件: 2 2 💬 |
471 | Autologous adult bone marrow mononuclear cells unexpanded | - | - | - | - | 1件: 2 2 💬 |
472 | Autologous cardiac stem cells (JRM-001) | - | - | - | - | 2件: 210 210, 211 💬 |
473 | Autologous Serum 50% | - | - | - | - | 1件: 53 53 💬 |
474 | Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells | - | - | - | - | 1件: 51 51 💬 |
475 | Autologous Umbilical Cord Blood | - | - | - | - | 2件: 211 211, 294 💬 |
476 | AVB-S6-500 | - | - | - | - | 1件: 66 66 💬 |
477 | AVCN583601 (3% Cannabidiol cream) | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 36 36 💬 |
478 | AVONEX - 30 MCG (6 MILIONI UI) POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 4 FLACONI CON DISPOSITIVO BIOSET + 4 SIRINGHE PRERIEMPITE USO INTRAMUSCOLARE | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
479 | Avonex 30 microgram/0.5 ml Solution for Injection | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
480 | AVONEX 30 microgramos/0,5 ml (Interferón Beta - 1a) Solución inyectable | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
481 | Avonex 30 microgramos/0.5 ml Solución para inyección | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
482 | AVONEX 30 µg/0,5 ml solution for injection | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
483 | AVONEX IM 4SIR 30MCG/0,5ML 4AG | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
484 | AVONEX*IM 4SIR 30MCG/0,5ML+4AG | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
485 | Avonex® monotherapy (6.0 MIU administered i.m. each week) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
486 | AVR-RD-01 | - | - | - | - | 1件: 19 19 💬 |
487 | AVR-RD-02 | - | - | - | - | 1件: 19 19 💬 |
488 | AZAFOR - 50 MG COMPRESSE RIVESTITE CON FILM 50 COMPRESSE IN BLISTER PVC/PVDC/AL | - | - | - | - | 1件: 97 97 💬 |
489 | AZAFOR 50mg | - | - | - | - | 1件: 97 97 💬 |
490 | Azathioprin-ratiopharm 50 mg Filmtabletten | - | - | - | - | 1件: 96 96 💬 |
491 | Azathioprine (Imuran) 50 mg Overencapsulated Tablet | 1件: Azathioprine Azathioprine | 1件: Azathioprine
Azathioprine
💬 | - | - | 1件: 97 97 💬 |
492 | Azathioprine - ratiopharm 50 mg | 1件: Azathioprine Azathioprine | 1件: Azathioprine
Azathioprine
💬 | - | - | 1件: 96 96 💬 |
493 | AZATIOPRINA ASPEN - 50 COMPRESSE | 1件: Azathioprine Azathioprine | 1件: Azathioprine
Azathioprine
💬 | - | - | 1件: 96 96 💬 |
494 | AZATIOPRINA HEX. 50CPR 50MG BL | 1件: Azathioprine Azathioprine | 1件: Azathioprine
Azathioprine
💬 | - | - | 1件: 13 13 💬 |
495 | AZD3241 300 mg BID | - | - | - | - | 1件: 6 6 💬 |
496 | AZD3241 300mg | - | - | - | - | 1件: 17 17 💬 |
497 | Azithromycin 500 mg film-coated tablet | 1件: Azithromycin Azithromycin | 2件: Azithromycin
Azithromycin
,
Azithromycin
💬 | - | - | 1件: 299 299 💬 |
498 | AZP-3601 | - | - | - | - | 1件: 235 235 💬 |
499 | AZP-531 | - | - | - | - | 1件: 193 193 💬 |
500 | AZT/3TC | - | - | - | - | 1件: 265 265 💬 |
501 | B / Phuket / 3073/2013-like virus) | - | - | - | - | 1件: 53 53 💬 |
502 | Baclofen ER Capsules (GRS) 30mg | 1件: Baclofen Baclofen | 1件: Baclofen
Baclofen
💬 | 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
503 | Baclofen ER Capsules (GRS) 50 mg | 1件: Baclofen Baclofen | 1件: Baclofen
Baclofen
💬 | 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
504 | Baclofen Tablets USP | 1件: Baclofen Baclofen | 1件: Baclofen
Baclofen
💬 | 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
505 | Baclofen Tablets USP 10 mg | 1件: Baclofen Baclofen | 1件: Baclofen
Baclofen
💬 | 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
506 | BAF312 0,25 mg tablet | - | - | - | - | 1件: 13 13 💬 |
507 | BAF312 0,5 mg tablet | - | - | - | - | 1件: 50 50 💬 |
508 | BAF312 0.25 mg | - | - | - | - | 1件: 50 50 💬 |
509 | BAF312 0.25 mg tablet | - | - | - | - | 1件: 50 50 💬 |
510 | BAF312 0.25mg tablet | - | - | - | - | 1件: 50 50 💬 |
511 | BAF312 0.5 mg | - | - | - | - | 1件: 50 50 💬 |
512 | BAF312 0.50 mg | - | - | - | - | 1件: 50 50 💬 |
513 | BAF312 5 mg tablet | - | - | - | - | 1件: 50 50 💬 |
514 | Bardoxolone methyl 5 mg | 2件: Bardoxolone Bardoxolone, Bardoxolone methyl | 2件: Bardoxolone
Bardoxolone
,
Bardoxolone methyl
💬 | - | - | 1件: 67 67 💬 |
515 | BARDOXOLONE METHYL, CDDO-Me, CDDO-Methyl Ester, NSC 713200, Chemical Name: Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester | 2件: Bardoxolone Bardoxolone, Bardoxolone methyl | 2件: Bardoxolone
Bardoxolone
,
Bardoxolone methyl
💬 | - | - | 1件: 86 86 💬 |
516 | Batoclimab 340 mg SC bi-weekly | 1件: Batoclimab Batoclimab | 1件: Batoclimab
Batoclimab
💬 | 1件: FCGRT FCGRT 💬 | - | 1件: 11 11 💬 |
517 | Batoclimab 340 mg SC weekly | 1件: Batoclimab Batoclimab | 1件: Batoclimab
Batoclimab
💬 | 1件: FCGRT FCGRT 💬 | - | 2件: 11 11, 14 💬 |
518 | BAY 59-7939 | - | - | - | - | 1件: 210 210 💬 |
519 | BAY 63-2521 0.06 % | - | - | - | - | 1件: 86 86 💬 |
520 | BAY 63-2521 0.3 % | - | - | - | - | 1件: 86 86 💬 |
521 | BAY 63-2521 coated tablets 0.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
522 | BAY 63-2521 coated tablets 1.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
523 | BAY 63-2521 coated tablets 2.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
524 | BAY 63-2521 IR coated tablet 1.0 mg | - | - | - | - | 1件: 88 88 💬 |
525 | BAY 63-2521 IR coated tablet 1.5 mg | - | - | - | - | 1件: 88 88 💬 |
526 | BAY 63-2521 IR coated tablet 2.0 mg | - | - | - | - | 1件: 88 88 💬 |
527 | BAY 63-2521 IR coated tablet 2.5 mg | - | - | - | - | 1件: 88 88 💬 |
528 | BAY 63-2521 IR tablet 0.5 mg | - | - | - | - | 1件: 88 88 💬 |
529 | BAY 63-2521 IR tablet 1.0 mg | - | - | - | - | 1件: 88 88 💬 |
530 | BAY 63-2521 IR tablet 1.5 mg | - | - | - | - | 1件: 88 88 💬 |
531 | BAY 63-2521 IR tablet 2.0 mg | - | - | - | - | 1件: 88 88 💬 |
532 | BAY 63-2521 IR tablet 2.5 mg | - | - | - | - | 1件: 88 88 💬 |
533 | BAY 63-2521 IR tablets 0.5 mg | - | - | - | - | 1件: 86 86 💬 |
534 | BAY 63-2521 IR tablets 1.0 mg | - | - | - | - | 1件: 86 86 💬 |
535 | BAY 63-2521 IR tablets 1.5 mg | - | - | - | - | 1件: 86 86 💬 |
536 | BAY 63-2521 IR tablets 2.0 mg | - | - | - | - | 1件: 86 86 💬 |
537 | BAY 63-2521 IR tablets 2.5 mg | - | - | - | - | 1件: 86 86 💬 |
538 | BAY 63-2521 tablets 0.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
539 | BAY 63-2521 tablets 1.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
540 | BAY 63-2521 tablets 2.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
541 | BAY q 3939 | - | - | - | - | 1件: 299 299 💬 |
542 | BAY86-5046 | - | - | - | - | 1件: 13 13 💬 |
543 | BAY86-5046_Interferon-beta-1b | - | - | - | - | 1件: 13 13 💬 |
544 | BCD-033 (interferon beta 1a) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
545 | BCD-054 180 mcg | - | - | - | - | 1件: 13 13 💬 |
546 | BCD-054 240 mcg | - | - | - | - | 1件: 13 13 💬 |
547 | BCD-055 | - | - | - | - | 2件: 46 46, 271 💬 |
548 | BCD-063 | - | - | - | - | 1件: 13 13 💬 |
549 | BCD-085 | - | - | - | - | 2件: 93 93, 271 💬 |
550 | BCD-089 | - | - | - | - | 1件: 46 46 💬 |
551 | BCD-089, 162 mg, s/c, q2w | - | - | - | - | 1件: 46 46 💬 |
552 | BCD-089, 162 mg, s/c, qw | - | - | - | - | 1件: 46 46 💬 |
553 | BCD-132, 500 mg | - | - | - | - | 1件: 13 13 💬 |
554 | BCG20-0134 | - | - | - | - | 1件: 13 13 💬 |
555 | Belantamab mafodotin 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks or 8 weeks as determined by Part 1 recommended dosages | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: Belantamab mafodotin
Belantamab mafodotin
💬 | 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬 |
556 | Belantamab mafodotin 2.5 mg/kg (4 weeks) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: Belantamab mafodotin
Belantamab mafodotin
💬 | 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬 |
557 | Belantamab mafodotin 2.5 mg/kg (6 weeks) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: Belantamab mafodotin
Belantamab mafodotin
💬 | 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬 |
558 | Belantamab mafodotin 2.5 mg/kg (8 weeks) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: Belantamab mafodotin
Belantamab mafodotin
💬 | 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬 |
559 | BENLYSTA - 120 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 120 MG 1 FLACONCINO | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 53 53 💬 |
560 | Benzimidazole,5-methoxy-2-[[(4-methoxy- 3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole | 1件: Benzimidazole Benzimidazole | - | - | - | 1件: 46 46 💬 |
561 | Benzimidazole,5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole | 1件: Benzimidazole Benzimidazole | - | - | - | 1件: 46 46 💬 |
562 | Beraprost Sodium 314d Modified Release Tablets | 1件: Beraprost Beraprost | 1件: Beraprost
Beraprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
563 | Beta-1,3/1,6-D-Glucan | - | - | - | - | 1件: 97 97 💬 |
564 | BETAFERON - 15 FLACONCINI 0.25 MG + 15 FLACONCINI 2 ML | 1件: Interferon beta-1b Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
565 | BETAFERON 500 mcg | 1件: Interferon beta-1b Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
566 | Betaferon 500 µg | - | - | - | - | 1件: 13 13 💬 |
567 | Betaferon 500mcg | - | - | - | - | 1件: 13 13 💬 |
568 | Betaferon 500µg | 1件: Interferon beta-1b Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
569 | BETAFERON SC 15F 0,25MG 15SIR | 1件: Interferon beta-1b Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
570 | BETAFERON*15CONFEZ 0,25MG/ML+ | 1件: Interferon beta-1b Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
571 | Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days | 3件: Acetate Acetate, Betamethasone, Phosphate ion | 1件: Betamethasone
Betamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 2 2 💬 |
572 | Betaseron (Interferon beta-1b, BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
573 | Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
574 | BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA P | 4件: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle, Neisseria meningitidis serogroup b fhbp fusion protein antigen, Neisseria meningitidis serogroup b nada protein antigen, Neisseria meningitidis serogroup b nhba fusion protein antigen | - | - | - | 1件: 62 62 💬 |
575 | BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA PRERIEMPITA (VETRO) - 0.5ML - 1 SIRINGA PRERIEMPITA CON AGO | 4件: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle, Neisseria meningitidis serogroup b fhbp fusion protein antigen, Neisseria meningitidis serogroup b nada protein antigen, Neisseria meningitidis serogroup b nhba fusion protein antigen | - | - | - | 1件: 66 66 💬 |
576 | Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy | 2件: Bezafibrate Bezafibrate, Ursodeoxycholic acid | 2件: Ursodiol
Ursodiol
,
Bezafibrate
💬 | 2件: NR1H4 NR1H4, PPARA 💬 | 11件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 94 94 💬 |
577 | Bezafibrate (INN 3968) | 1件: Bezafibrate Bezafibrate | 1件: Bezafibrate
Bezafibrate
💬 | 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 324 324 💬 |
578 | BF 2.649 5 mg | - | - | - | - | 1件: 6 6 💬 |
579 | BGC20-0134 | - | - | - | - | 1件: 13 13 💬 |
580 | BGP-014 | - | - | - | - | 1件: 97 97 💬 |
581 | BGP-014 Capsules | - | - | - | - | 1件: 97 97 💬 |
582 | BGX-0214 | - | - | - | - | 1件: 46 46 💬 |
583 | BH4 5mg | - | - | - | - | 1件: 299 299 💬 |
584 | BHT-3009 | - | - | - | - | 1件: 13 13 💬 |
585 | BHT-3009 0.5 mg | - | - | - | - | 1件: 13 13 💬 |
586 | BHT-3009 1.5 mg | - | - | - | - | 1件: 13 13 💬 |
587 | BHT-3009-01 | - | - | - | - | 1件: 13 13 💬 |
588 | BHV-0223 | - | - | - | - | 1件: 2 2 💬 |
589 | BHV-3241 | - | - | - | - | 1件: 17 17 💬 |
590 | BI 1265162 50 µg | - | - | - | - | 1件: 299 299 💬 |
591 | BIA 3-202 | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
592 | BIA 3-202 (200 mg) | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
593 | BIA 5-1058 | 1件: BIA BIA | - | - | - | 1件: 86 86 💬 |
594 | BIA 6-512 | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
595 | BIA 6-512 100 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
596 | BIA 6-512 100 mg dose | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
597 | BIA 6-512 200 mg dose | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
598 | BIA 6-512 25 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
599 | BIA 6-512 25 mg dose | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
600 | BIA 6-512 400 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
601 | BIA 6-512 50 mg dose | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
602 | BIA 9-1067 30 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
603 | BIA 9-1067 5 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
604 | BIA-5-1058 | 1件: BIA BIA | - | - | - | 1件: 86 86 💬 |
605 | BIBR 796 BS, 5 mg | - | - | - | - | 1件: 96 96 💬 |
606 | Bifidobacterium infantis 35624 | 1件: Bifidobacterium longum infantis Bifidobacterium longum infantis | - | - | - | 2件: 96 96, 97 💬 |
607 | BIIB 017 | - | - | - | - | 1件: 13 13 💬 |
608 | BIRT 2584 XX | - | - | - | - | 1件: 13 13 💬 |
609 | Bitterschleifenblume-ganzpflanze 1,5ml/10ml | - | - | - | - | 1件: 97 97 💬 |
610 | BIVV001 (rFVIIIFc-VWF-XTEN) | - | - | - | - | 1件: 288 288 💬 |
611 | Blokium 50 | - | - | - | - | 1件: 167 167 💬 |
612 | BLOKIUM 50 mg comprimidos | - | - | - | - | 1件: 167 167 💬 |
613 | Blood and urine sampling | - | - | - | - | 1件: 195 195 💬 |
614 | Blood coagulation factor XIII | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 1件: 51 51 💬 |
615 | BMN 044 | - | - | - | - | 1件: 113 113 💬 |
616 | BMN 044 IV 6 mg/kg | - | - | - | - | 1件: 113 113 💬 |
617 | BMN 044 IV 9 mg/kg | - | - | - | - | 1件: 113 113 💬 |
618 | BMN 044 SC 6 mg/kg | - | - | - | - | 1件: 113 113 💬 |
619 | BMN 045 | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
620 | BMN 053 | - | - | - | - | 1件: 113 113 💬 |
621 | BMN 307 | - | - | - | - | 1件: 240 240 💬 |
622 | BMS-582949 | 1件: BMS-582949 BMS-582949 | - | - | - | 1件: 46 46 💬 |
623 | BMS-582949 and Methotrexate | 2件: BMS-582949 BMS-582949, Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
624 | BMS-986089-01 (RO7239361) , anti-myostatin | - | - | - | - | 1件: 113 113 💬 |
625 | BMS-986089-01 (RO7239361) Injections, 15 mg/Syringe (21.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
626 | BMS-986089-01 (RO7239361) Injections, 35 mg/Syringe (50 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
627 | BMS-986089-01 (RO7239361) Injections, 50 mg/Syringe (71.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
628 | BMS-986089-01 (RO7239361) Injections, 7.5 mg/Syringe (10.7 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
629 | BMS-986089-01 (RO7239361), anti-myostatin | - | - | - | - | 1件: 113 113 💬 |
630 | BMS-986089-01 Injections, 15 mg/Syringe (21.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
631 | BMS-986089-01 Injections, 35 mg/Syringe (50 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
632 | BMS-986089-01 Injections, 50 mg/Syringe (71.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
633 | BMS-986089-01 Injections, 7.5 mg/Syringe (10.7 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
634 | BMS-986089-01, Anti-myostatin | - | - | - | - | 1件: 113 113 💬 |
635 | BMS-986142 350mg | 1件: BMS-986142 BMS-986142 | - | - | - | 1件: 46 46 💬 |
636 | BMS-986256-06, TLR7/8 Antagonist | 1件: Afimetoran Afimetoran | 1件: Afimetoran
Afimetoran
💬 | - | - | 1件: 49 49 💬 |
637 | Bosentan 62.5 mg | 1件: Bosentan Bosentan | 2件: Bosentan
Bosentan
,
Bosentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
638 | BOTOX 100 UNITES ALLERGAN (PR1) | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 2 2 💬 |
639 | Botox 100 UNT Injection | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
640 | Botulinum Toxin Type A 300U | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
641 | Botulinum toxin type B (2500 units / vial) | 1件: Botulinum toxin type B Botulinum toxin type B | 1件: Rimabotulinumtoxin B
Rimabotulinumtoxin B
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 51 51 💬 |
642 | Botulinum Toxin: Xeomin | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 6 6 💬 |
643 | BPLG-003 | - | - | - | - | 1件: 78 78 💬 |
644 | BPS-314d-MR | - | - | - | - | 1件: 86 86 💬 |
645 | BPS804, UX143 | - | - | - | - | 1件: 274 274 💬 |
646 | BPX-501 | - | - | - | - | 3件: 60 60, 285, 326 💬 |
647 | BPX-501 cells | - | - | - | - | 3件: 60 60, 285, 326 💬 |
648 | BPX-501 T cells | - | - | - | - | 4件: 65 65, 284, 285, 326 💬 |
649 | BRAMITOB - 300 MG/4 ML SOLUZIONE DA NEBULIZZARE 56 CONTENITORI MONODOSE 4 ML | - | - | - | - | 1件: 299 299 💬 |
650 | Bramitob 300mg/4ml Nebuliser Solution | - | - | - | - | 1件: 299 299 💬 |
651 | BRAMITOB*NEBUL 28F 300MG/4ML | - | - | - | - | 1件: 299 299 💬 |
652 | BRAMITOB*NEBUL 56F 300MG/4ML | - | - | - | - | 1件: 299 299 💬 |
653 | Bredinin tablet 50mg | 1件: Mizoribine Mizoribine | 1件: Mizoribine
Mizoribine
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 46 46 💬 |
654 | Brepocitinib 5 mg | - | - | - | - | 2件: 96 96, 97 💬 |
655 | Brepocitinib 5mg | - | - | - | - | 1件: 96 96 💬 |
656 | Brivaracetam 50 mg | 1件: Brivaracetam Brivaracetam | 1件: Brivaracetam
Brivaracetam
💬 | 1件: SV2A SV2A 💬 | 1件: ECM-receptor interaction ECM-receptor interaction 💬 | 1件: 309 309 💬 |
657 | BRL-049653 | - | - | - | - | 1件: 46 46 💬 |
658 | BRV 2.5 mg | - | - | - | - | 1件: 309 309 💬 |
659 | BRV 50 mg | - | - | - | - | 1件: 309 309 💬 |
660 | BRX-345 | - | - | - | - | 2件: 2 2, 15 💬 |
661 | BT-11 (500 mg) | - | - | - | - | 1件: 97 97 💬 |
662 | BT-11 1,000 mg | - | - | - | - | 1件: 96 96 💬 |
663 | BT-11 500 mg | - | - | - | - | 2件: 96 96, 97 💬 |
664 | BT-11 500mg | - | - | - | - | 1件: 98 98 💬 |
665 | BT051 3200 mg | - | - | - | - | 1件: 97 97 💬 |
666 | BTT1023 IV Infusion 20 mg/mL, 5 mL Drug Product | - | - | - | - | 1件: 94 94 💬 |
667 | Budenofalk 3mg | - | - | - | - | 2件: 93 93, 97 💬 |
668 | Budenofalk 3mg gastro-resistant capsules | - | - | - | - | 1件: 96 96 💬 |
669 | Budesonide ( Zentacort Capsules 3mg ) | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
670 | Budesonide 0.5 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
671 | Budesonide 0.5 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
672 | Budesonide 0.5mg orodispersible tablet twice daily | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
673 | Budesonide [0.4mg/ml] viscous suspension | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
674 | Budesonide oral suspension [0.2 mg/ml] | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
675 | BUET 0.5 mg | - | - | - | - | 1件: 98 98 💬 |
676 | BUL 0.5 mg | - | - | - | - | 1件: 98 98 💬 |
677 | Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer) | 1件: Bupivacaine Bupivacaine | 1件: Bupivacaine
Bupivacaine
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 46 46 💬 |
678 | Bupivacaine Injection 0.5% | 1件: Bupivacaine Bupivacaine | 1件: Bupivacaine
Bupivacaine
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 168 168 💬 |
679 | Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine | 3件: Bupivacaine Bupivacaine, Clonidine, Epinephrine | 3件: Epinephrine
Epinephrine
,
Clonidine
,
Bupivacaine
💬 | 14件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 16件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 70 70 💬 |
680 | Bupivacaïne HCl 0,125% / Sufentanil 50 µg flacon à 50 ml | 1件: Sufentanil Sufentanil | 1件: Sufentanil
Sufentanil
💬 | 1件: OPRM1 OPRM1 💬 | 3件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬 | 1件: 70 70 💬 |
681 | BUSILVEX - 6 MG/ML - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 10 ML 8 FLACONCINI | 1件: Busulfan Busulfan | 1件: Busulfan
Busulfan
💬 | - | - | 2件: 19 19, 65 💬 |
682 | BUU 0.4mg/ml | - | - | - | - | 1件: 98 98 💬 |
683 | Byetta 5 micrograms | 1件: Exenatide Exenatide | 1件: Exenatide
Exenatide
💬 | 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
684 | C-028380 | - | - | - | - | 1件: 106 106 💬 |
685 | C-Trelin OD Tab(5mg Taltirelin Hydrate) | - | - | - | - | 1件: 18 18 💬 |
686 | Cabaseril, 1,0 mg Tablette | - | - | - | - | 1件: 6 6 💬 |
687 | Cabaseril, 2,0 mg Tablette | - | - | - | - | 1件: 6 6 💬 |
688 | CALCIUM D3 SANDOZ - 1000 MG + 880 U.I. COMPRESSE EFFERVESCENTI 30 COMPRESSE DIVISIBILI | 2件: Calcium Calcium, Calcium carbonate | 2件: Calcium carbonate
Calcium carbonate
,
Calcium carbonate
💬 | - | - | 1件: 274 274 💬 |
689 | CALY-002 | - | - | - | - | 1件: 98 98 💬 |
690 | CAM-3001 | 1件: Mavrilimumab Mavrilimumab | 1件: Mavrilimumab
Mavrilimumab
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 46 46 💬 |
691 | Camoteskimab (CERC-007, AVTX-007, AEVI-007) | - | - | - | - | 1件: 107 107 💬 |
692 | Cannabidiol / Dronabinol capsule 5 mg+2,5 mg | 2件: Cannabidiol Cannabidiol, Dronabinol | 2件: Dronabinol
Dronabinol
,
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 💬 |
693 | Cannabidiol capsule 5 mg | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 💬 |
694 | Cannabidiol Oral Solution, is known as Epidyolex 100 mg/mL oral solution and is the approved name in the EU. Epidiolex (cannabidiol) oral solution is the approved name in the US. | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 158 158 💬 |
695 | Caplacizumab (ALX-0081) | 1件: Caplacizumab Caplacizumab | 1件: Caplacizumab
Caplacizumab
💬 | 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 💬 |
696 | Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081) | 2件: Caplacizumab Caplacizumab, Von Willebrand factor human | 1件: Caplacizumab
Caplacizumab
💬 | 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 💬 |
697 | Carbidopa 27.5 mg | 1件: Carbidopa Carbidopa | 1件: Carbidopa
Carbidopa
💬 | 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
698 | Carbidopa and Levodopa Tablets, USP | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
699 | Care as usual | - | - | - | - | 1件: 15 15 💬 |
700 | CAS # in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid) | - | - | - | - | 1件: 254 254 💬 |
701 | CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4- (trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4- (trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one | - | - | - | - | 1件: 58 58 💬 |
702 | CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4-(trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one | - | - | - | - | 1件: 58 58 💬 |
703 | CAS# in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid) | - | - | - | - | 1件: 254 254 💬 |
704 | CAT-354 | - | - | - | - | 1件: 97 97 💬 |
705 | Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) | - | - | - | - | 1件: 85 85 💬 |
706 | Cayston 75 mg Pulver und Lösungsmittel zur Herstellung einer Lösung für einen Vernebler | 1件: Aztreonam Aztreonam | 1件: Aztreonam
Aztreonam
💬 | - | - | 1件: 299 299 💬 |
707 | CB-01-02 | - | - | - | - | 1件: 97 97 💬 |
708 | CB-01-05-MMX | - | - | - | - | 1件: 97 97 💬 |
709 | CBD - Oral Solution, is known as Epidiolex, and is the approved name in the USA. | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 2件: 140 140, 144 💬 |
710 | CBD - Solution Orale, conosciuto come Epidiolex, questo è il nome approvato negli Stati Uniti | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 156 156 💬 |
711 | CBD soluzione orale nota come Epidyolex e con tale nome è stato approvato in UE | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 156 156 💬 |
712 | CBD-Oral Solution, is known as Epidiolex, and is the approved name in the USA. | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 158 158 💬 |
713 | CBP-307 | - | - | - | - | 1件: 97 97 💬 |
714 | CC-220 0.3 mg Daily | - | - | - | - | 1件: 84 84 💬 |
715 | CC-220 0.6mg Daily | - | - | - | - | 1件: 84 84 💬 |
716 | CC-5013 | - | - | - | - | 2件: 28 28, 96 💬 |
717 | CC-99677 30mg Capsule | - | - | - | - | 1件: 271 271 💬 |
718 | CCP-020 | - | - | - | - | 1件: 36 36 💬 |
719 | CCP-690-550-10 | - | - | - | - | 1件: 107 107 💬 |
720 | CCX 354 | - | - | - | - | 1件: 46 46 💬 |
721 | CCX 354-C | - | - | - | - | 1件: 46 46 💬 |
722 | CCX-354 | 1件: CCX-354 CCX-354 | - | - | - | 1件: 46 46 💬 |
723 | CCX-354-C | 1件: CCX-354 CCX-354 | - | - | - | 1件: 46 46 💬 |
724 | CE 224,535 | - | - | - | - | 1件: 46 46 💬 |
725 | CE-224,535 | - | - | - | - | 1件: 46 46 💬 |
726 | CEBION 500*20CPR MAST 500MG | - | - | - | - | 1件: 10 10 💬 |
727 | CEBION 500MG 20CPR MAST.ARAN | - | - | - | - | 1件: 10 10 💬 |
728 | CellCept 500 mg | - | - | - | - | 1件: 11 11 💬 |
729 | CellCept 500 mg comprimidos recubiertos | - | - | - | - | 1件: 35 35 💬 |
730 | CellCept 500 mg film-coated tablets | 1件: Mycophenolate mofetil Mycophenolate mofetil | 1件: Mycophenolate mofetil
Mycophenolate mofetil
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 11 11 💬 |
731 | CellCept 500 mg tablets | 1件: Mycophenolate mofetil Mycophenolate mofetil | 1件: Mycophenolate mofetil
Mycophenolate mofetil
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 11 11 💬 |
732 | CellCept®500 mg comprimidos | - | - | - | - | 1件: 35 35 💬 |
733 | CellCept®500 mg tablets | 1件: Mycophenolate mofetil Mycophenolate mofetil | 1件: Mycophenolate mofetil
Mycophenolate mofetil
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 11 11 💬 |
734 | Cenerimod 0.5 mg | 1件: Cenerimod Cenerimod | 1件: Cenerimod
Cenerimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 49 49 💬 |
735 | CEP-1347 50mg | 1件: CEP-1347 CEP-1347 | - | - | - | 1件: 6 6 💬 |
736 | CEP-33457 | - | - | - | - | 1件: 49 49 💬 |
737 | CER-001 | - | - | - | - | 1件: 79 79 💬 |
738 | CERC-006 | - | - | - | - | 1件: 278 278 💬 |
739 | Cerezyme 400 Units Powder for concentrate for solution for infusion | 1件: Imiglucerase Imiglucerase | 1件: Imiglucerase
Imiglucerase
💬 | 1件: GBA1 GBA1 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
740 | Certican 0,5 | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 💬 |
741 | Certican 0,5 mg Tabletten | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 💬 |
742 | Certican 0,75mg | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 💬 |
743 | Certican 0,75mg Tabletten | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 💬 |
744 | CFZ533 active - Cohort 3 | - | - | - | - | 1件: 53 53 💬 |
745 | CFZ533 active -Cohort 3 | - | - | - | - | 1件: 53 53 💬 |
746 | Cholecalciferol 10,000 IU | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
747 | Cholecalciferol and C. Xanthorrhiza | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 49 49 💬 |
748 | Chronocort 5mg | - | - | - | - | 1件: 81 81 💬 |
749 | Chronocort® 5 mg | - | - | - | - | 1件: 81 81 💬 |
750 | CHS-0214 | - | - | - | - | 1件: 46 46 💬 |
751 | CIALIS - 20 MG 2 COMPRESSE RIVESTITE CON FILM IN BLISTER USO ORALE | 1件: Tadalafil Tadalafil | 1件: Tadalafil
Tadalafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 75 75 💬 |
752 | Cialis 2.5 mg film-coated tablets | 1件: Tadalafil Tadalafil | 1件: Tadalafil
Tadalafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 113 💬 |
753 | Cialis 5 mg film-coated tablets | 1件: Tadalafil Tadalafil | 1件: Tadalafil
Tadalafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 113 💬 |
754 | Ciliary Neurotrophic Factor Implant NT-501 | 1件: Ciliary neurotrophic factor Ciliary neurotrophic factor | - | - | - | 1件: 90 90 💬 |
755 | CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI | 1件: Certolizumab pegol Certolizumab pegol | 1件: Certolizumab pegol
Certolizumab pegol
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
756 | CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI ALCOOL | 1件: Certolizumab pegol Certolizumab pegol | 1件: Certolizumab pegol
Certolizumab pegol
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
757 | CIPROXIN - 500 MG COMPRESSE RIVESTITE 14 COMPRESSE | - | - | - | - | 1件: 299 299 💬 |
758 | CIPROXIN*6CPR RIV 500MG | - | - | - | - | 1件: 299 299 💬 |
759 | CITICOLIN*1G/4ML IM IV 5 F | - | - | - | - | 1件: 6 6 💬 |
760 | CJNJ-68150420-ZZZ-G001 (ACT- 064992D) | - | - | - | - | 1件: 86 86 💬 |
761 | CJNJ-68150420-ZZZ-G001 (ACT-064992D) | - | - | - | - | 1件: 86 86 💬 |
762 | CJNJ-68150420-ZZZ-G001(ACT-064992D) | - | - | - | - | 1件: 86 86 💬 |
763 | CK-3773274 | - | - | - | - | 1件: 58 58 💬 |
764 | CK-3773274 (10 - 30 mg) | - | - | - | - | 1件: 58 58 💬 |
765 | CK-3773274 (5 - 15 mg) | - | - | - | - | 1件: 58 58 💬 |
766 | CK-3773274 (5 - 20 mg) | - | - | - | - | 1件: 58 58 💬 |
767 | CK-3773274 (5 mg, 10 mg, 15 mg and 20 mg) | - | - | - | - | 1件: 58 58 💬 |
768 | CK-3773274 - Granules in Capsule | - | - | - | - | 1件: 58 58 💬 |
769 | CK-3773274 - Tablets | - | - | - | - | 1件: 58 58 💬 |
770 | CKD-374 5mg Tab. | - | - | - | - | 1件: 46 46 💬 |
771 | CKD-504 | - | - | - | - | 1件: 8 8 💬 |
772 | CKD-506 | - | - | - | - | 1件: 46 46 💬 |
773 | Cladribine 3.5 mg/kg | 1件: Cladribine Cladribine | 1件: Cladribine
Cladribine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
774 | Cladribine 5.25 mg/kg | 1件: Cladribine Cladribine | 1件: Cladribine
Cladribine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
775 | Clarithromycin (Not used as of 4/2020) | 1件: Clarithromycin Clarithromycin | 1件: Clarithromycin
Clarithromycin
💬 | - | - | 1件: 6 6 💬 |
776 | Claritromycin 500mg film coated tablets | - | - | - | - | 1件: 299 299 💬 |
777 | Clarium 50 mg Retardtabletten | - | - | - | - | 1件: 6 6 💬 |
778 | Clipper 30 cpr 5mg R.M. | - | - | - | - | 1件: 97 97 💬 |
779 | CLIPPER*30CPR 5MG R.M. | - | - | - | - | 1件: 97 97 💬 |
780 | Clobazam Tablets 5mg | 1件: Clobazam Clobazam | 1件: Clobazam
Clobazam
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 144 144 💬 |
781 | Clobetasol 0.05% ointment | 1件: Clobetasol Clobetasol | 1件: Clobetasol
Clobetasol
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 39 39 💬 |
782 | Clobetasol 0.05% Topical Ointment | 1件: Clobetasol Clobetasol | 1件: Clobetasol
Clobetasol
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 162 162 💬 |
783 | Clonidine HCl CF 0,150 mg, tabletten | 1件: Clonidine Clonidine | 1件: Clonidine
Clonidine
💬 | 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 78 78 💬 |
784 | CLTX-305 | - | - | - | - | 1件: 235 235 💬 |
785 | Cnp-MS-0601 | - | - | - | - | 1件: 13 13 💬 |
786 | CNSA-001 | - | - | - | - | 1件: 240 240 💬 |
787 | CNT-02 | - | - | - | - | 1件: 160 160 💬 |
788 | CNTO 136 50 mg | - | - | - | - | 1件: 46 46 💬 |
789 | CNTO 1959 + MTX (Group 5) | - | - | - | - | 1件: 46 46 💬 |
790 | CNTO 328 | - | - | - | - | 1件: 331 331 💬 |
791 | CNTO 6785 50 mg | - | - | - | - | 1件: 46 46 💬 |
792 | CNTO 888 5 mg/kg | - | - | - | - | 1件: 85 85 💬 |
793 | Coagulation factor X | 1件: Coagulation factor X human Coagulation factor X human | - | - | - | 1件: 288 288 💬 |
794 | Coagulation factor XIII | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 1件: 288 288 💬 |
795 | Cobitolimod 500 mg | 1件: Cobitolimod Cobitolimod | 1件: Cobitolimod
Cobitolimod
💬 | 1件: TLR9 TLR9 💬 | 9件: African trypanosomiasis African trypanosomiasis, Chagas disease, Herpes simplex virus 1 infection, Malaria, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Salmonella infection, Toll-like receptor signaling pathway, Tuberculosis 💬 | 1件: 97 97 💬 |
796 | Cobitolimod 500mg | 1件: Cobitolimod Cobitolimod | 1件: Cobitolimod
Cobitolimod
💬 | 1件: TLR9 TLR9 💬 | 9件: African trypanosomiasis African trypanosomiasis, Chagas disease, Herpes simplex virus 1 infection, Malaria, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Salmonella infection, Toll-like receptor signaling pathway, Tuberculosis 💬 | 1件: 97 97 💬 |
797 | Coenzym Q10, Ubiquinon, Ubichinon | - | - | - | - | 1件: 5 5 💬 |
798 | Cohort 1 0.225g | - | - | - | - | 1件: 240 240 💬 |
799 | Cohort 1: 1.0 x 10^8 PolyTregs | - | - | - | - | 1件: 35 35 💬 |
800 | Cohort 1:Nilotinib Oral Capsules (150mg or 300mg) | 1件: Nilotinib Nilotinib | 1件: Nilotinib
Nilotinib
💬 | 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 6 6 💬 |
801 | Cohort 2 0.75g | - | - | - | - | 1件: 240 240 💬 |
802 | Cohort 2: 2.5x10^8 PolyTregs | - | - | - | - | 1件: 35 35 💬 |
803 | Cohort 2: hATG, CsA, EPAG Day 14 to Month 3 | 1件: Antilymphocyte immunoglobulin (horse) Antilymphocyte immunoglobulin (horse) | - | - | - | 1件: 60 60 💬 |
804 | Cohort 3 2.25 g | - | - | - | - | 1件: 240 240 💬 |
805 | Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6 | 1件: Antilymphocyte immunoglobulin (horse) Antilymphocyte immunoglobulin (horse) | - | - | - | 1件: 60 60 💬 |
806 | COLIMICINA - 1000000 U/4 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE1 FLACONCINO POLVERE + 1 FIALA SOLVENTE 4 ML | - | - | - | - | 1件: 299 299 💬 |
807 | Colistimethate sodium (BAN, USAN), Colistimethatum natricum, Colistin sodium methanesulfonate | 2件: Colistimethate Colistimethate, Colistin | 1件: Colistin
Colistin
💬 | - | - | 1件: 299 299 💬 |
808 | Collection of blood and urine | - | - | - | - | 1件: 25 25 💬 |
809 | Collection of samples of blood and urine | - | - | - | - | 1件: 167 167 💬 |
810 | Combination Product: EGCG 300 mg + Nintedanib | 2件: Epigallocatechin gallate Epigallocatechin gallate, Nintedanib | 1件: Nintedanib
Nintedanib
💬 | 8件: FGFR1 FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 | 34件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 1件: 85 85 💬 |
811 | Combination Product: EGCG 300 mg + Pirfenidone | 2件: Epigallocatechin gallate Epigallocatechin gallate, Pirfenidone | 1件: Pirfenidone
Pirfenidone
💬 | 6件: CCL2 CCL2, IL10, IL1A, IL1B, IL6, TNF 💬 | 84件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Chemokine signaling pathway, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 85 85 💬 |
812 | Combination Product: L-dopa 35 mg | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
813 | Combivir (zidovudine [AZT] / lamivudine [3TC]) | 2件: Lamivudine Lamivudine, Zidovudine | 2件: Lamivudine
Lamivudine
,
Zidovudine
💬 | - | - | 1件: 265 265 💬 |
814 | Comparator: naproxen tablet 500 mg | 1件: Naproxen Naproxen | 1件: Naproxen
Naproxen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
815 | Compound thrombosis capsule sig: 1.5g/tid | - | - | - | - | 1件: 90 90 💬 |
816 | Compressa effervescente 0,5 mg di budesonide per uso orodispersibile | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
817 | Compressa effervescente 1 mg di budesonide per uso orodispersibile | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
818 | Concentration unit: mg milligram(s) | - | - | - | - | 1件: 254 254 💬 |
819 | Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d | 1件: Conjugated estrogens Conjugated estrogens | 1件: Estrogens, conjugated
Estrogens, conjugated
💬 | - | - | 1件: 49 49 💬 |
820 | Contrast enhanced ultrasound | - | - | - | - | 1件: 96 96 💬 |
821 | Contrast Enhanced Voiding Urosonography with Urodynamic Testing | - | - | - | - | 1件: 118 118 💬 |
822 | Control Group 0.9% Isotonic Saline | - | - | - | - | 1件: 299 299 💬 |
823 | Conventional therapy users for the last 5 years | - | - | - | - | 1件: 271 271 💬 |
824 | COPAXONE - 20 MG/ML SOLUZIONE INIETTABILE IN SIRINGHE PRERIEMPITE 30 SIRINGHE | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 💬 |
825 | COR-003 | - | - | - | - | 1件: 75 75 💬 |
826 | Cord Blood Units | - | - | - | - | 1件: 60 60 💬 |
827 | Cortancyl ® 5 mg | 1件: Prednisone acetate Prednisone acetate | 1件: Prednisone acetate
Prednisone acetate
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 💬 |
828 | Cortef 5 mg | 1件: Hydrocortisone cypionate Hydrocortisone cypionate | 1件: Hydrocortisone cypionate
Hydrocortisone cypionate
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 83 83 💬 |
829 | Corticosteroids for Systemic Use | - | - | - | - | 1件: 41 41 💬 |
830 | Corticotrophin 80 units | 1件: Corticotropin Corticotropin | 1件: Corticotropin
Corticotropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 46 46 💬 |
831 | COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 1 SIRINGA PRERIEMPITA | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 107 107 💬 |
832 | COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 2 SIRINGHE PRERIEMPITE | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 107 107 💬 |
833 | Cosentyx 300 mg solution for injection in pre-filled syringe | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 41 41 💬 |
834 | Cosentyx 300mg solution for injection in pre-filled syringe | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 41 41 💬 |
835 | CosmoFer 50mg/ml solution for infusion or injection | - | - | - | - | 2件: 96 96, 97 💬 |
836 | COVID-19 mRNA vaccine Moderna (CX-024414) | - | - | - | - | 4件: 13 13, 46, 51, 299 💬 |
837 | Cozaar 50 | 1件: Losartan Losartan | 1件: Losartan
Losartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 167 167 💬 |
838 | COZAAR 50 mg comprimidos recubierto con pelicula | 1件: Losartan Losartan | 1件: Losartan
Losartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 179 179 💬 |
839 | COZAAR INICIO 12,5 mg comprimidos recubiertos con pelicula | 1件: Losartan Losartan | 1件: Losartan
Losartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 167 167 💬 |
840 | CP 690,550 | - | - | - | - | 1件: 46 46 💬 |
841 | CP- 690 550 | - | - | - | - | 1件: 97 97 💬 |
842 | CP-195,543 | - | - | - | - | 1件: 46 46 💬 |
843 | CP-690, 550 - 10 | - | - | - | - | 1件: 46 46 💬 |
844 | CP-690, 550-10 | - | - | - | - | 2件: 97 97, 107 💬 |
845 | CP-690,500 5 mg | - | - | - | - | 1件: 97 97 💬 |
846 | CP-690,55-10 | - | - | - | - | 1件: 46 46 💬 |
847 | CP-690,550 | - | - | - | - | 5件: 46 46, 96, 97, 107, 271 💬 |
848 | CP-690,550 (tasocitinib) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
849 | CP-690,550 (tofacitinib) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 107 💬 |
850 | CP-690,550 + methotrexate | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
851 | CP-690,550 10 mg | - | - | - | - | 1件: 97 97 💬 |
852 | CP-690,550 – 10 | - | - | - | - | 1件: 46 46 💬 |
853 | CP-690,550-10 | - | - | - | - | 5件: 46 46, 96, 97, 107, 271 💬 |
854 | CP-690-550 | - | - | - | - | 1件: 46 46 💬 |
855 | CP-690-550-10 | - | - | - | - | 1件: 107 107 💬 |
856 | CP-690-550-10 (DMID D1600180) | - | - | - | - | 1件: 107 107 💬 |
857 | CP690,550 | - | - | - | - | 2件: 46 46, 97 💬 |
858 | CR 3 | - | - | - | - | 1件: 46 46 💬 |
859 | CR845 1.0 mg | - | - | - | - | 1件: 93 93 💬 |
860 | CRC3357, ZK-355322, Leukoton | - | - | - | - | 1件: 299 299 💬 |
861 | CRD-TMH-001 | - | - | - | - | 1件: 113 113 💬 |
862 | Creon 10.000, hårde enterokapsler | - | - | - | - | 1件: 299 299 💬 |
863 | Creon 25.000, hårde enterokapsler | - | - | - | - | 1件: 299 299 💬 |
864 | Creon 40.000, hårde enterokapsler | - | - | - | - | 1件: 299 299 💬 |
865 | Creon® 25,000 | - | - | - | - | 1件: 299 299 💬 |
866 | CRx-102 (2.7/360) | - | - | - | - | 1件: 46 46 💬 |
867 | CS-0777 tablets | - | - | - | - | 1件: 13 13 💬 |
868 | CSTI-500 | - | - | - | - | 1件: 193 193 💬 |
869 | CTNS-RD-04 or CTNS-RD-04-LB (where the suffix -LB stands for LentiBOOST) | - | - | - | - | 1件: 19 19 💬 |
870 | Cudetaxestat (BLD-0409) | - | - | - | - | 1件: 85 85 💬 |
871 | Curcuma Longa Extract cpl formaat 00 23,2 x 8,5 mm 723 mg | 1件: Turmeric Turmeric | - | - | - | 1件: 299 299 💬 |
872 | CVT-301 | - | - | - | - | 1件: 6 6 💬 |
873 | CVT-301 (Dose Level 1) | - | - | - | - | 1件: 6 6 💬 |
874 | CVT-301 (Dose Level 2) | - | - | - | - | 1件: 6 6 💬 |
875 | CVT-301 35mg | - | - | - | - | 1件: 6 6 💬 |
876 | CVT-301 50mg | - | - | - | - | 1件: 6 6 💬 |
877 | CVT-301 High Dose | - | - | - | - | 1件: 6 6 💬 |
878 | CVT-301 Low Dose | - | - | - | - | 1件: 6 6 💬 |
879 | CVT-301, LIP | - | - | - | - | 1件: 6 6 💬 |
880 | CVXL-0107 | - | - | - | - | 1件: 6 6 💬 |
881 | CX-016492 | - | - | - | - | 1件: 245 245 💬 |
882 | CX-017950 | - | - | - | - | 1件: 245 245 💬 |
883 | Cyclophosphamide 30 | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 3件: 65 65, 285, 326 💬 |
884 | Cyclophosphamide 50mg | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 1件: 60 60 💬 |
885 | Cyclophosphamide 50Mg Oral Tablet | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 1件: 162 162 💬 |
886 | Cyclophosphamide Dose Level 3 | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 2件: 65 65, 284 💬 |
887 | Cyclophosphamidum 500 mg | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 1件: 44 44 💬 |
888 | Cyclosporine (USAN) | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 97 97 💬 |
889 | Cyclosporine 0.09% Ophthalmic Solution | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 53 53 💬 |
890 | Cyclosporine 5 mg/kg bid days 0-14 | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 38 38, 39 💬 |
891 | CYSTADROPS 0.55% eye drops, solution | 1件: Cysteamine Cysteamine | 1件: Cysteamine
Cysteamine
💬 | - | - | 1件: 19 19 💬 |
892 | Cystagon 50mg | 1件: Cysteamine Cysteamine | 1件: Cysteamine
Cysteamine
💬 | - | - | 1件: 19 19 💬 |
893 | Cystic Fibrosis Ready to Use Supplemental Food | - | - | - | - | 1件: 299 299 💬 |
894 | Cystoscopic injection of Botox into the urinary bladder | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 6 6 💬 |
895 | Cápsulas de Laquinimod 0.6 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
896 | Células mesenquimales troncales adultas alogénicas de médula ósea no expandidas(ref cruzada PEI nº 12-088) | - | - | - | - | 1件: 274 274 💬 |
897 | D-glucitol, 1-deoxy-1-(methylamino)-, 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1) | 1件: Sorbitol Sorbitol | 1件: Sorbitol solution
Sorbitol solution
💬 | - | - | 1件: 28 28 💬 |
898 | D-glucitol, 1-deoxy-1-(methylamino)-,2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1) | 1件: Sorbitol Sorbitol | 1件: Sorbitol solution
Sorbitol solution
💬 | - | - | 1件: 28 28 💬 |
899 | D.3.2 Product code where applicable13: | - | - | - | - | 1件: 193 193 💬 |
900 | D.3.6.2 - dose massima specificare: giornaliera | - | - | - | - | 1件: 86 86 💬 |
901 | D.3.6.2.1 - valore: 45 / 0.45 mg/ml | - | - | - | - | 1件: 97 97 💬 |
902 | D.3.6.2.1 - valore: 5 o 10 mg/kg | - | - | - | - | 1件: 97 97 💬 |
903 | D9421-C capsule 3 mg | - | - | - | - | 1件: 96 96 💬 |
904 | Dacepton 5 mg/ml | - | - | - | - | 1件: 6 6 💬 |
905 | Dacepton 5 mg/ml infuusioneste, liuos | - | - | - | - | 1件: 6 6 💬 |
906 | Dacortín 2,5mg | - | - | - | - | 1件: 222 222 💬 |
907 | Dacortín 30mg | - | - | - | - | 1件: 222 222 💬 |
908 | Dacortín 5mg | - | - | - | - | 1件: 222 222 💬 |
909 | Dalfampridine-ER 5mg | 1件: Dalfampridine Dalfampridine | 1件: Dalfampridine
Dalfampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
910 | Daratumumab coformulato con ialuronidasi umana ricombinante (rHuPH20) | 1件: Daratumumab Daratumumab | 1件: Daratumumab
Daratumumab
💬 | 1件: CD38 CD38 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Hematopoietic cell lineage, Metabolic pathways, Nicotinate and nicotinamide metabolism, Oxytocin signaling pathway, Pancreatic secretion, Salivary secretion 💬 | 1件: 28 28 💬 |
911 | DAS-001 | - | - | - | - | 1件: 11 11 💬 |
912 | Dazucorilant 300 mg | - | - | - | - | 1件: 2 2 💬 |
913 | DECORTIN (PREDNISONA) 5 MG COMPRIMIDOS | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
914 | Decortin 5 mg | - | - | - | - | 1件: 96 96 💬 |
915 | Decortin 5mg tablets | - | - | - | - | 1件: 46 46 💬 |
916 | Decortin H 50 mg | - | - | - | - | 1件: 97 97 💬 |
917 | Decortin H 5mg | - | - | - | - | 1件: 97 97 💬 |
918 | Defanyl 50 and 100 mg | - | - | - | - | 1件: 46 46 💬 |
919 | Deferiprone 30mg | 1件: Deferiprone Deferiprone | 1件: Deferiprone
Deferiprone
💬 | - | - | 1件: 6 6 💬 |
920 | Dekristol 20.000 ie | - | - | - | - | 1件: 96 96 💬 |
921 | Deltacortene 20 cpr 5mg | - | - | - | - | 1件: 97 97 💬 |
922 | DELTACORTENE*20CPR 5MG | - | - | - | - | 3件: 49 49, 97, 113 💬 |
923 | DEPAKINE CHRONO 500 mg | - | - | - | - | 1件: 233 233 💬 |
924 | DEPAKINE CHRONO® 500 mg | - | - | - | - | 1件: 233 233 💬 |
925 | DEPALGOS*20+325MG 28CPR RP | - | - | - | - | 1件: 46 46 💬 |
926 | Depot leuprolide acetate 3.75 mg | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 51 51 💬 |
927 | Descartes-08 | - | - | - | - | 1件: 11 11 💬 |
928 | Desmotabs® 0,2 mg Tabletten | - | - | - | - | 1件: 6 6 💬 |
929 | Desmotabs® 0,2mg Tabletten | - | - | - | - | 1件: 6 6 💬 |
930 | Dexamethasone (50mg 1dd6, 3 consecutive days/month) | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 35 35 💬 |
931 | Dexamethasone 0,1 mg Tablets | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
932 | Dexamethasone 0,5mg | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 84 84 💬 |
933 | Dexamethasone 0.5mg Tablet | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
934 | Dexamethasone 0.5mg/5ml solution | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 35 35, 162 💬 |
935 | Dexamethasone 0.5mg/5ml solution in Mucolox™ | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 35 35, 162 💬 |
936 | Dexamethasone 1,5 mg Tablets | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
937 | Dexmedetomidine 3 | 1件: Dexmedetomidine Dexmedetomidine | 1件: Dexmedetomidine
Dexmedetomidine
💬 | 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 280 280 💬 |
938 | Dextran Sodium Sulfur Salt 5, Mw 5 kDa. a type of Low Molecular Weight Dextran Sulfate (LMW-DS) | 2件: Dextran Dextran, Sulfate ion | 1件: Dextran 1
Dextran 1
💬 | - | - | 1件: 2 2 💬 |
939 | Dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg | 3件: Dextromethorphan Dextromethorphan, Quinidine, Sulfate ion | 2件: Dextromethorphan
Dextromethorphan
,
Quinidine
💬 | 11件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SIGMAR1 💬 | 22件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, Taste transduction, cAMP signaling pathway 💬 | 2件: 2 2, 13 💬 |
940 | Dextrose, 5% in Water | 2件: Dextrose, unspecified form Dextrose, unspecified form, Water | 1件: Water
Water
💬 | - | - | 1件: 65 65 💬 |
941 | DIBASE*IM OS 2F 1ML 300000UI/M | - | - | - | - | 1件: 46 46 💬 |
942 | Diclofenac 50 milligrams | 1件: Diclofenac Diclofenac | 1件: Diclofenac
Diclofenac
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 💬 |
943 | Digoxin 0.25 mg | 1件: Digoxin Digoxin | 1件: Digoxin
Digoxin
💬 | 4件: ATP1A1 ATP1A1, ATP1A2, ATP1A3, ATP1A4 💬 | 18件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Bile secretion, Carbohydrate digestion and absorption, Cardiac muscle contraction, Endocrine and other factor-regulated calcium reabsorption, Gastric acid secretion, Insulin secretion, Mineral absorption, Pancreatic secretion, Protein digestion and absorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Thyroid hormone signaling pathway, Thyroid hormone synthesis, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 46 46 💬 |
944 | Diosminex, 500 mg, tabletki powlekane | - | - | - | - | 1件: 265 265 💬 |
945 | DIURF-006 | - | - | - | - | 1件: 81 81 💬 |
946 | Dl-3-n-butylphthalide (NBP) | 1件: Butylphthalide Butylphthalide | - | - | - | 1件: 22 22 💬 |
947 | Docosahexaenoic acid administration: 50 mg/kg/day during 12 months | 1件: Doconexent Doconexent | - | - | - | 1件: 299 299 💬 |
948 | Dolutegravir 50 MG | 1件: Dolutegravir Dolutegravir | 1件: Dolutegravir
Dolutegravir
💬 | - | - | 1件: 265 265 💬 |
949 | Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO] | 2件: Dolutegravir Dolutegravir, Lamivudine | 2件: Lamivudine
Lamivudine
,
Dolutegravir
💬 | - | - | 1件: 265 265 💬 |
950 | Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO] | 4件: Doravirine Doravirine, Lamivudine, Tenofovir, Tenofovir disoproxil | 3件: Lamivudine
Lamivudine
,
Tenofovir
,
Doravirine
💬 | - | - | 1件: 265 265 💬 |
951 | Dose level 3 | - | - | - | - | 1件: 46 46 💬 |
952 | Dose-Establishing Study 1 Niacin 500mg | 1件: Niacin Niacin | 1件: Niacin
Niacin
💬 | - | - | 1件: 78 78 💬 |
953 | Dose-Establishing Study 2 Niacin 500mg | 1件: Niacin Niacin | 1件: Niacin
Niacin
💬 | - | - | 1件: 78 78 💬 |
954 | Dotarem 0,5mmol/ml, | 1件: Gadoteric acid Gadoteric acid | 1件: Gadoteric acid
Gadoteric acid
💬 | - | - | 1件: 13 13 💬 |
955 | Dr. Reddy’s Rituximab (DRL_RI) 500mg | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
956 | Dronabinol capsule 2,5 mg | 1件: Dronabinol Dronabinol | 1件: Dronabinol
Dronabinol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 💬 |
957 | Dronabinol capsule 2.5. mg | 1件: Dronabinol Dronabinol | 1件: Dronabinol
Dronabinol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 2件: 46 46, 271 💬 |
958 | Drug-Carbamazepine (Tegretol XR) | 1件: Carbamazepine Carbamazepine | 1件: Carbamazepine
Carbamazepine
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 231 231 💬 |
959 | DS-5141b | - | - | - | - | 1件: 113 113 💬 |
960 | Dulaglutide 0.75Mg/0.5Ml Inj Pen | 1件: Dulaglutide Dulaglutide | 1件: Dulaglutide
Dulaglutide
💬 | 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
961 | Dummy Qing Re Huo Xue (QRHX) | - | - | - | - | 1件: 46 46 💬 |
962 | DUOC-01 | - | - | - | - | 3件: 13 13, 19, 20 💬 |
963 | Duodopa LD/CD 20/5 mg/mL | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
964 | Duodopa, 20 mg/ml + 5 mg/ml, intestinal gel | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
965 | Duodopa, levodopa 20 mg/ml + carbidopa 5 mg/ml, intestinal gel | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
966 | Dupilumab 300Mg Solution for Injection | 1件: Dupilumab Dupilumab | 1件: Dupilumab
Dupilumab
💬 | 1件: IL4R IL4R 💬 | 8件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | 1件: 51 51 💬 |
967 | DYSPORT*SC IM 2FL 500U | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
968 | E5501 40 mg 2 x 20-mg tablets, orally, fasted | - | - | - | - | 1件: 63 63 💬 |
969 | E5501 40 mg 2 x 20-mg tablets, orally, with food | - | - | - | - | 1件: 63 63 💬 |
970 | E5501 40mg 2 x 20-mg tablets, orally, fasted | - | - | - | - | 1件: 63 63 💬 |
971 | E6011 5 mg/kg | - | - | - | - | 1件: 96 96 💬 |
972 | Ebetrex 15 mg = 0,75 ml, oplossing voor injectie in voorgevulde injectiespuit 20 mg/ml | - | - | - | - | 1件: 96 96 💬 |
973 | EC 3.1.3.1 | - | - | - | - | 1件: 46 46 💬 |
974 | EDG-5506 | - | - | - | - | 1件: 113 113 💬 |
975 | EDG-5506 Dose 1 | - | - | - | - | 1件: 113 113 💬 |
976 | EDG-5506 Dose 2 | - | - | - | - | 1件: 113 113 💬 |
977 | EDG-5506 Dose 3 | - | - | - | - | 1件: 113 113 💬 |
978 | EDG-5506 Dose 4 | - | - | - | - | 1件: 113 113 💬 |
979 | EDG-5506 Dose 5 | - | - | - | - | 1件: 113 113 💬 |
980 | EDP-305 | - | - | - | - | 1件: 93 93 💬 |
981 | EDP-305 Dose 1 | - | - | - | - | 1件: 93 93 💬 |
982 | EDP-305 Dose 2 | - | - | - | - | 1件: 93 93 💬 |
983 | EDS-EP dose range of ~5-10 mg DSP/infusion | - | - | - | - | 1件: 65 65 💬 |
984 | Efexor XL 75 mg | - | - | - | - | 1件: 46 46 💬 |
985 | Efexor XL 75 mg (venlafaxine) | 1件: Venlafaxine Venlafaxine | 1件: Venlafaxine
Venlafaxine
💬 | 2件: SLC6A2 SLC6A2, SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 46 46 💬 |
986 | Efficacy of Gammagard subcutaneously at Week 36 | - | - | - | - | 1件: 65 65 💬 |
987 | Efficacy of Gammagard subdermally at Week 36 | - | - | - | - | 1件: 65 65 💬 |
988 | EFI/ACT-385781A | - | - | - | - | 1件: 86 86 💬 |
989 | Efmody 5 mg modified release hard capsules | 2件: Hydrocortisone Hydrocortisone, Manganese citrate | 1件: Hydrocortisone
Hydrocortisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
990 | Efzofitimod 3 mg/kg | - | - | - | - | 1件: 84 84 💬 |
991 | Efzofitimod 5 mg/kg | - | - | - | - | 1件: 84 84 💬 |
992 | EHP-101 50 mg BID | - | - | - | - | 1件: 13 13 💬 |
993 | EHP-101 50 mg OD | - | - | - | - | 1件: 13 13 💬 |
994 | Elaprase_0.5mg/kg | - | - | - | - | 1件: 19 19 💬 |
995 | Elelyso 60 units/kg | 1件: Taliglucerase alfa Taliglucerase alfa | 1件: Taliglucerase alfa
Taliglucerase alfa
💬 | 1件: GBA1 GBA1 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
996 | Elexacaftor 100 MG / Ivacaftor 75 MG / Tezacaftor 50 MG, 2 tablets each morning + Ivacaftor 150 mg one tablet each evening | 3件: Elexacaftor Elexacaftor, Ivacaftor, Tezacaftor | 3件: Ivacaftor
Ivacaftor
,
Tezacaftor
,
Elexacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
997 | Eltrombopag 12.5 mg | 1件: Eltrombopag Eltrombopag | - | - | - | 1件: 60 60 💬 |
998 | ELX-02 | 1件: ELX-02 ELX-02 | - | - | - | 3件: 19 19, 218, 299 💬 |
999 | EMD 525797 | - | - | - | - | 1件: 51 51 💬 |
1000 | EMEA/H/C/000109 | - | - | - | - | 1件: 203 203 💬 |
1001 | EMEA/H/C/000125 | - | - | - | - | 1件: 299 299 💬 |
1002 | EMEA/H/C/000240 | - | - | - | - | 2件: 96 96, 97 💬 |
1003 | EMEA/H/C/000481 | - | - | - | - | 1件: 97 97 💬 |
1004 | EMEA/H/C/000638 | - | - | - | - | 1件: 113 113 💬 |
1005 | EMEA/H/C/000701 | - | - | - | - | 1件: 50 50 💬 |
1006 | EMEA/H/C/000712 | - | - | - | - | 1件: 227 227 💬 |
1007 | EMEA/H/C/002576 | - | - | - | - | 1件: 96 96 💬 |
1008 | EMEA/H/C/002778 | - | - | - | - | 1件: 96 96 💬 |
1009 | EMEA/H/C/004214 | - | - | - | - | 1件: 46 46 💬 |
1010 | EMSELEX 7,5 mg Retardtabletten | 1件: Darifenacin Darifenacin | 1件: Darifenacin
Darifenacin
💬 | 1件: CHRM3 CHRM3 💬 | 11件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction 💬 | 1件: 13 13 💬 |
1011 | EnalHexal®, 5 mg | - | - | - | - | 1件: 113 113 💬 |
1012 | ENB-0040 | - | - | - | - | 1件: 172 172 💬 |
1013 | ENBREL - 50 MG POLV SOLUZ INIET SOTTOC. POLV. FLAC VETRO SOLV. SIRI. VET. SOLV 1 ML (50 MG/ML) 12 FLAC+12 SIRI. PRE+12 AGHI+12 ADAT PER FLAC+24 TAMP. PRE INIEZ | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1014 | ENBREL - 50 MG SOLUZIONE INIETTABILE IN SIRINGA (VETRO DA 1 ML) PRERIEMPITA - USO SOTTOCUTANEO 12 SIRINGHE PRERIEMPITE + 24 TAMPONI IMBEVUTI DI ALCOL | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1015 | ENBREL 25 mg/ml polvo y disolvente para solución inyectable para uso pediátrico | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 107 107 💬 |
1016 | Enbrel 50 mg | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1017 | Enbrel 50 mg powder and solvent for solution for injection | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1018 | ENBREL 50 mg solución inyectable en jeringas precargadas | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 107 107 💬 |
1019 | Enbrel 50 mg solution for injection in pre-filled syringe | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1020 | Enbrel 50mg PFS | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1021 | Enbrel 50mg pre-filled pen | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1022 | Enbrel 50mg pre-filled syringe | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1023 | ENBREL*SC 4FL 50MG+4SIR+4AGHI+ | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1024 | ENBREL*SC 4SIR 25MG 0,5ML+8TAM | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1025 | ENBREL*SC 4SIR 50MG 1ML+8TAMP | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1026 | Enbrel® 50 mg Solution for Injection in Pre-filled Syringe | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1027 | Encorton, 5 mg, tablets | - | - | - | - | 1件: 46 46 💬 |
1028 | End-of-life nursing education consortium-pediatric palliative care as web based-training plus usual care | - | - | - | - | 2件: 113 113, 299 💬 |
1029 | ENDOPROST - 0.05 MG/0.5 ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FIALA | - | - | - | - | 1件: 51 51 💬 |
1030 | ENDOPROST 0,05MG/0,5ML 1F | - | - | - | - | 1件: 51 51 💬 |
1031 | ENDOPROST 50*INFUS 1F 0,050MG/ | - | - | - | - | 1件: 51 51 💬 |
1032 | Endothelin-3 | - | - | - | - | 1件: 86 86 💬 |
1033 | ENDOXAN BAXTER*50CPR RIV 50MG | - | - | - | - | 1件: 222 222 💬 |
1034 | Endoxan® 500 mg | - | - | - | - | 1件: 44 44 💬 |
1035 | ENT-01 | - | - | - | - | 1件: 6 6 💬 |
1036 | EnteraBio's Oral Parathyroid Hormone (1-34) | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
1037 | Entocort EC® 3 mg | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
1038 | ENTYVIO - 300 MG - POLVERE PE RCONCENTRATO PER SOLUZIONE PER INFU | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 💬 |
1039 | ENTYVIO - 300 MG - POLVERE PE RCONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) (20ML) - 1 FLACONCINO | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 2件: 96 96, 97 💬 |
1040 | ENTYVIO - 300 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) (20ML) - 1 FLACONCINO | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 💬 |
1041 | Entyvio 300 mg | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 💬 |
1042 | Entyvio 300mg | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 💬 |
1043 | Eosinophilic Esophagitis (EoE) Food introduction-3rd dose | - | - | - | - | 1件: 98 98 💬 |
1044 | Epanova™ (Omega-3 Free Fatty Acids) | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 1件: 96 96 💬 |
1045 | EPARMEFOLIN 30 CPR 0,1/0,5MG | - | - | - | - | 1件: 13 13 💬 |
1046 | EPAX 6000 EE 1000mg (0.6 gr DHA+EPA) | - | - | - | - | 1件: 46 46 💬 |
1047 | EPI-589 | 1件: EPI-589 EPI-589 | - | - | - | 2件: 2 2, 6 💬 |
1048 | Epigallocatechin-3-gallate | 2件: Epigallocatechin Epigallocatechin, Epigallocatechin gallate | - | - | - | 3件: 8 8, 28, 85 💬 |
1049 | Epigallocatechin-3-gallate (EGCG) | 2件: Epigallocatechin Epigallocatechin, Epigallocatechin gallate | - | - | - | 2件: 28 28, 85 💬 |
1050 | Epilim Chrono 300 Controlled Released tablets | - | - | - | - | 1件: 256 256 💬 |
1051 | Epilim Chrono 500 Controlled Released tablets | - | - | - | - | 1件: 256 256 💬 |
1052 | Epithelial sheet generated from transduced autologous keratinocytes using pCCL-INVO-SP | - | - | - | - | 1件: 160 160 💬 |
1053 | EPREX IV SC 1FL 1ML 40000 UI | - | - | - | - | 1件: 2 2 💬 |
1054 | Equfina 50 mg | - | - | - | - | 1件: 6 6 💬 |
1055 | ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan) | 4件: Bosentan Bosentan, Macitentan, Sildenafil, Tadalafil | 5件: Bosentan
Bosentan
,
Tadalafil
,
Bosentan
,
Sildenafil
,
Macitentan
💬 | 3件: EDNRA EDNRA, EDNRB, PDE5A 💬 | 11件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
1056 | ERB-041 | - | - | - | - | 3件: 46 46, 96, 226 💬 |
1057 | ESBRIET - 267 MG - CAPSULA RIGIDA - USO ORALE - FLACONE (HDPE) 270 CAPSULE | 1件: Pirfenidone Pirfenidone | 1件: Pirfenidone
Pirfenidone
💬 | 6件: CCL2 CCL2, IL10, IL1A, IL1B, IL6, TNF 💬 | 84件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Chemokine signaling pathway, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 85 85 💬 |
1058 | Etanercept (50mg per week) | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 💬 |
1059 | Etanercept (50mg per week, for 2 weeks) | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 💬 |
1060 | Etanercept (50mg per week, for 4 weeks) | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 💬 |
1061 | Etanercept 50 mg sc day 0 and day 3 | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 38 38, 39 💬 |
1062 | Etanercept 50mg | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1063 | Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester (**See other 2 names below) | - | - | - | - | 1件: 6 6 💬 |
1064 | EU Orphan Designation Number EU/3/02/120 | - | - | - | - | 1件: 299 299 💬 |
1065 | EU/1/03/256/001 | - | - | - | - | 1件: 107 107 💬 |
1066 | EU/1/03/268/002 | - | - | - | - | 1件: 96 96 💬 |
1067 | EU/1/06/362/003: 5µg (1 pen) | - | - | - | - | 1件: 193 193 💬 |
1068 | EU/1/07/389/001 | - | - | - | - | 1件: 107 107 💬 |
1069 | EU/1/08/454/001-002, EU/1/08/454/005-007 | - | - | - | - | 1件: 13 13 💬 |
1070 | EU/1/14/980/002 | - | - | - | - | 1件: 269 269 💬 |
1071 | EU/1/14/980/003 | - | - | - | - | 1件: 269 269 💬 |
1072 | EU/1/95/003/005-010 | - | - | - | - | 1件: 13 13 💬 |
1073 | EU/1/97/033/002 | - | - | - | - | 1件: 13 13 💬 |
1074 | EU/1/98/063/001-003 | - | - | - | - | 1件: 13 13 💬 |
1075 | EU/1/98/063/004-006 | - | - | - | - | 1件: 13 13 💬 |
1076 | EU/1/99/116/003 | - | - | - | - | 1件: 96 96 💬 |
1077 | EU/1/99/126/001 | - | - | - | - | 1件: 107 107 💬 |
1078 | EU/1/99/126/017 | - | - | - | - | 1件: 46 46 💬 |
1079 | EU/1/99/126/020 | - | - | - | - | 1件: 46 46 💬 |
1080 | EU/3/13/1208 orphan | - | - | - | - | 1件: 301 301 💬 |
1081 | EU1/97/031-032 | - | - | - | - | 1件: 18 18 💬 |
1082 | EU1/97/031/031-032 | - | - | - | - | 1件: 18 18 💬 |
1083 | EUR-1008 25,000 Units | - | - | - | - | 1件: 299 299 💬 |
1084 | EVP-0334 | - | - | - | - | 1件: 127 127 💬 |
1085 | Exelon 1,5 mg Hartkapseln | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 5 5 💬 |
1086 | Exelon 3,0 mg Hartkapseln | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 5 5 💬 |
1087 | Exelon 6,0 mg Hartkapseln | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 5 5 💬 |
1088 | Exelon 9.5 mg/24 h transdermal patch | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 6 6 💬 |
1089 | Exenatide 5 micrograms | 1件: Exenatide Exenatide | 1件: Exenatide
Exenatide
💬 | 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1090 | EXG001-307 injection | - | - | - | - | 1件: 3 3 💬 |
1091 | EXN-32 | - | - | - | - | 1件: 6 6 💬 |
1092 | EXN-32 (CARBIDOPA E LEVODOPA) | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1093 | Exondys 51 | 1件: Eteplirsen Eteplirsen | 1件: Eteplirsen
Eteplirsen
💬 | 1件: DMD DMD 💬 | 4件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Viral myocarditis 💬 | 1件: 113 113 💬 |
1094 | EXONDYS 51™ | 1件: Eteplirsen Eteplirsen | 1件: Eteplirsen
Eteplirsen
💬 | 1件: DMD DMD 💬 | 4件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Viral myocarditis 💬 | 1件: 113 113 💬 |
1095 | Experimental: Seladelpar / MBX-8025 50 mg | 1件: Seladelpar Seladelpar | 1件: Seladelpar
Seladelpar
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 93 93 💬 |
1096 | Exposure to one or more disease-modifying drug(s)(DMDs) used to treat MS | - | - | - | - | 1件: 13 13 💬 |
1097 | EZ-2053 5mg/kg | - | - | - | - | 2件: 85 85, 299 💬 |
1098 | EZOGABINE (US ONLY) | 1件: Ezogabine Ezogabine | 1件: Ezogabine
Ezogabine
💬 | 5件: KCNQ1 KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5 💬 | 6件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Cholinergic synapse, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Vibrio cholerae infection 💬 | 1件: 144 144 💬 |
1099 | F-18 3F4AP | - | - | - | - | 1件: 13 13 💬 |
1100 | FABRAZYME - 35 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE ENDOVENOSA 1 FLACONCINO | 1件: Agalsidase beta Agalsidase beta | 1件: Agalsidase beta
Agalsidase beta
💬 | 1件: GLA GLA 💬 | 6件: Galactose metabolism Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
1101 | Fabrazyme 35 mg | 1件: Agalsidase beta Agalsidase beta | 1件: Agalsidase beta
Agalsidase beta
💬 | 1件: GLA GLA 💬 | 6件: Galactose metabolism Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
1102 | Fabrazyme 5 mg | 1件: Agalsidase beta Agalsidase beta | 1件: Agalsidase beta
Agalsidase beta
💬 | 1件: GLA GLA 💬 | 6件: Galactose metabolism Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
1103 | FACTOR X | 1件: Coagulation factor X human Coagulation factor X human | - | - | - | 1件: 288 288 💬 |
1104 | Factor XIIa antagonist monoclonal antibody | - | - | - | - | 1件: 85 85 💬 |
1105 | Factor XIII | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 3件: 51 51, 97, 288 💬 |
1106 | Factor XIII Concentrate (Human) | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 1件: 288 288 💬 |
1107 | Factor XIII Concentrate (Human), Pasteurized | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 1件: 288 288 💬 |
1108 | FAMPYRA - 10 MG - COMPRESSA A RILASCIO PROLUNGATO - USO ORALE - FLACONE (HDPE) 56 COMPRESSE (4 FLACONI DA 14) | 1件: Dalfampridine Dalfampridine | 1件: Dalfampridine
Dalfampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
1109 | FANG(30) | - | - | - | - | 1件: 46 46 💬 |
1110 | FANHDI 100 UI | - | - | - | - | 1件: 288 288 💬 |
1111 | Fanhdi 100 UI FVIII-120 UI FVW | - | - | - | - | 1件: 288 288 💬 |
1112 | FANHDI 25 UI | - | - | - | - | 1件: 288 288 💬 |
1113 | Fanhdi 25 UI FVIII-30 UI FVW | - | - | - | - | 1件: 288 288 💬 |
1114 | FANHDI 50 UI | - | - | - | - | 1件: 288 288 💬 |
1115 | Fanhdi 50 UI FVIII-60 UI FVW | - | - | - | - | 1件: 288 288 💬 |
1116 | FANHDI*INF FL 500UI+SIR SOLV+S | - | - | - | - | 1件: 288 288 💬 |
1117 | Fasudil (WP-0512) | 1件: Fasudil Fasudil | 1件: Fasudil
Fasudil
💬 | 2件: ROCK1 ROCK1, ROCK2 💬 | 23件: Axon guidance Axon guidance, Chemokine signaling pathway, Focal adhesion, Human cytomegalovirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, MicroRNAs in cancer, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Proteoglycans in cancer, Regulation of actin cytoskeleton, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, TGF-beta signaling pathway, Tight junction, Vascular smooth muscle contraction, Wnt signaling pathway, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 2 2 💬 |
1118 | FCX-007 | - | - | - | - | 1件: 36 36 💬 |
1119 | FCX-013 | - | - | - | - | 1件: 51 51 💬 |
1120 | Fenofibrate Combined With Ursodeoxycholic Acid | 2件: Fenofibrate Fenofibrate, Ursodeoxycholic acid | 2件: Fenofibrate
Fenofibrate
,
Ursodiol
💬 | 2件: NR1H4 NR1H4, PPARA 💬 | 11件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 💬 |
1121 | Ferriprox 500 mg | 1件: Deferiprone Deferiprone | 1件: Deferiprone
Deferiprone
💬 | - | - | 1件: 6 6 💬 |
1122 | FERRIPROX*100CPR RIV 500MG | 1件: Deferiprone Deferiprone | 1件: Deferiprone
Deferiprone
💬 | - | - | 1件: 120 120 💬 |
1123 | Ferrous sulfate 325mg | 1件: Sulfate ion Sulfate ion | - | - | - | 1件: 299 299 💬 |
1124 | FG-3019 | - | - | - | - | 3件: 85 85, 113, 222 💬 |
1125 | FG-3019 10mg/mL in 10 mL vials | - | - | - | - | 1件: 85 85 💬 |
1126 | Fibrogammin®P, coagulation factor XIII concentrate (Human) | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 1件: 51 51 💬 |
1127 | Fibrovein 3% | - | - | - | - | 1件: 279 279 💬 |
1128 | Fingolimod 0.5 mg | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1129 | Fingolimod 0.5mg | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1130 | Fipamezole hydrochloride 30 mg oral disintegrating tablets | 1件: Fipamezole Fipamezole | - | - | - | 2件: 6 6, 17 💬 |
1131 | Firategrast (USAN approved name) | 1件: Firategrast Firategrast | 1件: Firategrast
Firategrast
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
1132 | Firategrast 300 mg | 1件: Firategrast Firategrast | 1件: Firategrast
Firategrast
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
1133 | FIRDAPSE - 10 MG - COMPRESSE - USO ORALE - BLISTER(ALU/PVC/PVDC) 100 X 1 COMPRESSE | 1件: Amifampridine Amifampridine | 1件: Amifampridine
Amifampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 2件: 3 3, 11 💬 |
1134 | FISH OIL, RICH IN OMEGA-3-ACIDS | 2件: Fish oil Fish oil, Omega-3 fatty acids | - | - | - | 1件: 13 13 💬 |
1135 | FISH OIL,RICH IN OMEGA 3 ACIDS | 1件: Fish oil Fish oil | - | - | - | 1件: 13 13 💬 |
1136 | FK-506 | - | - | - | - | 1件: 60 60 💬 |
1137 | FK506 level 2-3 ng/ml | - | - | - | - | 1件: 86 86 💬 |
1138 | FK506 level 3-5 ng/ml | - | - | - | - | 1件: 86 86 💬 |
1139 | FLEBOGAMMA 5% | - | - | - | - | 1件: 15 15 💬 |
1140 | Flebogamma 5% DIF | - | - | - | - | 1件: 65 65 💬 |
1141 | Florence 30 µg/mL | - | - | - | - | 1件: 98 98 💬 |
1142 | Flucloxacillin 250mg/5ml Sugar-Free Powder for Oral Solution | 1件: Flucloxacillin Flucloxacillin | 1件: Floxacillin
Floxacillin
💬 | - | - | 1件: 299 299 💬 |
1143 | FLUDARABINA ACCORD - 25 MG/ML CONCENTRATO PER SOLUZIONE INIETTABILE O PER INFUSIONE 5 FLACONCINI IN VETRO DA 2 ML | 1件: Fludarabine Fludarabine | 1件: Fludarabine
Fludarabine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 19 19 💬 |
1144 | Fludarabine phosphate 30 mg | 2件: Fludarabine Fludarabine, Phosphate ion | 1件: Fludarabine
Fludarabine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 2件: 65 65, 164 💬 |
1145 | Fluticasone Propionate, USP | 2件: Fluticasone Fluticasone, Fluticasone propionate | 2件: Fluticasone propionate
Fluticasone propionate
,
Fluticasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1146 | FMP-30 | - | - | - | - | 1件: 53 53 💬 |
1147 | Foliglurax 30 mg (treatment B) | 1件: Foliglurax Foliglurax | - | - | - | 1件: 6 6 💬 |
1148 | Follow-up study of the treated cohort | - | - | - | - | 1件: 193 193 💬 |
1149 | Fosmetpantotenate (RE-024) | - | - | - | - | 1件: 120 120 💬 |
1150 | Fospropofol (Lusedra®) 6.5 | 1件: Fospropofol Fospropofol | - | - | - | 1件: 226 226 💬 |
1151 | Fostamatinib 50 mg blue film-coated tablet | 1件: Fostamatinib Fostamatinib | 1件: Fostamatinib
Fostamatinib
💬 | 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
1152 | FP-CYA-050 | - | - | - | - | 1件: 97 97 💬 |
1153 | FP-CYA-053 | - | - | - | - | 1件: 97 97 💬 |
1154 | FPF 300 (thalidomide) | 1件: Thalidomide Thalidomide | 1件: Thalidomide
Thalidomide
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 16 16 💬 |
1155 | FRISIUM*30CPS 10MG | - | - | - | - | 1件: 140 140 💬 |
1156 | FRM-0334 | - | - | - | - | 1件: 127 127 💬 |
1157 | G2-SFM (IFN-beta-1a from clone 484-39,FBS-free process) | - | - | - | - | 1件: 13 13 💬 |
1158 | Gabapentin (neurontin® capsule 300mg) treatment | 1件: Gabapentin Gabapentin | 1件: Gabapentin
Gabapentin
💬 | 5件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 | 1件: 70 70 💬 |
1159 | Gabapentine 300mg | 1件: Gabapentin Gabapentin | 1件: Gabapentin
Gabapentin
💬 | 5件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
1160 | Gaboxadol (HLX-0206) | 1件: Gaboxadol Gaboxadol | 1件: Gaboxadol
Gaboxadol
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 206 206 💬 |
1161 | Gaboxadol monohydrate 0.5 mg | 1件: Gaboxadol Gaboxadol | 1件: Gaboxadol
Gaboxadol
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 💬 |
1162 | Gaboxadol monohydrate 0.5 mg (intended commercial formulation) | 1件: Gaboxadol Gaboxadol | 1件: Gaboxadol
Gaboxadol
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 💬 |
1163 | Gaboxadol monohydrate 0.5 mg capsule | 1件: Gaboxadol Gaboxadol | 1件: Gaboxadol
Gaboxadol
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 💬 |
1164 | Gaboxadol monohydrate 5 mg | 1件: Gaboxadol Gaboxadol | 1件: Gaboxadol
Gaboxadol
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 💬 |
1165 | Gaboxadol monohydrate 5 mg (intended commercial formulation) | 1件: Gaboxadol Gaboxadol | 1件: Gaboxadol
Gaboxadol
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 💬 |
1166 | Gadovist 1.0 mmol/ml Injektionslösung | 1件: Gadobutrol Gadobutrol | 1件: Gadobutrol
Gadobutrol
💬 | - | - | 1件: 13 13 💬 |
1167 | Gammaplex (5%) | - | - | - | - | 1件: 65 65 💬 |
1168 | Ganaxolone, SPT3162, MD 9150000, CCD-1042, Mepalon 1042, (3a-hydroxy-3beta-methyl-5a-pregnan-20-one) | 1件: Ganaxolone Ganaxolone | 1件: Ganaxolone
Ganaxolone
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 152 152 💬 |
1169 | Ganaxolone, SPT3162, MD 9150000, CCD-1042, Mepalon 1042, (3a-hydroxy-3ß-methyl-5a-pregnan-20-one) | 1件: Ganaxolone Ganaxolone | 1件: Ganaxolone
Ganaxolone
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 152 152 💬 |
1170 | GAZYVARO - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 1000MG/40ML - 1 FLACONCINO | 1件: Obinutuzumab Obinutuzumab | 1件: Obinutuzumab
Obinutuzumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 222 222 💬 |
1171 | GB-0998 | - | - | - | - | 1件: 50 50 💬 |
1172 | GB-0998 (Intravenous immunoglobulin) | - | - | - | - | 1件: 11 11 💬 |
1173 | GB224 30mg | - | - | - | - | 1件: 46 46 💬 |
1174 | GB224 5mg | - | - | - | - | 1件: 46 46 💬 |
1175 | GBT440 300 mg capsule | - | - | - | - | 1件: 85 85 💬 |
1176 | GBT440 300 mg tablet | - | - | - | - | 1件: 85 85 💬 |
1177 | GC1111_0.5mg/kg | - | - | - | - | 1件: 19 19 💬 |
1178 | GC1111_1.0mg/kg | - | - | - | - | 1件: 19 19 💬 |
1179 | GCK 300 mg | - | - | - | - | 1件: 46 46 💬 |
1180 | GDC-0134 | 1件: GDC-0134 GDC-0134 | - | - | - | 1件: 2 2 💬 |
1181 | GDC-0853 | - | - | - | - | 3件: 13 13, 46, 49 💬 |
1182 | GDC-0853 RO7010939 | - | - | - | - | 3件: 13 13, 46, 49 💬 |
1183 | GED-0301 | - | - | - | - | 2件: 96 96, 97 💬 |
1184 | GED-0507-34-LEVO | 1件: GED-0507-34-Levo GED-0507-34-Levo | - | - | - | 1件: 97 97 💬 |
1185 | GED-0507-34-Levo 160 mg | 1件: GED-0507-34-Levo GED-0507-34-Levo | - | - | - | 1件: 97 97 💬 |
1186 | GED-0507-34-Levo 80 mg | 1件: GED-0507-34-Levo GED-0507-34-Levo | - | - | - | 1件: 97 97 💬 |
1187 | Gene Therapy-vMCO-010 | - | - | - | - | 1件: 301 301 💬 |
1188 | Genistein (Unconjugated Isoflavones 100) | 1件: Genistein Genistein | 1件: Genistein
Genistein
💬 | - | - | 1件: 299 299 💬 |
1189 | Genisteine Plus 150 mg cpl formaat 1 18,7 x 6,4 mm 438 mg | - | - | - | - | 1件: 299 299 💬 |
1190 | Genotonorm Kabipen 5.3 mg polvo y disolvente para sol. inyectable (Marca internacional Genotropin) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1191 | Genotonorm Kabipen 5.3 mg polvo y disolvente para solución inyectable (Marca internacional Genotropin) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1192 | Genotonorm Miniquick 0,2 mg | - | - | - | - | 1件: 193 193 💬 |
1193 | Genotropin (PN-180,307) Somatropin | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1194 | Genotropin 5 mg/ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1195 | Genotropin 5.3 mg in injection system Genotropin pen | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1196 | Genotropin 5.3mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1197 | Genotropin Miniquick 0.2mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1198 | Genotropin Miniquick 0.4mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1199 | Genotropin miniquick 0.5 mg, injection | - | - | - | - | 1件: 78 78 💬 |
1200 | Genotropin Miniquick 0.6mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1201 | Genotropin Miniquick 0.8mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1202 | Genotropin Miniquick 1.0mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1203 | GENOTROPIN*1TBF 5,3MG (16UI) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 274 274 💬 |
1204 | Gentamicin sulfate 0.1% ointment | 2件: Gentamicin Gentamicin, Sulfate ion | 1件: Gentamicin
Gentamicin
💬 | - | - | 1件: 36 36 💬 |
1205 | GFI 38518168-AEK-B-007 | - | - | - | - | 1件: 46 46 💬 |
1206 | GILENYA - 0.25 MG - CAPSULE RIGIDE - USO ORALE | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1207 | GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1208 | GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE - BLISTER DIVISIBILE PER DOSE UNITARIA(PVC/PVDC/ALU) SCATOLA DA 7X1 CAPSULE | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1209 | GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE - BLISTER(PVC/PVDC/ALU) SCATOLA DA 28 CAPSULE | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1210 | GILENYA 0,5 mg cápsulas duras | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 14 14 💬 |
1211 | Gilenya 0,5 mg Hartkapseln | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1212 | Ginkgo biloba pills sig: 300mg/tid | 1件: Ginkgo biloba Ginkgo biloba | - | - | - | 1件: 90 90 💬 |
1213 | Glatiramer Acetate 20 mg/0.5 mL | 2件: Acetate Acetate, Glatiramer | - | - | - | 1件: 13 13 💬 |
1214 | Glentek 50 mg compresse rivestite con film | - | - | - | - | 1件: 18 18 💬 |
1215 | Glentek 50 mg film-coated tablets | - | - | - | - | 1件: 18 18 💬 |
1216 | Glicerol-1,3-didecanoato-2-octadeca-(6Z,9Z,12Z)-trienoato | - | - | - | - | 1件: 13 13 💬 |
1217 | GLPG1837 dose 3 | - | - | - | - | 1件: 299 299 💬 |
1218 | GLPG2222 300 mg q.d. | - | - | - | - | 1件: 299 299 💬 |
1219 | GLPG2222 50 mg | - | - | - | - | 1件: 299 299 💬 |
1220 | GLUCOCEREBROSIDASE UMANO GENE-ATTIVATO | - | - | - | - | 1件: 19 19 💬 |
1221 | GLWL-01 | - | - | - | - | 1件: 193 193 💬 |
1222 | Glycerol-1,3-didecanoate-2-octadeca-(6Z,9Z,12Z)-trienoate | 1件: Glycerin Glycerin | 1件: Glycerin
Glycerin
💬 | - | - | 1件: 13 13 💬 |
1223 | GLYPRESSINE 1 mg/5 mL, poudre et solvant pour solution injectable (I.V.) | - | - | - | - | 1件: 299 299 💬 |
1224 | GNR-055 | - | - | - | - | 1件: 19 19 💬 |
1225 | GNR-055 1.0-2.0-3.0 mg/kg | - | - | - | - | 1件: 19 19 💬 |
1226 | GNR-055 2.0 mg/kg | - | - | - | - | 1件: 19 19 💬 |
1227 | GNR-055 3.0 mg/kg | - | - | - | - | 1件: 19 19 💬 |
1228 | GNR-069 | - | - | - | - | 1件: 63 63 💬 |
1229 | Golimumab 50 mg | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 97 💬 |
1230 | Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1231 | Golimumab 50 mg injections | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1232 | Golimumab 50 mg SC | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1233 | Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53] | 1件: Golodirsen Golodirsen | 1件: Golodirsen
Golodirsen
💬 | 1件: DMD DMD 💬 | 4件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Viral myocarditis 💬 | 1件: 113 113 💬 |
1234 | GRANOCYTE - 34 million IU (Lenograstim rHuG-CSF) | 1件: Lenograstim Lenograstim | 1件: Lenograstim
Lenograstim
💬 | 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 57 57 💬 |
1235 | Group 2 ustekinumab 130 mg | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
1236 | Group 2- UCD Diet | - | - | - | - | 1件: 97 97 💬 |
1237 | Group 3: ustekinumab approximately 6 mg/kg | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
1238 | GS-5718 | - | - | - | - | 1件: 46 46 💬 |
1239 | GS-5737 | - | - | - | - | 1件: 299 299 💬 |
1240 | GS-5745 | 1件: GS-5745 GS-5745 | - | - | - | 4件: 46 46, 96, 97, 299 💬 |
1241 | GS-5745 IV | 1件: GS-5745 GS-5745 | - | - | - | 1件: 97 97 💬 |
1242 | GS-5745 SC | 1件: GS-5745 GS-5745 | - | - | - | 1件: 97 97 💬 |
1243 | GS-6615 3 mg | - | - | - | - | 1件: 58 58 💬 |
1244 | GS-6615 3 mg Pink | - | - | - | - | 1件: 58 58 💬 |
1245 | GS-6615 3 mg White | - | - | - | - | 1件: 58 58 💬 |
1246 | GS-9674 30 mg | - | - | - | - | 1件: 93 93 💬 |
1247 | GSK 3196165 | - | - | - | - | 1件: 46 46 💬 |
1248 | GSK1605786 500 mg | - | - | - | - | 1件: 96 96 💬 |
1249 | GSK2402968 3mg/kg/week | - | - | - | - | 1件: 113 113 💬 |
1250 | GSK2586184 50 mg | - | - | - | - | 1件: 49 49 💬 |
1251 | GSK3196165 Dose 3 | - | - | - | - | 1件: 46 46 💬 |
1252 | GTG003.08 | - | - | - | - | 1件: 65 65 💬 |
1253 | Guselkumab Dose 3 | 1件: Guselkumab Guselkumab | 1件: Guselkumab
Guselkumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 2件: 96 96, 97 💬 |
1254 | Guselkumab Dose 5 | 1件: Guselkumab Guselkumab | 1件: Guselkumab
Guselkumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 96 96 💬 |
1255 | Gutron 2,5mg | - | - | - | - | 1件: 58 58 💬 |
1256 | Gutron 5mg | - | - | - | - | 1件: 58 58 💬 |
1257 | GW-1000-02 | - | - | - | - | 1件: 13 13 💬 |
1258 | GWP42003-P 5 mg/kg/day Dose | - | - | - | - | 1件: 140 140 💬 |
1259 | GYLENIA 0,5 mg | - | - | - | - | 1件: 13 13 💬 |
1260 | GYPP-06 (GKT137831 free base), C10071301-D | - | - | - | - | 1件: 93 93 💬 |
1261 | H5.001CBCFTR | - | - | - | - | 1件: 299 299 💬 |
1262 | HA 1A ANTICORPO MONOCLONALE UMANO CLASSE IGM | - | - | - | - | 2件: 6 6, 49 💬 |
1263 | Haploidentical HSCT using TBI free regimen, ''ATG'' with ''Post transplant cyclophosphamide'' | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 1件: 60 60 💬 |
1264 | HBM9161 Injection (340 mg) | - | - | - | - | 1件: 11 11 💬 |
1265 | HBM9161 Injection (680mg and 340 mg) | - | - | - | - | 1件: 11 11 💬 |
1266 | HBVAXPRO 5 micrograms/0.5 ml | 1件: Hepatitis B Vaccine (Recombinant) Hepatitis B Vaccine (Recombinant) | - | - | - | 1件: 46 46 💬 |
1267 | HBVAXPRO 5 micrograms/0.5 ml Suspension for injection Hepatitis B vaccine (rDNA) | 1件: Hepatitis B Vaccine (Recombinant) Hepatitis B Vaccine (Recombinant) | - | - | - | 1件: 46 46 💬 |
1268 | HC-58 | - | - | - | - | 1件: 149 149 💬 |
1269 | Helium-3 | 2件: Helium Helium, Helium He-3 | 1件: Helium
Helium
💬 | - | - | 2件: 228 228, 299 💬 |
1270 | HIBERIX - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE 1 FLACONCINO DI POLVERE + 1 SIRINGA PRERIEMPITA DI SOLVENTE DA 0.5 ML | 1件: Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen | - | - | - | 3件: 61 61, 62, 66 💬 |
1271 | HIDONAC*EV 1FL 5G 25ML | - | - | - | - | 1件: 51 51 💬 |
1272 | Hiomega-3 supplement of Naturalis® company - | - | - | - | - | 1件: 49 49 💬 |
1273 | HK-001 | - | - | - | - | 1件: 2 2 💬 |
1274 | HL-085 | - | - | - | - | 1件: 34 34 💬 |
1275 | HLA-B*5801 test | - | - | - | - | 1件: 38 38 💬 |
1276 | HLADQA1*05A>G screening | - | - | - | - | 2件: 96 96, 97 💬 |
1277 | HLB-001 | - | - | - | - | 1件: 246 246 💬 |
1278 | HMPL-004 | - | - | - | - | 2件: 96 96, 97 💬 |
1279 | HMPL-004 1800 mg/day | - | - | - | - | 1件: 97 97 💬 |
1280 | HMPL-004 2400 mg/day | - | - | - | - | 1件: 97 97 💬 |
1281 | HMPL-004 high dose | - | - | - | - | 1件: 97 97 💬 |
1282 | HMPL-004 low dose | - | - | - | - | 1件: 97 97 💬 |
1283 | HMPL-523 | - | - | - | - | 2件: 46 46, 63 💬 |
1284 | HMPL-523(300mg PO QD) | - | - | - | - | 1件: 61 61 💬 |
1285 | Hologene 5 | - | - | - | - | 1件: 36 36 💬 |
1286 | Hologene 5 DS | - | - | - | - | 1件: 36 36 💬 |
1287 | HORA-PDE6B (AAV2/5.hPDE6B) | - | - | - | - | 1件: 90 90 💬 |
1288 | HP 3He | - | - | - | - | 1件: 299 299 💬 |
1289 | HP-3000 (ropinirole hydrochloride patch) | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1290 | HP-3000 placebo | - | - | - | - | 1件: 6 6 💬 |
1291 | HP-3000(ropinirole hydrochloride patch) | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1292 | Humalog Mix50 100 U/ml sospensione iniettabile | - | - | - | - | 1件: 78 78 💬 |
1293 | Human Coagulation FACTOR X | 1件: Coagulation factor X human Coagulation factor X human | - | - | - | 1件: 288 288 💬 |
1294 | Human factor X | 1件: Coagulation factor X human Coagulation factor X human | - | - | - | 1件: 288 288 💬 |
1295 | Human monoclonal antibody directed against complement 5 protein | - | - | - | - | 1件: 62 62 💬 |
1296 | HUMAN NORMAL IMMUNOGLOBULIN FOR INTRAVENOUS USE | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 2件: 63 63, 65 💬 |
1297 | Human normal immunoglobulin for intravenous use (IVIG) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 💬 |
1298 | HUMAN NORMAL IMMUNOGLOBULIN FOR INTRVENOUS USE | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 63 63 💬 |
1299 | Human Umbilical Cord Blood-derived Mesenchymal Stem Cells | - | - | - | - | 1件: 36 36 💬 |
1300 | Human umbilical cord derived MSC transplantation for SLE | - | - | - | - | 1件: 49 49 💬 |
1301 | Human umbilical cord mesenchymal stem cell injection | - | - | - | - | 1件: 85 85 💬 |
1302 | Human Umbilical Cord Mesenchymal Stem Cells | 1件: Human Umbilical Cord Mesenchymal Stem Cells Human Umbilical Cord Mesenchymal Stem Cells | - | - | - | 3件: 13 13, 96, 113 💬 |
1303 | Human umbilical cord mesenchymal stem cells (UC-MSCs) | 1件: Human Umbilical Cord Mesenchymal Stem Cells Human Umbilical Cord Mesenchymal Stem Cells | - | - | - | 1件: 96 96 💬 |
1304 | Human umbilical cord-derived MSCs | - | - | - | - | 1件: 271 271 💬 |
1305 | HuMax-CD38, 3003-005 | - | - | - | - | 1件: 28 28 💬 |
1306 | Humira (adalimumab) 40 mg in 0.4 ml s.c. injection | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1307 | Humira (adalimumab) 40mg in 0.4 ml s.c. injection | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1308 | Humira (adalimumab) 40mg in 0.4ml s.c.injection | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1309 | HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 1 SIRINGA PRERIEMPITA 0.8 ML + 1 TAMPONE IMBEVUTO DI ALCOL IN UN BLISTER | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 56 56, 97 💬 |
1310 | HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 2 SIRINGHE PRERIEMPITE 0.8 ML + 2 TAMPONI IMBEVUTI DI ALCOL IN 1 BLISTER | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1311 | HUMIRA - 40MG/0.8ML SOLUZ. INIETTABILE- USO SOTTOCUTANEO-FLACONCINO(VETRO) 0.8ML 2 ASTUCCI:1 FLACONCINO+1SIRINGA+1AGO+1ADATT.STERILE-2TAMPONI IMBEVUTI ALCOOL | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 96 💬 |
1312 | Humira 20 mg solution for injection in pre-filled syringe (20 mg/0.2mL) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1313 | Humira 40 mg solution for injection in pre-filled syringe (40 mg/0.4 mL) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1314 | Humira 40 mg/0.8 ml solution for injection | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 4件: 46 46, 96, 97, 271 💬 |
1315 | Humira 40 mg/0.8 ml solution for injection for paediatric use | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1316 | Humira 40mg/0.4ml pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
1317 | Humira 40mg/0.8 ml solution for injection for paediatric use | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1318 | Humira 40mg/0.8ml solution for injection for paediatric use | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
1319 | Humira 40mg/0.8ml solution for injection in pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1320 | Humira 80 mg solution for injection in pre-filled syringe (80 mg/0.8 mL) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1321 | Humira ® (Adalimumab) 40mg/0.8mL Pre-filled Syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1322 | HUMIRA*SC 2SIR+F 40MG 0,8ML+2T | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 96 💬 |
1323 | Humira® 40 mg/ 0.8 ml solution for injection in pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1324 | Hydrocortisone tablet 2.5 mg | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
1325 | Hydrokortison APL kapsel 2,5 mg | - | - | - | - | 1件: 83 83 💬 |
1326 | Hydrokortison Glostrup 5 mg | - | - | - | - | 1件: 78 78 💬 |
1327 | Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 85 85 💬 |
1328 | Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 85 85 💬 |
1329 | Hyperpolarized 129-Xenon gas | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 85 85 💬 |
1330 | Hyperpolarized Helium-3 | 2件: Helium Helium, Helium He-3 | 1件: Helium
Helium
💬 | - | - | 1件: 299 299 💬 |
1331 | Hyperpolarized Helium-3 MRI | 2件: Helium Helium, Helium He-3 | 1件: Helium
Helium
💬 | - | - | 1件: 228 228 💬 |
1332 | Hyperpolarized Helium-3 MRI of the chest | 2件: Helium Helium, Helium He-3 | 1件: Helium
Helium
💬 | - | - | 1件: 299 299 💬 |
1333 | Hyperpolarized Xe129 | - | - | - | - | 4件: 51 51, 85, 86, 299 💬 |
1334 | Hyperpolarized Xenon | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 299 299 💬 |
1335 | Hyperpolarized Xenon 129 | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 299 299 💬 |
1336 | Hyperpolarized Xenon gas | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 299 299 💬 |
1337 | Hyperpolarized xenon-129 | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 299 299 💬 |
1338 | Hypertonic saline (7 %) and isotonic saline (0.9%) | - | - | - | - | 1件: 299 299 💬 |
1339 | HyQvia 100 mg/ml solution for infusion for subcutaneous use | 2件: Human immunoglobulin G Human immunoglobulin G, Hyaluronidase (human recombinant) | - | - | - | 1件: 65 65 💬 |
1340 | HZT-501 | 1件: HZT-501 HZT-501 | - | - | - | 1件: 46 46 💬 |
1341 | I-123-5-IA85380 | 1件: Iodide I-123 Iodide I-123 | - | - | - | 1件: 6 6 💬 |
1342 | ICP-022 | - | - | - | - | 2件: 46 46, 49 💬 |
1343 | ICX-RHY-013 | - | - | - | - | 1件: 36 36 💬 |
1344 | IdeS (0.25 mg/kg) | 1件: Imlifidase Imlifidase | 1件: Imlifidase
Imlifidase
💬 | - | - | 1件: 64 64 💬 |
1345 | IdeS (0.50 mg/kg) | 1件: Imlifidase Imlifidase | 1件: Imlifidase
Imlifidase
💬 | - | - | 1件: 64 64 💬 |
1346 | IDROCORTISONE ACETATO DYNACREN - 1 % CREMA 1 TUBO DA 30 G | - | - | - | - | 1件: 272 272 💬 |
1347 | Idursulfase IT (30 mg) | 1件: Idursulfase Idursulfase | 1件: Idursulfase
Idursulfase
💬 | 1件: IDS IDS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
1348 | IFB-088 | - | - | - | - | 1件: 2 2 💬 |
1349 | IFB-088 50mg/day | - | - | - | - | 1件: 2 2 💬 |
1350 | Ig VENA 50 g/l solution for infusion 100 ml vial + infusion set | - | - | - | - | 2件: 63 63, 65 💬 |
1351 | Iloprost (5 µg) | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
1352 | Iloprost Injection, for intravenous use | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 51 51 💬 |
1353 | Iloprost therapy up to 2 ng/kg x min | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 51 51 💬 |
1354 | ILV-094 | - | - | - | - | 1件: 46 46 💬 |
1355 | IMCY-0141 | 1件: IMCY-0141 IMCY-0141 | - | - | - | 1件: 13 13 💬 |
1356 | Imiquimod 5% Cream | 1件: Imiquimod Imiquimod | 1件: Imiquimod
Imiquimod
💬 | 1件: TLR7 TLR7 💬 | 5件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Influenza A, Measles, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway 💬 | 2件: 34 34, 51 💬 |
1357 | Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™ | - | - | - | - | 1件: 65 65 💬 |
1358 | Immunoglobulin G1, anti-(human type I interferon receptor) (human monoclonal MEDI-546 heavy chain), disulfide with human monoclonal MEDI-546-chain, dimer | - | - | - | - | 1件: 49 49 💬 |
1359 | Immunoglobulina normale umana | - | - | - | - | 1件: 51 51 💬 |
1360 | Immunoglobulina Normale Umana per somministrazione endovenosa | - | - | - | - | 1件: 51 51 💬 |
1361 | Immunoglobulina Normale Umana per somministrazione sottocutanea | - | - | - | - | 1件: 51 51 💬 |
1362 | IMMUNOGLOBULINA UMANA NORMALE | - | - | - | - | 2件: 51 51, 65 💬 |
1363 | IMMUNOGLOBULINA UMANA NORMALE per somministrazione endovenosa | - | - | - | - | 1件: 14 14 💬 |
1364 | IMP will be labeled as ''PF-04236921 106mg/vial, Clonal SC lyophilized form''. | - | - | - | - | 1件: 96 96 💬 |
1365 | IMP will be labeled as PF-04236921 106mg/vial, Clonal SC lyophilized form | - | - | - | - | 1件: 96 96 💬 |
1366 | IMU-838 (30 mg/day) | - | - | - | - | 1件: 13 13 💬 |
1367 | IMUKIN - 6 FLACONI 0.5 ML 100 MCG | - | - | - | - | 2件: 18 18, 58 💬 |
1368 | IMUKIN*SC 6F 0,5ML 100MCG | - | - | - | - | 1件: 18 18 💬 |
1369 | Imurek 50mg Filmtabletten | - | - | - | - | 1件: 97 97 💬 |
1370 | Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus | - | - | - | - | 1件: 53 53 💬 |
1371 | INCB050465 0.3 mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 35 35 💬 |
1372 | INCB050465 0.3mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 35 35 💬 |
1373 | INCB050465 1.0 mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 35 35 💬 |
1374 | INCB050465 1.0mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 35 35 💬 |
1375 | INCB050465 2.5 mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 61 61 💬 |
1376 | INCB050465 2.5mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 35 35 💬 |
1377 | IncobotulinumtoxinA (100 Units) | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 6 6 💬 |
1378 | IncobotulinumtoxinA (75 Units) | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 6 6 💬 |
1379 | INDUSIL*OS GTT FL 30MG+FL 15ML | - | - | - | - | 1件: 299 299 💬 |
1380 | Infigratinib 0.016 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
1381 | Infigratinib 0.032 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
1382 | Infigratinib 0.064 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
1383 | Infigratinib 0.128 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
1384 | Infigratinib 0.25 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
1385 | INFLECTRA - 100 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 1 FLACONCINO | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 56 56 💬 |
1386 | Infliximab (BCD-055) | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 💬 |
1387 | Infliximab 3 mg/kg | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1388 | Infliximab 5 mg/kg | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 96 96, 97 💬 |
1389 | Infliximab 5 mg/kg body weight infused over 2 hours | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
1390 | Infliximab 5 mg/kg every 6 weeks | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
1391 | Infliximab [infliximab biosimilar 3] | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 4件: 37 37, 46, 96, 97 💬 |
1392 | Infliximab and azathioprine combination at week 0 | 2件: Azathioprine Azathioprine, Infliximab | 2件: Azathioprine
Azathioprine
,
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
1393 | Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab | 5件: Adalimumab Adalimumab, Golimumab, Infliximab, Ustekinumab, Vedolizumab | 5件: Adalimumab
Adalimumab
,
Infliximab
,
Golimumab
,
Vedolizumab
,
Ustekinumab
💬 | 6件: IL12A IL12A, IL12B, IL23A, ITGA4, ITGB7, TNF 💬 | 81件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Arrhythmogenic right ventricular cardiomyopathy, Asthma, C-type lectin receptor signaling pathway, Cell adhesion molecules, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, ECM-receptor interaction, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Leukocyte transendothelial migration, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 96 96, 97 💬 |
1394 | Infliximab, adalimumab, golimumab, vedolizumab, ustekinumab | 5件: Adalimumab Adalimumab, Golimumab, Infliximab, Ustekinumab, Vedolizumab | 5件: Adalimumab
Adalimumab
,
Infliximab
,
Golimumab
,
Vedolizumab
,
Ustekinumab
💬 | 6件: IL12A IL12A, IL12B, IL23A, ITGA4, ITGB7, TNF 💬 | 81件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Arrhythmogenic right ventricular cardiomyopathy, Asthma, C-type lectin receptor signaling pathway, Cell adhesion molecules, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, ECM-receptor interaction, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Leukocyte transendothelial migration, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1395 | Infusion of ADR-001 (Mesenchymal stem cell) | - | - | - | - | 1件: 66 66 💬 |
1396 | Inhaled AR-501 | - | - | - | - | 1件: 299 299 💬 |
1397 | Inhaled Iloprost (5 µg) | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
1398 | Inhaled Nitric Oxide (iNO) use | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 1件: 294 294 💬 |
1399 | Inhaled Nitric Oxide - 30 mcg/kg IBW/hr | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 1件: 85 85 💬 |
1400 | Inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 1件: 85 85 💬 |
1401 | Injection of Umbilical cord derived MSCs | - | - | - | - | 1件: 6 6 💬 |
1402 | INTELENCE - 200 MG - COMPRESSA -USO ORALE - FLACONE (HDPE) 60 COMPRESSE | 1件: Etravirine Etravirine | 1件: Etravirine
Etravirine
💬 | - | - | 1件: 18 18 💬 |
1403 | Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046) | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
1404 | Interferon beta 1a 30 ug IM once weekly | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1405 | Interferon beta 1b (Betaseron, BAY86-5046) | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
1406 | Interferon beta-1a 30 µg | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1407 | Interferon beta-1a, 30 µg/0.5 ml | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1408 | Interferon beta-1b (Betaferon, BAY 86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1409 | Interferon beta-1b (Betaferon, BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1410 | Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1411 | Interferon beta-1b (Betaferon®, BAY 86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1412 | Interferon beta-1b (Betaseron, BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1413 | Interferon beta-1b (Betaseron, Betaferon, BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1414 | Interferon beta-1b, (Betaseron BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1415 | Interferon ß-1a 30 µg | - | - | - | - | 1件: 13 13 💬 |
1416 | Interferon-1beta (Betaseron, BAY86-5046) | 1件: Interferon beta-1b Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1417 | Interferon-beta-1b (BETASERON, BAY 86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1418 | Intratect 5% | - | - | - | - | 1件: 35 35 💬 |
1419 | Iohexol Inj 300 milligrams per milliliter (MG/ML) | 1件: Iohexol Iohexol | 1件: Iohexol
Iohexol
💬 | - | - | 1件: 67 67 💬 |
1420 | IPN60130 50 mg capsules | - | - | - | - | 1件: 272 272 💬 |
1421 | IPX054 300 mg | - | - | - | - | 1件: 6 6 💬 |
1422 | IPX056 30 mg | - | - | - | - | 1件: 13 13 💬 |
1423 | IPX056 35 mg | - | - | - | - | 1件: 13 13 💬 |
1424 | IPX056-30 mg | - | - | - | - | 1件: 13 13 💬 |
1425 | IPX056-35 mg | - | - | - | - | 1件: 13 13 💬 |
1426 | IPX203 350 mg | - | - | - | - | 1件: 6 6 💬 |
1427 | Irbesartan 150-300mg capsules daily for 6 months | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 167 167 💬 |
1428 | Irbesartan tablets (Approved in the USA. Reference listed drug Avapro) NDC # 43547-0374-03 | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 66 66, 222 💬 |
1429 | Irbesartan tablets (NDA 020 757) | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 66 66 💬 |
1430 | Irbesartan tablets (NDC# 31722-729-30 approved in the United states) | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
1431 | Irbesartan tablets (NDC# 43547-0374-03 and NDC 43547-374-09, approved in the USA) Generic tablets distributed by Solco Healthcare US, LLC | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
1432 | Iron supplement 300-600 mg/day | 1件: Iron Iron | - | - | - | 2件: 96 96, 97 💬 |
1433 | ISIS 301012 | - | - | - | - | 1件: 79 79 💬 |
1434 | ISIS 301012 phosphorothioate oligonucleotide | - | - | - | - | 1件: 79 79 💬 |
1435 | ISIS 304801 | - | - | - | - | 1件: 265 265 💬 |
1436 | ISIS 333611 | - | - | - | - | 1件: 2 2 💬 |
1437 | ISIS 396443 | - | - | - | - | 1件: 3 3 💬 |
1438 | ISIS 396443 (BIIB058) | - | - | - | - | 1件: 3 3 💬 |
1439 | ISIS 396443, BIIB058 | - | - | - | - | 1件: 3 3 💬 |
1440 | ISIS 443139 30 mg | - | - | - | - | 1件: 8 8 💬 |
1441 | Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung | - | - | - | - | 1件: 50 50 💬 |
1442 | Isotonic saline 0.9% | 1件: Sodium chloride Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
1443 | Isotopic Intravenous [13C]-Urea | 1件: Urea Urea | 2件: Urea
Urea
,
Urea C13
💬 | - | - | 1件: 251 251 💬 |
1444 | Isradipine CR 5mg | 1件: Isradipine Isradipine | 1件: Isradipine
Isradipine
💬 | 4件: CACNA1C CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 | 37件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
1445 | Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally. | 2件: Itraconazole Itraconazole, Terbinafine | 2件: Itraconazole
Itraconazole
,
Terbinafine
💬 | - | - | 1件: 96 96 💬 |
1446 | IUPAC name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one | - | - | - | - | 1件: 17 17 💬 |
1447 | IUPAC name: 2-[4-[(2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylam ino]benzoyl]amino | - | - | - | - | 1件: 337 337 💬 |
1448 | IVA 336 | - | - | - | - | 1件: 19 19 💬 |
1449 | IVACAFTOR 59,5mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
1450 | IVACAFTOR 59.5mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
1451 | IW-3300 rectal foam | - | - | - | - | 1件: 226 226 💬 |
1452 | J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0 | - | - | - | - | 1件: 96 96 💬 |
1453 | JAK 3 | - | - | - | - | 1件: 46 46 💬 |
1454 | JAK 3 Ritlecitinib | - | - | - | - | 1件: 46 46 💬 |
1455 | Jaktinib Dihydrochloride Monohydrate 50mg BID and Mimic tablets of jakitinib hydrochloride 75mg BID and Acetylcysteine Effervescent Tablets | 1件: Acetylcysteine Acetylcysteine | 1件: Acetylcysteine
Acetylcysteine
💬 | - | - | 1件: 85 85 💬 |
1456 | Jaktinib Dihydrochloride Monohydrate 75mg BID and Mimic tablets of jakitinib hydrochloride 50mg BID and Acetylcysteine Effervescent Tablets | 1件: Acetylcysteine Acetylcysteine | 1件: Acetylcysteine
Acetylcysteine
💬 | - | - | 1件: 85 85 💬 |
1457 | Jevity 1.0 | - | - | - | - | 1件: 2 2 💬 |
1458 | Jevity 1.5 | - | - | - | - | 1件: 2 2 💬 |
1459 | JINARC - 15 MG +45 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28X15 MG + 28 X 45 MG) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
1460 | JINARC - 15 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
1461 | JINARC - 30 MG + 60 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 60 MG) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
1462 | JINARC - 30 MG +90 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 90 MG) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
1463 | JINARC - 30 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
1464 | Jinarc 30 mg Tablet | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
1465 | Jinarc 30 mg tablets, 90 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
1466 | Jinarc 30 mg tablets, Jinarc 60 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
1467 | Jinarc® 30 Tablet | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
1468 | JM-010 | - | - | - | - | 1件: 6 6 💬 |
1469 | JNJ 38518168 | - | - | - | - | 1件: 46 46 💬 |
1470 | JnJ 54767414 | - | - | - | - | 1件: 28 28 💬 |
1471 | JNJ-31001074 | - | - | - | - | 1件: 6 6 💬 |
1472 | JNJ-38518168 | - | - | - | - | 1件: 46 46 💬 |
1473 | JNJ-38518168 (10 mg) | - | - | - | - | 1件: 46 46 💬 |
1474 | JNJ-38518168 (3 mg) | - | - | - | - | 1件: 46 46 💬 |
1475 | JNJ-38518168 (30 mg) | - | - | - | - | 1件: 46 46 💬 |
1476 | JNJ-38518168 / MTX | - | - | - | - | 1件: 46 46 💬 |
1477 | JNJ-38518168 50-mg Over Encapsulated Tablet | - | - | - | - | 1件: 46 46 💬 |
1478 | JNJ-38518168-AEK - Over Encapsulated Tablet - 50 mg | - | - | - | - | 1件: 46 46 💬 |
1479 | JNJ-38518168-ZBQ | - | - | - | - | 1件: 46 46 💬 |
1480 | JNJ-38518168-ZBQ - film-coated tablet - 10 mg | - | - | - | - | 1件: 46 46 💬 |
1481 | JNJ-38518168-ZBQ - film-coated tablet - 10mg | - | - | - | - | 1件: 46 46 💬 |
1482 | JNJ-38518168-ZBQ - film-coated tablet - 3 mg | - | - | - | - | 1件: 46 46 💬 |
1483 | JNJ-38518168-ZBQ - film-coated tablet - 30 mg | - | - | - | - | 1件: 46 46 💬 |
1484 | JNJ-38518168-ZBQ - film-coated tablet - 30mg | - | - | - | - | 1件: 46 46 💬 |
1485 | JNJ-38518168-ZBQ - film-coated tablet - 3mg | - | - | - | - | 1件: 46 46 💬 |
1486 | JNJ-39039039 | - | - | - | - | 1件: 210 210 💬 |
1487 | JNJ-39758979 | - | - | - | - | 1件: 46 46 💬 |
1488 | JNJ-39758979 (10 mg) | - | - | - | - | 1件: 46 46 💬 |
1489 | JNJ-39758979 (100 mg) | - | - | - | - | 1件: 46 46 💬 |
1490 | JNJ-39758979 (30 mg) | - | - | - | - | 1件: 46 46 💬 |
1491 | JNJ-39758979 (300 mg) | - | - | - | - | 1件: 46 46 💬 |
1492 | JNJ-39758979 / MTX | - | - | - | - | 1件: 46 46 💬 |
1493 | JNJ-39758979-AAC - enteric coated tablet - 10 mg | - | - | - | - | 1件: 46 46 💬 |
1494 | JNJ-39758979-AAC - enteric coated tablet - 100 mg | - | - | - | - | 1件: 46 46 💬 |
1495 | JNJ-39758979-AAC - enteric coated tablet - 30 mg | - | - | - | - | 1件: 46 46 💬 |
1496 | JNJ-40346527-AAC - capsule - 50 mg | 1件: JNJ-40346527 JNJ-40346527 | - | - | - | 1件: 46 46 💬 |
1497 | JNJ-54767414 | - | - | - | - | 2件: 28 28, 49 💬 |
1498 | JNJ-54781532 150 mg once daily | - | - | - | - | 1件: 97 97 💬 |
1499 | JNJ-54781532 25 mg once daily | - | - | - | - | 1件: 97 97 💬 |
1500 | JNJ-54781532 75 mg once daily | - | - | - | - | 1件: 97 97 💬 |
1501 | JNJ-54781532 75 mg twice daily | - | - | - | - | 1件: 97 97 💬 |
1502 | JNJ-54781532-AAD-10 mg | - | - | - | - | 1件: 97 97 💬 |
1503 | JNJ-54781532-AAD-30 mg | - | - | - | - | 1件: 97 97 💬 |
1504 | JNJ-54781532-AAD-5 mg | - | - | - | - | 1件: 97 97 💬 |
1505 | JNJ-55920839 | - | - | - | - | 1件: 49 49 💬 |
1506 | JNJ-56022473 | - | - | - | - | 1件: 49 49 💬 |
1507 | JNJ-67896062 / ACT-064992 | - | - | - | - | 2件: 86 86, 88 💬 |
1508 | JNJ-67896062/ ACT-064992 | - | - | - | - | 2件: 86 86, 88 💬 |
1509 | JNJ-67896062/ACT-064922 | - | - | - | - | 1件: 86 86 💬 |
1510 | JNJ31-31001074 | - | - | - | - | 1件: 6 6 💬 |
1511 | Jorveza 0.5 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1512 | Jorveza 0.5 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1513 | JTE-051 | - | - | - | - | 1件: 46 46 💬 |
1514 | Kamillenblüten 3ml/10ml | - | - | - | - | 1件: 97 97 💬 |
1515 | KCT-0809 ophthalmic solution | - | - | - | - | 1件: 53 53 💬 |
1516 | KDT-3594 | 1件: KDT-3594 KDT-3594 | - | - | - | 1件: 6 6 💬 |
1517 | Keppra 500mg | 1件: Levetiracetam Levetiracetam | 1件: Levetiracetam
Levetiracetam
💬 | 1件: SV2A SV2A 💬 | 1件: ECM-receptor interaction ECM-receptor interaction 💬 | 1件: 13 13 💬 |
1518 | KINERET*SC 7SIR 100MG 0,67ML | 1件: Anakinra Anakinra | 1件: Anakinra
Anakinra
💬 | 2件: IL1R1 IL1R1, IL1R2 💬 | 15件: Amoebiasis Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer 💬 | 3件: 28 28, 46, 107 💬 |
1519 | KIO-301 | - | - | - | - | 1件: 90 90 💬 |
1520 | KN019, 5mg/kg | - | - | - | - | 1件: 46 46 💬 |
1521 | KPL-301 | - | - | - | - | 1件: 41 41 💬 |
1522 | KPS-0373 | - | - | - | - | 1件: 18 18 💬 |
1523 | KPS-0373, High dose | - | - | - | - | 1件: 18 18 💬 |
1524 | KPS-0373, Low dose | - | - | - | - | 1件: 18 18 💬 |
1525 | Kreon 25 000 | - | - | - | - | 1件: 299 299 💬 |
1526 | Kreon 25,000 Units | - | - | - | - | 1件: 299 299 💬 |
1527 | Kreon® 25,000 | - | - | - | - | 1件: 299 299 💬 |
1528 | KVD824 300 mg Compresse a rilascio modificato | - | - | - | - | 1件: 65 65 💬 |
1529 | KVD824 300 mg Modified Release Tablets | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 65 65 💬 |
1530 | KVD900 300 mg | - | - | - | - | 1件: 65 65 💬 |
1531 | KVD900 300 mg Film Coated Tablet | - | - | - | - | 1件: 65 65 💬 |
1532 | KW-0761 | - | - | - | - | 1件: 26 26 💬 |
1533 | KW-0761 0.3 mg/kg IV | - | - | - | - | 1件: 26 26 💬 |
1534 | KW-6356 X Dose | 1件: KW-6356 KW-6356 | - | - | - | 1件: 6 6 💬 |
1535 | L-000124467 | - | - | - | - | 2件: 13 13, 46 💬 |
1536 | L-000124467 (freebase) | - | - | - | - | 1件: 46 46 💬 |
1537 | L-000124467-009J (succinat | - | - | - | - | 1件: 46 46 💬 |
1538 | L-000883191 | - | - | - | - | 1件: 46 46 💬 |
1539 | L-001069957 | - | - | - | - | 1件: 46 46 💬 |
1540 | L-3-(3,4-Dihydroxyphenyl)alanine | 1件: Alanine Alanine | 1件: Alanine
Alanine
💬 | - | - | 1件: 6 6 💬 |
1541 | L03 AB 08 | - | - | - | - | 1件: 13 13 💬 |
1542 | L04AA04 - IMMUNOGLOBULINA ANTITIMOCITARIA (DI CONIGLIO) IMMUNOGLOBULINA DI CONIGLIO ANTITIMOCITI UMANI THYMOGLOBULINE | 1件: Antithymocyte immunoglobulin (rabbit) Antithymocyte immunoglobulin (rabbit) | - | - | - | 1件: 13 13 💬 |
1543 | L606 (Liposomal Treprostinil) Inhalation Solution 51ug | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
1544 | Lactobacillus acidophilus 10 billion colony forming unit (CFU) and prebiotic fibers | 1件: Lactobacillus acidophilus Lactobacillus acidophilus | 1件: Lactomin
Lactomin
💬 | - | - | 1件: 6 6 💬 |
1545 | Lactobacillus rhamnosus GG ATCC 53103 | 1件: Lactobacillus delbrueckii bulgaricus Lactobacillus delbrueckii bulgaricus | - | - | - | 1件: 97 97 💬 |
1546 | Lactobacillus salivarius UCC118 | 1件: Lactobacillus salivarius Lactobacillus salivarius | - | - | - | 2件: 96 96, 97 💬 |
1547 | Lamotrigin ”Nordic Prime 50 mg | - | - | - | - | 1件: 114 114 💬 |
1548 | Lansoprazole 30mg | 1件: Lansoprazole Lansoprazole | 1件: Lansoprazole
Lansoprazole
💬 | 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 166 166 💬 |
1549 | Lantus 100 units/ml solution for injection in a cartridge | - | - | - | - | 1件: 299 299 💬 |
1550 | LANTUS*SC 5CAR3ML100UI/ML | 1件: Insulin glargine Insulin glargine | 1件: Insulin glargine
Insulin glargine
💬 | 1件: INSR INSR 💬 | 22件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Diabetic cardiomyopathy, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 299 299 💬 |
1551 | Lantus® 100 Units/ml solution for injection in a vial. Lantus® 100 Units/ml solution for injection in a cartridge. Lantus® 100 Units/ml solution for injection in a pre-filled pen | - | - | - | - | 1件: 299 299 💬 |
1552 | Laquinimod 0.3 | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
1553 | Laquinimod 0.6 | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
1554 | Laquinimod Capsulas 0.6 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
1555 | Laquinimod Capsules 0.3 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
1556 | Laquinimod capsules 0.5 mg | 1件: Laquinimod Laquinimod | - | - | - | 2件: 8 8, 96 💬 |
1557 | Laquinimod Capsules 0.6 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
1558 | Laquinimod Cápsulas 0.5 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 96 96 💬 |
1559 | Laquinimod Sodium (USAN) | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
1560 | Laquinimod Tablets 0.3 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
1561 | LC51-0255 | - | - | - | - | 1件: 97 97 💬 |
1562 | LCI699, 5 mg | - | - | - | - | 1件: 75 75 💬 |
1563 | LCZ696 50 mg | - | - | - | - | 1件: 58 58 💬 |
1564 | LDP-02 | - | - | - | - | 2件: 96 96, 97 💬 |
1565 | Leflunomide 20 mg+prednisone 0.5mg/kg/d | 2件: Leflunomide Leflunomide, Prednisone | 2件: Prednisone
Prednisone
,
Leflunomide
💬 | 2件: DHODH DHODH, NR3C1 💬 | 4件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Neuroactive ligand-receptor interaction, Pyrimidine metabolism 💬 | 1件: 66 66 💬 |
1566 | Lenabasum 5 mg | - | - | - | - | 2件: 51 51, 299 💬 |
1567 | Lenabasum 5 mg Powder in Capsule | - | - | - | - | 1件: 51 51 💬 |
1568 | Lenabasum 5mg Powder in Capsule | - | - | - | - | 1件: 51 51 💬 |
1569 | Letairis 5 mg | 1件: Ambrisentan Ambrisentan | 1件: Ambrisentan
Ambrisentan
💬 | 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 85 85 💬 |
1570 | Leuprolide Acetate 3 Month Depot | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
1571 | Leuprolide acetate 30 mg | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
1572 | Leuprorelin Acetate 3.75mg Injection | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
1573 | Leuprorelin Acetate Depot 3M | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
1574 | Levemir 100 U/ml solution for injection in a cartridge, Levemir 100 U/ml solution for injection in a pre-filled pen | 1件: Insulin detemir Insulin detemir | 1件: Insulin detemir
Insulin detemir
💬 | 1件: INSR INSR 💬 | 22件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Diabetic cardiomyopathy, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 299 299 💬 |
1575 | LEVODOPA / BENSERAZIDE 200 + 50 MG | 2件: Benserazide Benserazide, Levodopa | 2件: Levodopa
Levodopa
,
Benserazide
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1576 | Levodopa-Carbidopa XL tablet (M) | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1577 | Levodopa/Carbidopa(200mg/50mg) | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1578 | LEVOFOLENE 4 MG 30 CPR | 1件: Levoleucovorin Levoleucovorin | - | - | - | 1件: 13 13 💬 |
1579 | Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1 | 1件: Aminolevulinic acid Aminolevulinic acid | 1件: Aminolevulinic acid
Aminolevulinic acid
💬 | - | - | 1件: 34 34 💬 |
1580 | Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2 | 1件: Aminolevulinic acid Aminolevulinic acid | 1件: Aminolevulinic acid
Aminolevulinic acid
💬 | - | - | 1件: 34 34 💬 |
1581 | Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3 | 1件: Aminolevulinic acid Aminolevulinic acid | 1件: Aminolevulinic acid
Aminolevulinic acid
💬 | - | - | 1件: 34 34 💬 |
1582 | Lidocaine patch 5% | 1件: Lidocaine Lidocaine | 2件: Lidocaine
Lidocaine
,
Lidocaine hydrochloride monohydrate
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 13 13 💬 |
1583 | Liofen XL | - | - | - | - | 1件: 13 13 💬 |
1584 | LIORESAL*50CPR 10MG | 1件: Baclofen Baclofen | 1件: Baclofen
Baclofen
💬 | 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 2 2 💬 |
1585 | Lipiodol® Ultra Fluid with surgical glues | 1件: Ethiodized oil Ethiodized oil | 2件: Ethiodized oil
Ethiodized oil
,
Ethiodized oil I 131
💬 | - | - | 1件: 280 280 💬 |
1586 | Lipoic acid and omega-3 fatty acids | 2件: Lipoic acid Lipoic acid, Omega-3 fatty acids | - | - | - | 1件: 13 13 💬 |
1587 | Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. | 1件: Amikacin Amikacin | 1件: Amikacin
Amikacin
💬 | - | - | 1件: 299 299 💬 |
1588 | Liposomal Cyclosporine A 5 mg | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 228 228 💬 |
1589 | LIQ861 26.5 µg | - | - | - | - | 1件: 86 86 💬 |
1590 | LIQ861 50 µg | - | - | - | - | 1件: 86 86 💬 |
1591 | LIQ861 53 µg | - | - | - | - | 1件: 86 86 💬 |
1592 | LIQ861 79.5 µg | - | - | - | - | 1件: 86 86 💬 |
1593 | Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field | - | - | - | - | 1件: 13 13 💬 |
1594 | LJN452, 0,01 mg | - | - | - | - | 1件: 93 93 💬 |
1595 | LJN452, 0,03 mg | - | - | - | - | 1件: 93 93 💬 |
1596 | LJN452, 0,1 mg | - | - | - | - | 1件: 93 93 💬 |
1597 | LJP 394 | - | - | - | - | 1件: 49 49 💬 |
1598 | LOBIVON*28CPR 5MG | - | - | - | - | 1件: 167 167 💬 |
1599 | Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol) | 4件: Acetate Acetate, Estradiol, Ethinylestradiol, Norethisterone | 3件: Estradiol
Estradiol
,
Norethindrone
,
Ethinyl estradiol
💬 | 3件: ESR1 ESR1, ESR2, PGR 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 2件: 46 46, 49 💬 |
1600 | Lojuxta 5 mg hard capsules | 1件: Lomitapide Lomitapide | 1件: Lomitapide
Lomitapide
💬 | 1件: MTTP MTTP 💬 | 1件: Fat digestion and absorption Fat digestion and absorption 💬 | 1件: 79 79 💬 |
1601 | Long term follow up in all patients who received SAR422459 in previous study TDU13583 | - | - | - | - | 1件: 301 301 💬 |
1602 | Long-chain n-3 PUFA | - | - | - | - | 1件: 46 46 💬 |
1603 | LORTAAN*28CPR RIV DIV 50MG | - | - | - | - | 1件: 167 167 💬 |
1604 | Losartan Bluefish 50 mg | 2件: Bluefish Bluefish, Losartan | 1件: Losartan
Losartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 58 58 💬 |
1605 | LP-08 20mg | - | - | - | - | 1件: 226 226 💬 |
1606 | LP-08 80mg | - | - | - | - | 1件: 226 226 💬 |
1607 | LT-02 | - | - | - | - | 1件: 97 97 💬 |
1608 | LT-02 (modified-release PC pellets) | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 97 97 💬 |
1609 | LTS 0.25mg | - | - | - | - | 1件: 46 46 💬 |
1610 | LTS 0.5mg | - | - | - | - | 1件: 46 46 💬 |
1611 | LTS 1.0mg | - | - | - | - | 1件: 46 46 💬 |
1612 | Lu 00-800 | - | - | - | - | 1件: 6 6 💬 |
1613 | Luphere depot 3.75mg(Leuprolide acetate 3.75mg) | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
1614 | Lutein (10 or 30 mg/day) capsules | 1件: Lutein Lutein | - | - | - | 1件: 90 90 💬 |
1615 | LY3337641 5 mg | - | - | - | - | 1件: 46 46 💬 |
1616 | LYC-30937 | - | - | - | - | 1件: 97 97 💬 |
1617 | LYC-30937-EC | - | - | - | - | 1件: 97 97 💬 |
1618 | Lym-X-Sorb powder | - | - | - | - | 1件: 299 299 💬 |
1619 | M2951 50 mg BID | - | - | - | - | 1件: 46 46 💬 |
1620 | MABTHERA - 1 FIALA 500 MG 50 ML | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 2件: 14 14, 53 💬 |
1621 | MabThera 500 | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 271 271 💬 |
1622 | MabThera 500 mg | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
1623 | MabThera 500 mg (10 mg/ml) concentrate for solution for infusion | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
1624 | MabThera 500 mg (10mg/ml) | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
1625 | MABTHERA 500 mg concentrado para solución para perfusión | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
1626 | MabThera 500 mg concentrate for solution for infusion | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 2件: 46 46, 222 💬 |
1627 | MabThera 500 mg Konzentrat zur Herstellung einer Infusionslösung | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
1628 | MabThera 500mg | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
1629 | MABTHERA*EV 1FL 50ML 500MG | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 2件: 46 46, 222 💬 |
1630 | MabThera® 500MG | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 43 43 💬 |
1631 | Macitentan (ACT-064992) | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
1632 | Macitentan 3 mg | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
1633 | Macitentan 37.5 mg | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
1634 | Macitentan 3mg | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
1635 | Madopar 200+50 mg | - | - | - | - | 1件: 6 6 💬 |
1636 | Magnesiocard 2.5mmol | - | - | - | - | 1件: 298 298 💬 |
1637 | Masitinib (3.0) | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 1件: 2 2 💬 |
1638 | Masitinib (4.5) | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 2件: 2 2, 13 💬 |
1639 | Masitinib (6.0) | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 1件: 2 2 💬 |
1640 | Masitinib 3 mg | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 1件: 46 46 💬 |
1641 | Masitinib 6.0 mg | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 1件: 46 46 💬 |
1642 | MAVENCLAD - 10 MG - COMPRESSA - USO ORALE - BLISTER (AL/AL) - 6 COMPRESSE | 1件: Cladribine Cladribine | 1件: Cladribine
Cladribine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
1643 | Mavrilimumab 30 mg | 1件: Mavrilimumab Mavrilimumab | 1件: Mavrilimumab
Mavrilimumab
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 46 46 💬 |
1644 | Mavrilimumab 50 mg | 1件: Mavrilimumab Mavrilimumab | 1件: Mavrilimumab
Mavrilimumab
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 46 46 💬 |
1645 | Maximal oral 5ASA | - | - | - | - | 1件: 97 97 💬 |
1646 | Mayzent 0,25 mg Filmtabletten | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1647 | Mayzent 0.25 mg fi | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1648 | MBM-01 | - | - | - | - | 1件: 65 65 💬 |
1649 | MBS2320 5 mg | - | - | - | - | 1件: 46 46 💬 |
1650 | MBX-8025 50 mg (Dose Escalation Period 1) | - | - | - | - | 1件: 79 79 💬 |
1651 | MBX-8025 50 mg or 100 mg (Dose Escalation Period 2) | - | - | - | - | 1件: 79 79 💬 |
1652 | MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3) | - | - | - | - | 1件: 79 79 💬 |
1653 | MD-0901 | - | - | - | - | 1件: 97 97 💬 |
1654 | MDGN-002 | - | - | - | - | 1件: 96 96 💬 |
1655 | MEDI 545 | - | - | - | - | 1件: 49 49 💬 |
1656 | MEDI-522 | - | - | - | - | 1件: 46 46 💬 |
1657 | MEDI-545 | - | - | - | - | 2件: 49 49, 50 💬 |
1658 | MEDI-545 600 | - | - | - | - | 1件: 49 49 💬 |
1659 | MEDI-546 | - | - | - | - | 2件: 49 49, 51 💬 |
1660 | MEDI-551 | - | - | - | - | 2件: 13 13, 51 💬 |
1661 | MEDI-551 100 MG-IV | - | - | - | - | 1件: 13 13 💬 |
1662 | MEDI-551 30 MG-IV | - | - | - | - | 1件: 13 13 💬 |
1663 | MEDI-551 300 MG-SC | - | - | - | - | 1件: 13 13 💬 |
1664 | MEDI-551 60 MG-SC | - | - | - | - | 1件: 13 13 💬 |
1665 | MEDI-551 600 MG-IV | - | - | - | - | 1件: 13 13 💬 |
1666 | MEDI-563 | - | - | - | - | 5件: 44 44, 45, 98, 162, 299 💬 |
1667 | MEDI-570 0.03 MG | - | - | - | - | 1件: 49 49 💬 |
1668 | MEDI-570 0.1 MG | - | - | - | - | 1件: 49 49 💬 |
1669 | MEDI-570 0.3 MG | - | - | - | - | 1件: 49 49 💬 |
1670 | MEDI-570 1 MG | - | - | - | - | 1件: 49 49 💬 |
1671 | MEDROL - 4 MG COMPRESSE 30 COMPRESSE | - | - | - | - | 1件: 56 56 💬 |
1672 | Meloxicam 0.125 mg/kg | 1件: Meloxicam Meloxicam | 1件: Meloxicam
Meloxicam
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
1673 | Meloxicam 0.25 mg/kg | 1件: Meloxicam Meloxicam | 1件: Meloxicam
Meloxicam
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
1674 | MENVEO - POLV.E SOLUZ.PER SOLUZ. INIETT.-USO INTRAMUSCOLARE-COMP. CONIUG.LIOFILIZZ.MENA:FLAC.(VETRO) COMP. GONIUG.LIQUI.MENCWY:FLAC.(VETRO)-1 FLAC+1FLAC | 9件: Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine, Meningococcal polysaccharide vaccine group A, Meningococcal polysaccharide vaccine group C, Meningococcal polysaccharide vaccine group W-135, Meningococcal polysaccharide vaccine group Y, Neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen, Neisseria meningitidis group c capsular oligosaccharide diphtheria crm197 protein conjugate antigen, Neisseria meningitidis group w-135 capsular oligosaccharide diphtheria crm197 protein conjugate antigen, Neisseria meningitidis group y capsular oligosaccharide diphtheria crm197 protein conjugate antigen | 2件: Meningococcal polysaccharide vaccine group A
Meningococcal polysaccharide vaccine group A
,
Meningococcal polysaccharide vaccine group C
💬 | - | - | 2件: 62 62, 66 💬 |
1675 | Mepolizumab (a-IL-5 antibody) | 1件: Mepolizumab Mepolizumab | 1件: Mepolizumab
Mepolizumab
💬 | 1件: IL5 IL5 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 1件: 162 162 💬 |
1676 | Mepolizumab 300 mg | 1件: Mepolizumab Mepolizumab | 1件: Mepolizumab
Mepolizumab
💬 | 1件: IL5 IL5 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 1件: 98 98 💬 |
1677 | Mesalamine, 5-aminosalicylic acid | 2件: Aminosalicylic acid Aminosalicylic acid, Mesalazine | 2件: Aminosalicylic acid
Aminosalicylic acid
,
Mesalamine
💬 | - | - | 1件: 96 96 💬 |
1678 | Mesalamine, 5-aminosalicylic acid [5-ASA] | 2件: Aminosalicylic acid Aminosalicylic acid, Mesalazine | 2件: Aminosalicylic acid
Aminosalicylic acid
,
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1679 | Mesalamine, 5-ASA | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1680 | Mesalazine (3,600 mg) | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1681 | Mesalazine - TID 2x 500 mg | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1682 | Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet | 2件: Mesalazine Mesalazine, Nitazoxanide | 2件: Mesalamine
Mesalamine
,
Nitazoxanide
💬 | - | - | 1件: 97 97 💬 |
1683 | Mesalazine 500 mg gastro-resistant tablets (Salofa | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1684 | Mesalazine 500 mg gastro-resistant tablets (Salofalk® 500 mg) | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1685 | Mesalazine EC 500 mg | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 96 96 💬 |
1686 | Mesenchymal stem cell 0.5 | - | - | - | - | 1件: 228 228 💬 |
1687 | Mesenchymal stem cell 1.0 | - | - | - | - | 1件: 228 228 💬 |
1688 | Metalcaptase® 300 mg gastro-resistant tablet | - | - | - | - | 1件: 171 171 💬 |
1689 | Metex 2,5 mg Tabletten | - | - | - | - | 1件: 44 44 💬 |
1690 | Metex 2,5mg Tabletten | - | - | - | - | 1件: 46 46 💬 |
1691 | Metex 50 mg/ml injeksjonsvæske, oppløsning i ferdigfylt sprøyte | - | - | - | - | 1件: 46 46 💬 |
1692 | Metex 7,5mg Tabletten | - | - | - | - | 1件: 46 46 💬 |
1693 | Metex® 50 mg/ml Injektionslösung, Fertigspritze | - | - | - | - | 1件: 46 46 💬 |
1694 | Metformin 500 Mg Oral Tablet, up to 4 tablets a day | 1件: Metformin Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 13 13 💬 |
1695 | Metformin 500 mg TID Oral Tablet | 1件: Metformin Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1696 | Metformin 500mg | 1件: Metformin Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 113 113 💬 |
1697 | Metformin XR | 1件: Metformin Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 67 67 💬 |
1698 | Metformin/CP-690,550 | 1件: Metformin Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1699 | METFORMINA - 500 30 COMPRESSE 500 MG | 1件: Metformin Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 113 113 💬 |
1700 | METFORMINE ARROW 500mg | 1件: Metformin Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1701 | Metformine HCL 500 PCH | 1件: Metformin Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 299 299 💬 |
1702 | Methotrexat 2,5 mg Tabletten medac | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1703 | Methotrexat HEXAL® 2,5 mg Tabletten | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1704 | Methotrexat Lachema 2,5mg | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 50 50 💬 |
1705 | Methotrexat Lachema 2,5mg tbl. | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 50 50 💬 |
1706 | Methotrexat Lachema 5 inj. sol | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 50 50 💬 |
1707 | Methotrexat Lederle 2.5mg tablets | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1708 | Methotrexate 'Lederle' 2,5mg tablets | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1709 | Methotrexate 'Lederle' 2.5mg Tablets | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1710 | METHOTREXATE - 20 MG/0.8 ML SOLUZIONE INIETTABILE 4 SIRINGHE PRERIEMPITE MONOUSO DA 1.25 ML | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 96 96 💬 |
1711 | Methotrexate 2.5 mg | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 44 44 💬 |
1712 | METHOTREXATE 2.5 mg tablets | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1713 | Methotrexate 2.5mg Tablets | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1714 | Methotrexate 2.5mg Tablets BP | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1715 | Methotrexate 50mg/ml solution for injection, pre-filled syringe | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1716 | Methotrexate ``Lederle`` 2.5mg tablets | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1717 | METHOTREXATE HOSPIRA 2,5 mg tablety | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1718 | METHOTREXATE HOSPIRA 2.5 mg tablety | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1719 | Methotrexate Lachema 5inj. sol | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 50 50 💬 |
1720 | Methotrexate Lederle 2.5 mg Tablets | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1721 | Methotrexate Pfizer 2,5 mg tabletter | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1722 | Methotrexate plus ERB-041 for 12 weeks | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1723 | Methotrexate Sodium 2.5mg Tablets | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1724 | Methotrexate Sodium Tablets 2.5 mg | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1725 | Methotrexate Sodium Tablets 2.5mg | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1726 | Methotrexate tablets 2.5 mg | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1727 | Methotrexate Wyeth 2,5mg | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 50 50 💬 |
1728 | Methotrexate Wyeth 2,5mg tbl. | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 50 50 💬 |
1729 | Methotrexate ® 2.5mg Tablets | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1730 | METHOTREXATE*100CPR 2,5MG | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1731 | METHOTREXATE*10MG/1,33ML 4S | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1732 | METHOTREXATE*2,5MG 25CPR | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1733 | METHOTREXATE*25CPR 2,5MG | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 2件: 46 46, 107 💬 |
1734 | METHOTREXATE*7,5MG/ML 4SIR. | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1735 | Methotrexate® 2.5 mg tablets | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1736 | Methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-beta-Dribofuronamide | 1件: Adenine Adenine | 1件: Adenine
Adenine
💬 | - | - | 1件: 46 46 💬 |
1737 | Methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-ß-Dribofuronamide | 1件: Adenine Adenine | 1件: Adenine
Adenine
💬 | - | - | 1件: 46 46 💬 |
1738 | Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carb | - | - | - | - | 2件: 86 86, 88 💬 |
1739 | Methyl [4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]meth | - | - | - | - | 2件: 86 86, 88 💬 |
1740 | Methylphenidate modified release 30 mg | 1件: Methylphenidate Methylphenidate | 1件: Methylphenidate
Methylphenidate
💬 | 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
1741 | Methylprednisolone 1250 mg/24h x3 days | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 💬 |
1742 | Methylprednisolone bolus IV 15 mg/kg/d for 3 days. | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 84 84 💬 |
1743 | Methylprednisolone(intravenously in the 1st-2nd-3rd month ) | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 66 66 💬 |
1744 | Methylprednisolone(intravenously in the 1st-3rd-5th month) | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 66 66 💬 |
1745 | MetoHEXAL® Succ ® 47,5 mg Retardtabletten | - | - | - | - | 1件: 113 113 💬 |
1746 | Metoprolol tartrate 50 mg | 1件: Metoprolol Metoprolol | 1件: Metoprolol
Metoprolol
💬 | 1件: ADRB1 ADRB1 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 17 17 💬 |
1747 | METOTREXATO SANDOZ - 2.5 MG COMPRESSE 50 COMPRESSE IN FLACONE PP | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1748 | METOTREXATO-LEDERLE 2,5 MG COMPRIMIDOS | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1749 | Metronidazole capsule 50 mg | 1件: Metronidazole Metronidazole | 1件: Metronidazole
Metronidazole
💬 | - | - | 1件: 97 97 💬 |
1750 | Mezavant XL | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1751 | Mezavant XL 1200 mg gastro-resistant prolonged release tablets | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1752 | Mezavant XL 1200 mg gastro-resistant, prolonged release tablets | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1753 | Mezavant XL 1200 mg gastro-resistant, prolonged release tablets. | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1754 | Mezavant XL 1200mg gastro-resistant, prolonged release tablets | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1755 | Mezavant XL Gastro-resistant, prolonged release tablets | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1756 | MH004 Ia(0.1%) | - | - | - | - | 1件: 46 46 💬 |
1757 | MH004 Ia(0.3%) | - | - | - | - | 1件: 46 46 💬 |
1758 | MH004 Ia(3%) | - | - | - | - | 1件: 46 46 💬 |
1759 | MH004 Ib-1(0.1%) | - | - | - | - | 1件: 46 46 💬 |
1760 | MH004 Ib-1(0.3%) | - | - | - | - | 1件: 46 46 💬 |
1761 | MH004 Ib-2(0.3%) | - | - | - | - | 1件: 46 46 💬 |
1762 | MH004 Ib-2(3%) | - | - | - | - | 1件: 46 46 💬 |
1763 | Microgynon® 30 (Oral contraceptive) | - | - | - | - | 1件: 46 46 💬 |
1764 | Midazolam 3 mg | 1件: Midazolam Midazolam | 1件: Midazolam
Midazolam
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 96 96 💬 |
1765 | MIRAPEXIN*30CPR 0,7MG | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1766 | Mirdametinib (PD-0325901) oral capsule or dispersible tablet | 1件: Mirdametinib Mirdametinib | 1件: Mirdametinib
Mirdametinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
1767 | MK-0653 | - | - | - | - | 1件: 260 260 💬 |
1768 | MK-0663 | - | - | - | - | 2件: 46 46, 271 💬 |
1769 | MK-0859 | - | - | - | - | 1件: 79 79 💬 |
1770 | MK-0873 | 1件: MK-0873 MK-0873 | - | - | - | 1件: 46 46 💬 |
1771 | MK-3222 | - | - | - | - | 1件: 271 271 💬 |
1772 | MK-5475 | - | - | - | - | 1件: 86 86 💬 |
1773 | MM-093 | 1件: MM-093 MM-093 | - | - | - | 1件: 46 46 💬 |
1774 | MN-001 | - | - | - | - | 1件: 226 226 💬 |
1775 | MN-001 BID | - | - | - | - | 1件: 226 226 💬 |
1776 | MN-08 24 mg/day | - | - | - | - | 1件: 86 86 💬 |
1777 | MN-08 60 mg/day | - | - | - | - | 1件: 86 86 💬 |
1778 | Modafinil 50mg | 1件: Modafinil Modafinil | 1件: Modafinil
Modafinil
💬 | - | - | 1件: 6 6 💬 |
1779 | Modified Oral Glucose Tolerance Test (50g 4-hours) | 1件: Dextrose, unspecified form Dextrose, unspecified form | - | - | - | 1件: 299 299 💬 |
1780 | Modopar 62,5 | - | - | - | - | 1件: 6 6 💬 |
1781 | Molgramostim 300 mcg nebuliser solution | 1件: Molgramostim Molgramostim | 1件: Molgramostim
Molgramostim
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 229 229 💬 |
1782 | Molgramostim 300 µg nebulizer solution | 1件: Molgramostim Molgramostim | 1件: Molgramostim
Molgramostim
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 229 229 💬 |
1783 | Molgramostim Nebuliser solution 300 mcg | 1件: Molgramostim Molgramostim | 1件: Molgramostim
Molgramostim
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 229 229 💬 |
1784 | MONORES*30CPR 20MCG | - | - | - | - | 1件: 1 1 💬 |
1785 | Monotherapy (Lopinavir/ritonavir) + ABC/3TC | 2件: Lopinavir Lopinavir, Ritonavir | 2件: Ritonavir
Ritonavir
,
Lopinavir
💬 | - | - | 1件: 265 265 💬 |
1786 | Monovalent [B.1.351] CoV2 preS dTM-AS03 | - | - | - | - | 7件: 13 13, 35, 46, 49, 50, 51, 107 💬 |
1787 | Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 1件: 2 2 💬 |
1788 | MORAb-022 | - | - | - | - | 1件: 46 46 💬 |
1789 | MORF-057 | - | - | - | - | 1件: 97 97 💬 |
1790 | MOZOBIL - 20 MG/ML - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - F | 1件: Plerixafor Plerixafor | 1件: Plerixafor
Plerixafor
💬 | 1件: CXCR4 CXCR4 💬 | 14件: Axon guidance Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬 | 1件: 19 19 💬 |
1791 | MOZOBIL - 20 MG/ML - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) - 24 MG/1.2 ML 1 FLACONCINO | 1件: Plerixafor Plerixafor | 1件: Plerixafor
Plerixafor
💬 | 1件: CXCR4 CXCR4 💬 | 14件: Axon guidance Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬 | 1件: 65 65 💬 |
1792 | Mozobil 20mg/mL vial (injectable solution for subcutaneous use) | 1件: Plerixafor Plerixafor | 1件: Plerixafor
Plerixafor
💬 | 1件: CXCR4 CXCR4 💬 | 14件: Axon guidance Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬 | 1件: 65 65 💬 |
1793 | Mozobil 20mg/mL vial (injectable solution, subcutaneous use) | 1件: Plerixafor Plerixafor | 1件: Plerixafor
Plerixafor
💬 | 1件: CXCR4 CXCR4 💬 | 14件: Axon guidance Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬 | 1件: 65 65 💬 |
1794 | MP-376 | - | - | - | - | 1件: 299 299 💬 |
1795 | MP-376 (Levofloxacin Solution for Inhalation) | 1件: Levofloxacin Levofloxacin | 2件: Levofloxacin
Levofloxacin
,
Levofloxacin
💬 | - | - | 1件: 299 299 💬 |
1796 | MQX-503 | - | - | - | - | 1件: 51 51 💬 |
1797 | MR-MC-01 | - | - | - | - | 1件: 226 226 💬 |
1798 | MRA 003 US | - | - | - | - | 1件: 49 49 💬 |
1799 | MRNA che codifica l’enzima umano deramificante del glicogeno formulato in una nanopaticella lipidica | - | - | - | - | 1件: 257 257 💬 |
1800 | MRNA-3704 | - | - | - | - | 1件: 246 246 💬 |
1801 | MRNA-3705 | - | - | - | - | 1件: 246 246 💬 |
1802 | MRNA-3927 | - | - | - | - | 1件: 245 245 💬 |
1803 | MSC injection 01 | - | - | - | - | 1件: 96 96 💬 |
1804 | MSC injection 02 | - | - | - | - | 1件: 96 96 💬 |
1805 | MSC treatment 01 | - | - | - | - | 1件: 96 96 💬 |
1806 | MSC treatment 02 | - | - | - | - | 1件: 96 96 💬 |
1807 | MSC2430913A or ONO-4641 (to be used as synonyms) | - | - | - | - | 1件: 13 13 💬 |
1808 | MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1809 | MSTC-001 (MS-STAT) | - | - | - | - | 1件: 13 13 💬 |
1810 | MT-1303 [0.1] | - | - | - | - | 1件: 13 13 💬 |
1811 | MT-1303 [0.2] | - | - | - | - | 1件: 13 13 💬 |
1812 | MT-1303 [0.4] | - | - | - | - | 1件: 13 13 💬 |
1813 | MT-3921 | - | - | - | - | 1件: 26 26 💬 |
1814 | MTC TRx0014-001 capsules | - | - | - | - | 1件: 127 127 💬 |
1815 | MTX 12.5 | - | - | - | - | 1件: 97 97 💬 |
1816 | MTX HEXAL 2,5 mg Tabletten | - | - | - | - | 1件: 46 46 💬 |
1817 | MTX HEXAL 2,5mg Tabletten | - | - | - | - | 1件: 46 46 💬 |
1818 | Mycophenolate Mofetil (MMF) 3 g/Day | 2件: Mycophenolate mofetil Mycophenolate mofetil, Mycophenolic acid | 2件: Mycophenolate mofetil
Mycophenolate mofetil
,
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 35 35 💬 |
1819 | Mycophenolate Mofetil 500mg | 2件: Mycophenolate mofetil Mycophenolate mofetil, Mycophenolic acid | 2件: Mycophenolate mofetil
Mycophenolate mofetil
,
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 3件: 49 49, 51, 61 💬 |
1820 | MYELOSTIM - 34 1 FLACONCINO LIOFILIZZATO 33.6 MIU + SIRINGA PRERIEMPITA SOLVENTE 1 ML | - | - | - | - | 2件: 19 19, 65 💬 |
1821 | MYELOSTIM 34 milions UI/ml - powder and solvent for solution for injection/infusion | - | - | - | - | 1件: 65 65 💬 |
1822 | MYELOSTIM 34 milions UI/ml, powder and solvent for solution for injection or infusion | - | - | - | - | 1件: 65 65 💬 |
1823 | MYELOSTIM 34*1FL 263MCG+1SIR | - | - | - | - | 1件: 2 2 💬 |
1824 | Myfortic 360mg Tablets | 1件: Mycophenolic acid Mycophenolic acid | 1件: Mycophenolic acid
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 2件: 66 66, 222 💬 |
1825 | MYFORTIC*50CPR RIV 360MG | 1件: Mycophenolic acid Mycophenolic acid | 1件: Mycophenolic acid
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 49 49 💬 |
1826 | MYO-029 | 1件: Stamulumab Stamulumab | 1件: Stamulumab
Stamulumab
💬 | 1件: MSTN MSTN 💬 | 1件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction 💬 | 1件: 113 113 💬 |
1827 | MYONAL*30CPR RIV 100MG | - | - | - | - | 1件: 2 2 💬 |
1828 | Myozyme 50 mg powder for concentrate for solution for infusion | 1件: Alglucosidase alfa Alglucosidase alfa | 1件: Alglucosidase alfa
Alglucosidase alfa
💬 | 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 💬 |
1829 | N(4,5Bis methanesulfonyl2methylbenzoyl) guanidine hydrochloride monohydrate | 1件: Guanidine Guanidine | - | - | - | 1件: 113 113 💬 |
1830 | N,N,N',N'-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) | 1件: Phenothiazine Phenothiazine | 1件: Phenothiazine
Phenothiazine
💬 | - | - | 1件: 127 127 💬 |
1831 | N,N,N?,N?-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) | 1件: Phenothiazine Phenothiazine | 1件: Phenothiazine
Phenothiazine
💬 | - | - | 1件: 127 127 💬 |
1832 | N,N,N’,N’-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) | 1件: Phenothiazine Phenothiazine | 1件: Phenothiazine
Phenothiazine
💬 | - | - | 1件: 127 127 💬 |
1833 | N-(4,5-Bis methanesulfonyl-2-methyl-benzoyl)guanidine hydrochloride monohydrate | 1件: Guanidine Guanidine | - | - | - | 1件: 113 113 💬 |
1834 | N-(5-hydroxy-2,4- bis(trimethylsilyl)phenyl)-4-oxo- 1,4-dihydroquinoline-3-carboxamide | - | - | - | - | 1件: 299 299 💬 |
1835 | N-(5-hydroxy-2,4-bis(trimethylsilyl)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide | - | - | - | - | 1件: 299 299 💬 |
1836 | N-(5-{4-[(3,3-dimethyl-1-azetidinyl)carbonyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide | - | - | - | - | 1件: 49 49 💬 |
1837 | N-(trans-3-(5-((R)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)cyclobutyl)-3-phenylisoxazole-5-carboxamide | - | - | - | - | 1件: 299 299 💬 |
1838 | N-0923 | - | - | - | - | 1件: 6 6 💬 |
1839 | N-3 LC-PUFA | - | - | - | - | 1件: 46 46 💬 |
1840 | N-3 Polyunsaturated Fatty Acids | - | - | - | - | 1件: 96 96 💬 |
1841 | N-[1-((5-cyanopyridin-2-yl)methyl)-1H-pyrazol-3-yl]-2-[4-(1-(trifluoromethyl)cyclopropyl)phenyl]acetamide | 2件: Acetamide Acetamide, Pyrazole | - | - | - | 1件: 154 154 💬 |
1842 | N-methyl D-(2,3,4,5,6-pentahydroxy-hexyl)-ammonium | - | - | - | - | 1件: 28 28 💬 |
1843 | N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine | - | - | - | - | 1件: 13 13 💬 |
1844 | N-trans-3-Hexenoyl] Human Growth Hormone Releasing Factor (1-44) Acetate | 2件: Acetate Acetate, Somatotropin | - | - | - | 1件: 265 265 💬 |
1845 | Nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin) | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 86 86 💬 |
1846 | Nabilone 0.25 mg | 1件: Nabilone Nabilone | 1件: Nabilone
Nabilone
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 6 6 💬 |
1847 | NaCl 0.9% | - | - | - | - | 1件: 39 39 💬 |
1848 | Nanogam® 50 mg/ml | - | - | - | - | 1件: 65 65 💬 |
1849 | Naprosyn 500 mg | 1件: Naproxen Naproxen | 1件: Naproxen
Naproxen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
1850 | Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.) | 1件: Naproxen Naproxen | 1件: Naproxen
Naproxen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
1851 | Naproxen 500 mg tablets (PN 200 minus omeprazole) | 2件: Naproxen Naproxen, Omeprazole | 2件: Naproxen
Naproxen
,
Omeprazole
💬 | 4件: ATP4A ATP4A, ATP4B, PTGS1, PTGS2 💬 | 26件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Collecting duct acid secretion, Gastric acid secretion, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxidative phosphorylation, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 2件: 46 46, 271 💬 |
1852 | Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.) | 1件: Naproxen Naproxen | 1件: Naproxen
Naproxen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
1853 | Naproxen sodium 550mg tablet | 1件: Naproxen Naproxen | 1件: Naproxen
Naproxen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
1854 | Natalizumab 300 MG in 15 ML Injection | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
1855 | National Drug Code: 59762-0074 | - | - | - | - | 1件: 81 81 💬 |
1856 | Natriumchlorid 0,9 % | 1件: Sodium chloride Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 288 288 💬 |
1857 | NBI-5788 | - | - | - | - | 1件: 13 13 💬 |
1858 | NBTX-001 | - | - | - | - | 1件: 6 6 💬 |
1859 | NC-503 (Anti-amyloidotic (AA) Agent) | - | - | - | - | 1件: 46 46 💬 |
1860 | NCA 500mg | - | - | - | - | 1件: 93 93 💬 |
1861 | NDC0009-0436-01 | - | - | - | - | 1件: 78 78 💬 |
1862 | NDV-3A | - | - | - | - | 1件: 65 65 💬 |
1863 | NEB/01-07 | - | - | - | - | 1件: 299 299 💬 |
1864 | Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection | 3件: Testosterone Testosterone, Testosterone undecanoate, Undecanoic acid | 2件: Testosterone
Testosterone
,
Testosterone undecanoate
💬 | 1件: AR AR 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Oocyte meiosis, Pathways in cancer, Prostate cancer 💬 | 1件: 13 13 💬 |
1865 | Nebivolol 5 mg | 1件: Nebivolol Nebivolol | 1件: Nebivolol
Nebivolol
💬 | 1件: ADRB1 ADRB1 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 17 17 💬 |
1866 | Nerve Growt Factor - 2.5S | - | - | - | - | 1件: 90 90 💬 |
1867 | Neurontin 300 mg hard capsule | 1件: Gabapentin Gabapentin | 1件: Gabapentin
Gabapentin
💬 | 5件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
1868 | NeuroVax 300ug/mL Dose for IM Injection | 1件: NeuroVax NeuroVax | - | - | - | 1件: 13 13 💬 |
1869 | NI-0101 | - | - | - | - | 1件: 46 46 💬 |
1870 | NI-03 | - | - | - | - | 1件: 298 298 💬 |
1871 | NI-0401 (anti-CD3 mAB) | 1件: Muromonab Muromonab | - | - | - | 1件: 96 96 💬 |
1872 | NI-0501 | - | - | - | - | 1件: 107 107 💬 |
1873 | NI-071 | - | - | - | - | 1件: 46 46 💬 |
1874 | NI-0801 | - | - | - | - | 1件: 93 93 💬 |
1875 | Nicorette 5 mg/ 16 h | 1件: Nicotine Nicotine | 1件: Nicotine
Nicotine
💬 | 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 8件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬 | 1件: 6 6 💬 |
1876 | Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY) | 1件: Nicotine Nicotine | 1件: Nicotine
Nicotine
💬 | 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 8件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬 | 1件: 6 6 💬 |
1877 | Nicotinell 17,5 mg/24-Stunden-Pflaster | - | - | - | - | 1件: 6 6 💬 |
1878 | Nicotinell 35 mg/24-Stunden-Pflaster | - | - | - | - | 1件: 6 6 💬 |
1879 | Nilotinib 300mg oral capsule [Tasigna] | 1件: Nilotinib Nilotinib | 1件: Nilotinib
Nilotinib
💬 | 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 6 6 💬 |
1880 | Nilotinib 50 mg | 1件: Nilotinib Nilotinib | 1件: Nilotinib
Nilotinib
💬 | 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 86 86 💬 |
1881 | Nitazoxanide 500Mg Oral Tablet | 1件: Nitazoxanide Nitazoxanide | 1件: Nitazoxanide
Nitazoxanide
💬 | - | - | 2件: 46 46, 97 💬 |
1882 | NNC 0109-0000-0012 | - | - | - | - | 1件: 46 46 💬 |
1883 | NNC 0141-0000-0100 | - | - | - | - | 1件: 46 46 💬 |
1884 | NNC 0142-0000-0002 | - | - | - | - | 2件: 46 46, 96 💬 |
1885 | NNC 0151-0000-0000 | - | - | - | - | 2件: 46 46, 49 💬 |
1886 | NNC 126-0083 | - | - | - | - | 1件: 78 78 💬 |
1887 | NNC 142-0002 | - | - | - | - | 1件: 46 46 💬 |
1888 | NNC0109-0012 | - | - | - | - | 1件: 46 46 💬 |
1889 | NNC0114-0000-0005 | - | - | - | - | 1件: 46 46 💬 |
1890 | NNC0114-0006 | - | - | - | - | 3件: 46 46, 49, 96 💬 |
1891 | NNC0142-0000-0002 | - | - | - | - | 1件: 96 96 💬 |
1892 | NNC0142-0002 | - | - | - | - | 1件: 46 46 💬 |
1893 | NNC0151-0000-0000 | - | - | - | - | 1件: 46 46 💬 |
1894 | NNC0195-0092 | - | - | - | - | 1件: 78 78 💬 |
1895 | NNC0195-0092 10 mg/1.5 ml PDS290-10 | - | - | - | - | 1件: 78 78 💬 |
1896 | NNC0195-0092 15 mg/1.5 ml PDS290-15 | - | - | - | - | 1件: 78 78 💬 |
1897 | NNC0195-0092 5 mg/1.5 ml PDS290-10 | - | - | - | - | 1件: 78 78 💬 |
1898 | NNC0195-0092 DP 6.7 mg ml 3 ml cartridge | - | - | - | - | 1件: 78 78 💬 |
1899 | NNC0195-0092 PDS290 10 mg-1.5 ml | - | - | - | - | 1件: 78 78 💬 |
1900 | NNC0195-0092 PDS290 10 mg/1.5 ml | - | - | - | - | 1件: 78 78 💬 |
1901 | NNC0215-0384 | - | - | - | - | 2件: 46 46, 162 💬 |
1902 | NNC109-0012 | - | - | - | - | 1件: 46 46 💬 |
1903 | NNC126-0083 | 1件: Somatropin pegol Somatropin pegol | - | - | - | 1件: 78 78 💬 |
1904 | NNC142-0002 | - | - | - | - | 1件: 96 96 💬 |
1905 | NNC151-0000 | - | - | - | - | 1件: 46 46 💬 |
1906 | Norditropin FlexPro 10 mg/1.5 ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1907 | Norditropin FlexPro 10 mg/1.5 ml, solution for injection in pre-filled pen | 1件: Somatotropin Somatotropin | - | - | - | 1件: 195 195 💬 |
1908 | Norditropin FlexPro 5 mg/1.5 mL | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1909 | Norditropin FlexPro 5mg/1.5 ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1910 | Norditropin NordiFlex® 10 mg/1.5 ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1911 | Norditropin NordiFlex® 10mg/1.5 ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1912 | Norditropin SimplexX (5mg/1,5 ml) (INN:somatropin) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1913 | Norditropin SimpleXx 15 mg/1.5 ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 3 3 💬 |
1914 | Norditropin SimpleXx 5mg/1.5ml | 1件: Somatotropin Somatotropin | - | - | - | 2件: 78 78, 107 💬 |
1915 | Norditropin® SimpleXx® 5 mg/1.5ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1916 | Normal Saline 0.9% Infusion Solution | - | - | - | - | 1件: 22 22 💬 |
1917 | Norucholic acid (NCA) 500 mg | 1件: norUrsodeoxycholic acid norUrsodeoxycholic acid | - | - | - | 1件: 93 93 💬 |
1918 | NOVANTRONE*INF 2MG/ML 5ML | 1件: Mitoxantrone Mitoxantrone | 1件: Mitoxantrone
Mitoxantrone
💬 | 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 1件: 13 13 💬 |
1919 | NovoNorm 0.5 mg | - | - | - | - | 1件: 299 299 💬 |
1920 | NovoRapid 100 U/ml, solution for injection in a vial. NovoRapid Penfill 100 U/ml, solution for injection in a cartridge. NovoRapid FlexPen 100 U/ml, solution for injection in a pre-filled pen. | - | - | - | - | 1件: 299 299 💬 |
1921 | NOXAFIL - 40 MG/ML SOSPENSIONE ORALE USO ORALE FLACONE (VETRO) 105 ML 1 FLACONE | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 299 299 💬 |
1922 | NPB-01 | - | - | - | - | 3件: 13 13, 14, 162 💬 |
1923 | NPC-02 | - | - | - | - | 1件: 171 171 💬 |
1924 | NPC-09 | - | - | - | - | 1件: 30 30 💬 |
1925 | NPI-001 | - | - | - | - | 2件: 90 90, 303 💬 |
1926 | NPLATE 500 microgramos polvo para solución inyectable | 1件: Romiplostim Romiplostim | 1件: Romiplostim
Romiplostim
💬 | 1件: MPL MPL 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 1件: 63 63 💬 |
1927 | NPSP 558 | - | - | - | - | 1件: 235 235 💬 |
1928 | NS-065/NCNP-01 | - | - | - | - | 1件: 113 113 💬 |
1929 | NS-089/NCNP-02 | - | - | - | - | 1件: 113 113 💬 |
1930 | NS-304 | - | - | - | - | 3件: 70 70, 86, 88 💬 |
1931 | NS-304 Placebo | - | - | - | - | 2件: 70 70, 88 💬 |
1932 | NT-501 | - | - | - | - | 2件: 90 90, 303 💬 |
1933 | NT-KO-003 | - | - | - | - | 1件: 13 13 💬 |
1934 | NutropinAq 10 mg/2 ml (30 UI) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1935 | NUTROPINAq 10 mg/2 ml (30 UI), solución inyectable | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1936 | NutropinAq 10mg/2ml (30 I.E.) Injektionsllösung | 1件: Somatotropin Somatotropin | - | - | - | 1件: 65 65 💬 |
1937 | NX-13 500mg IR | - | - | - | - | 1件: 97 97 💬 |
1938 | NX-13 500mg MR | - | - | - | - | 1件: 97 97 💬 |
1939 | Obatoclax mesylate (GX15-070MS) | 1件: Obatoclax Obatoclax | - | - | - | 1件: 60 60 💬 |
1940 | Obeticholic Acid 5 MG | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
1941 | Observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi | 4件: Epoprostenol Epoprostenol, Iloprost, Macitentan, Selexipag | 4件: Epoprostenol
Epoprostenol
,
Iloprost
,
Selexipag
,
Macitentan
💬 | 3件: EDNRA EDNRA, EDNRB, PTGIR 💬 | 10件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Platelet activation, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
1942 | OCA 0.1 mg | - | - | - | - | 1件: 296 296 💬 |
1943 | OCA 0.1mg | - | - | - | - | 1件: 296 296 💬 |
1944 | OCA 1,5 mg | - | - | - | - | 1件: 94 94 💬 |
1945 | OCA 1.5mg | - | - | - | - | 1件: 296 296 💬 |
1946 | OCA 5 mg | - | - | - | - | 1件: 94 94 💬 |
1947 | OCA 5mg | - | - | - | - | 1件: 296 296 💬 |
1948 | Ocaliva 5mg | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
1949 | Ocrelizumab 300 mg | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1950 | Ocrelizumab 300mg | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1951 | Ocrelizumab 300mg /10ml | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1952 | Ocrelizumab 300mg/10 ml | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1953 | Ocrelizumab 300mg/10ml | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1954 | Ocrelizumab 500mg | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
1955 | Ocrelizumab Dose 2 and Dose 3 | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1956 | Ocrelizumabu 50mg | - | - | - | - | 1件: 46 46 💬 |
1957 | Ocrevus 300 mg, solution à diluer pour perfusion | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1958 | Ocrrelizumab 300 mg | - | - | - | - | 1件: 13 13 💬 |
1959 | Octagam 5% | - | - | - | - | 2件: 13 13, 65 💬 |
1960 | Octagam 50 mg/ml | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 13 13 💬 |
1961 | OCTAGAM 50 mg/ml oldatos infúzió | - | - | - | - | 1件: 65 65 💬 |
1962 | OCTANATE 100 UI/ml, poudre et solvant pour solution injectable | 1件: Beroctocog alfa Beroctocog alfa | - | - | - | 1件: 288 288 💬 |
1963 | OCTANATE 50 UI/ml, poudre et solvant pour solution injectable | 1件: Beroctocog alfa Beroctocog alfa | - | - | - | 1件: 288 288 💬 |
1964 | Octanorm 16.5% | - | - | - | - | 2件: 50 50, 65 💬 |
1965 | Octreotide a azione pronta 0,1 mg | 1件: Octreotide Octreotide | 1件: Octreotide
Octreotide
💬 | 1件: SSTR2 SSTR2 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 227 227 💬 |
1966 | ODSH at 0.125 mg/kg/h | - | - | - | - | 1件: 210 210 💬 |
1967 | ODSH at 0.250 mg/kg/h | - | - | - | - | 1件: 210 210 💬 |
1968 | ODSH at 0.375 mg/kg/h | - | - | - | - | 1件: 210 210 💬 |
1969 | Ofatumumab 300 | 1件: Ofatumumab Ofatumumab | 1件: Ofatumumab
Ofatumumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1970 | Ofatumumab 30mg | 1件: Ofatumumab Ofatumumab | 1件: Ofatumumab
Ofatumumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1971 | Ofatumumab 3mg | 1件: Ofatumumab Ofatumumab | 1件: Ofatumumab
Ofatumumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1972 | OLIGOG CF-5/20 | - | - | - | - | 1件: 299 299 💬 |
1973 | OligoG CF-5/20 - 17.5 mg | - | - | - | - | 1件: 299 299 💬 |
1974 | OligoG CF-5/20, 17,5 mg, Hartkapsel mit Pulver zur Inhalation | - | - | - | - | 1件: 299 299 💬 |
1975 | OligoG CF/20 - 27.5 mg | - | - | - | - | 1件: 299 299 💬 |
1976 | OligoG CF/20 - 37.5 mg | - | - | - | - | 1件: 299 299 💬 |
1977 | OligoG CF/20, 27,5 mg, Hartkapsel mit Pulver zur Inhalation | - | - | - | - | 1件: 299 299 💬 |
1978 | OligoG CF/20, 37,5 mg, Hartkapsel mit Pulver zur Inhalation | - | - | - | - | 1件: 299 299 💬 |
1979 | Oligomero morfolino fosforodiamidato per skipping dell’esone 53 | - | - | - | - | 1件: 113 113 💬 |
1980 | Olumiant - EU/1/16/1170/001-008 | 1件: Baricitinib Baricitinib | 1件: Baricitinib
Baricitinib
💬 | 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 49 49 💬 |
1981 | Olumiant - EU/1/16/1170/009-016 | 1件: Baricitinib Baricitinib | 1件: Baricitinib
Baricitinib
💬 | 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 49 49 💬 |
1982 | Omalizumab (Xolair) | 1件: Omalizumab Omalizumab | 1件: Omalizumab
Omalizumab
💬 | 1件: FCER1A FCER1A 💬 | 4件: Asthma Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬 | 1件: 65 65 💬 |
1983 | Omaveloxolone Capsules, 2.5 mg | 1件: Omaveloxolone Omaveloxolone | 1件: Omaveloxolone
Omaveloxolone
💬 | 1件: NFE2L2 NFE2L2 💬 | 7件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬 | 1件: 18 18 💬 |
1984 | Omaveloxolone Capsules, 300 mg | 1件: Omaveloxolone Omaveloxolone | 1件: Omaveloxolone
Omaveloxolone
💬 | 1件: NFE2L2 NFE2L2 💬 | 7件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬 | 1件: 18 18 💬 |
1985 | Omaveloxolone Capsules, 5 mg | 1件: Omaveloxolone Omaveloxolone | 1件: Omaveloxolone
Omaveloxolone
💬 | 1件: NFE2L2 NFE2L2 💬 | 7件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬 | 1件: 18 18 💬 |
1986 | Omega 3 | - | - | - | - | 3件: 13 13, 53, 299 💬 |
1987 | Omega 3 fatty acid | - | - | - | - | 1件: 53 53 💬 |
1988 | Omega 3 Premium | - | - | - | - | 1件: 299 299 💬 |
1989 | Omega-3 | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 7件: 13 13, 46, 49, 66, 79, 96, 299 💬 |
1990 | Omega-3 and Vitamin E supplementation | 2件: Omega-3 fatty acids Omega-3 fatty acids, Vitamin E | 1件: Vitamin E
Vitamin E
💬 | - | - | 1件: 46 46 💬 |
1991 | Omega-3 fatty acid | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 2件: 46 46, 66 💬 |
1992 | Omega-3 fatty acid ethylester90 | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 1件: 66 66 💬 |
1993 | Omega-3 Fatty Acid Fish Oil Supplement | 2件: Fish oil Fish oil, Omega-3 fatty acids | - | - | - | 1件: 66 66 💬 |
1994 | Omega-3 fatty acids | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 2件: 13 13, 79 💬 |
1995 | Omega-3 triglycerides | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 1件: 299 299 💬 |
1996 | OMEGA-3-ACID TRIGLYCERIDES | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 1件: 299 299 💬 |
1997 | Omeprazole (UK licensed generic product) | 1件: Omeprazole Omeprazole | 1件: Omeprazole
Omeprazole
💬 | 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 85 85 💬 |
1998 | OMNIPAQUE - 300 MG I/ML SOLUZIONE INIETTABILE FLACONE IN POLIPROPILENE DA 50 ML | 1件: Iohexol Iohexol | 1件: Iohexol
Iohexol
💬 | - | - | 1件: 222 222 💬 |
1999 | ON 01910.NA | - | - | - | - | 1件: 36 36 💬 |
2000 | Onasemnogene Abeparvovec-xioi | 1件: Onasemnogene abeparvovec Onasemnogene abeparvovec | 1件: Onasemnogene abeparvovec
Onasemnogene abeparvovec
💬 | 1件: SMN1 SMN1 💬 | - | 1件: 3 3 💬 |
2001 | Ongentys 50 mg capsule rigide | 1件: Opicapone Opicapone | 1件: Opicapone
Opicapone
💬 | 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
2002 | Ongentys 50 mg hard capsules | 1件: Opicapone Opicapone | 1件: Opicapone
Opicapone
💬 | 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
2003 | Ongentys 50mg | 1件: Opicapone Opicapone | 1件: Opicapone
Opicapone
💬 | 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
2004 | Only medicinal products registered in Austria will be used in this clinical trial. | - | - | - | - | 1件: 78 78 💬 |
2005 | Only medicinal products registered in Germany will be used in this clinical trial | - | - | - | - | 1件: 78 78 💬 |
2006 | Open label RAD001 (only used for post-extension phase) | - | - | - | - | 1件: 158 158 💬 |
2007 | Opicapone 50 mg | 1件: Opicapone Opicapone | 1件: Opicapone
Opicapone
💬 | 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
2008 | Opicapone 50 mg hard capsules | 1件: Opicapone Opicapone | 1件: Opicapone
Opicapone
💬 | 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
2009 | OPS-2071 300 mg | - | - | - | - | 1件: 96 96 💬 |
2010 | Optinate 5 mg filmcoated tablets | - | - | - | - | 1件: 274 274 💬 |
2011 | Oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone | 2件: Mesalazine Mesalazine, Methylprednisolone | 2件: Mesalamine
Mesalamine
,
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
2012 | Oral Methylprednisolone 625 mg/24h x3 days | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 💬 |
2013 | Oral Prednisone 5mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 49 49 💬 |
2014 | Oral selexipag (Uptravi) | 1件: Selexipag Selexipag | 1件: Selexipag
Selexipag
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
2015 | Oral treprostinil (UT-15C) Sustained Release Tablets | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
2016 | ORM-12471 30mg | - | - | - | - | 1件: 51 51 💬 |
2017 | Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg | 3件: Estradiol Estradiol, Ethinylestradiol, Norgestimate | 3件: Estradiol
Estradiol
,
Ethinyl estradiol
,
Norgestimate
💬 | 3件: ESR1 ESR1, ESR2, PGR 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 299 299 💬 |
2018 | Ortho-Novum® 1/35 | 1件: Mestranol Mestranol | 1件: Mestranol
Mestranol
💬 | 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 46 46 💬 |
2019 | Osilodrostat 5mg | 1件: Osilodrostat Osilodrostat | 1件: Osilodrostat
Osilodrostat
💬 | 1件: CYP11B2 CYP11B2 💬 | 3件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Metabolic pathways, Steroid hormone biosynthesis 💬 | 1件: 75 75 💬 |
2020 | OsrhAAT 3 mg/kg IV | - | - | - | - | 1件: 231 231 💬 |
2021 | OSSM-001 | - | - | - | - | 1件: 96 96 💬 |
2022 | OTEZLA - 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) IN UN ASTUCCIO - 4 COMPRESSE DA 10 MG + 4 COMPRESSE DA 20 MG +19 COMPRESSE DA 30 MG | 1件: Apremilast Apremilast | 1件: Apremilast
Apremilast
💬 | 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 2件: 56 56, 107 💬 |
2023 | OTEZLA - 30 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/ALU) - 56 COMPRESSE | 1件: Apremilast Apremilast | 1件: Apremilast
Apremilast
💬 | 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 1件: 107 107 💬 |
2024 | Ovastat 5000 | 1件: Treosulfan Treosulfan | 1件: Treosulfan
Treosulfan
💬 | - | - | 2件: 13 13, 65 💬 |
2025 | Ovastat 5000 (Treosulfan injection) | 1件: Treosulfan Treosulfan | 1件: Treosulfan
Treosulfan
💬 | - | - | 1件: 65 65 💬 |
2026 | Ovastat 5000 mg, powder for solution for infusion | 1件: Treosulfan Treosulfan | 1件: Treosulfan
Treosulfan
💬 | - | - | 1件: 65 65 💬 |
2027 | Overencapsulated Azathioprine (Imuran) 50 mg Tablet | 1件: Azathioprine Azathioprine | 1件: Azathioprine
Azathioprine
💬 | - | - | 1件: 97 97 💬 |
2028 | OXN 10 mg / 5 mg PR | - | - | - | - | 1件: 6 6 💬 |
2029 | OXN 10/5 mg PR | - | - | - | - | 1件: 226 226 💬 |
2030 | OXN 5 mg/2.5 mg PR | - | - | - | - | 1件: 6 6 💬 |
2031 | OXN 5/2.5 mg PR | - | - | - | - | 1件: 226 226 💬 |
2032 | Oxycodone/naloxone prolonged release tablets 10 mg /5 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
2033 | Oxycodone/naloxone prolonged release tablets 10/5 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 226 226 💬 |
2034 | Oxycodone/naloxone prolonged release tablets 5 mg /2.5 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
2035 | Oxycodone/naloxone prolonged release tablets 5/2.5 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 226 226 💬 |
2036 | Oxycontin LP 5mg | 1件: Oxycodone Oxycodone | 1件: Oxycodone
Oxycodone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
2037 | Ozanimod 0.5 mg | 1件: Ozanimod Ozanimod | 1件: Ozanimod
Ozanimod
💬 | 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
2038 | P-552 | - | - | - | - | 1件: 53 53 💬 |
2039 | P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg), | 2件: Pramipexole Pramipexole, Rasagiline | 3件: Pramipexole
Pramipexole
,
Rasagiline
,
Rasagiline tartrate
💬 | 4件: DRD2 DRD2, DRD3, DRD4, MAOB 💬 | 18件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Gap junction, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2040 | P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg), | 2件: Pramipexole Pramipexole, Rasagiline | 3件: Pramipexole
Pramipexole
,
Rasagiline
,
Rasagiline tartrate
💬 | 4件: DRD2 DRD2, DRD3, DRD4, MAOB 💬 | 18件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Gap junction, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2041 | P32/98 3% | - | - | - | - | 1件: 37 37 💬 |
2042 | P38 Inhibitor (4) 300mg | - | - | - | - | 1件: 46 46 💬 |
2043 | P38 Inhibitor (4) 50mg | - | - | - | - | 1件: 46 46 💬 |
2044 | PALOVAROTENE - 1.5mg | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
2045 | PALOVAROTENE - 2.5 mg | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
2046 | PALOVAROTENE - 3 mg | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
2047 | PALOVAROTENE - 5 mg | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
2048 | PALOVAROTENE 1.5 mg | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
2049 | Palovarotene dose level 3 | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
2050 | PALOVAROTENE-3 mg | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
2051 | Pamrevlumab (FG-3019) | 1件: Pamrevlumab Pamrevlumab | 1件: Pamrevlumab
Pamrevlumab
💬 | 1件: CCN2 CCN2 💬 | 2件: Apelin signaling pathway Apelin signaling pathway, Hippo signaling pathway 💬 | 1件: 113 113 💬 |
2052 | Pancrease MT 10.5, or MT 21 | - | - | - | - | 1件: 299 299 💬 |
2053 | Panzytrat 25.000 | - | - | - | - | 1件: 298 298 💬 |
2054 | Panzytrat 25.000 FIP-E units of Lipase | - | - | - | - | 1件: 298 298 💬 |
2055 | Panzytrat® 25,000 | - | - | - | - | 1件: 299 299 💬 |
2056 | Paracetamol 120Mg/5mL Oral Suspension | 1件: Acetaminophen Acetaminophen | 1件: Acetaminophen
Acetaminophen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 3 3 💬 |
2057 | Paracetamolo 500 mg | - | - | - | - | 1件: 13 13 💬 |
2058 | PARACETAMOLO NOVA ARGENTIA - 500 MG COMPRESSE 20 COMPRESSE | - | - | - | - | 1件: 300 300 💬 |
2059 | PARALEN 500 | - | - | - | - | 1件: 46 46 💬 |
2060 | Parsaclisib (2.5 mg) | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 61 61 💬 |
2061 | Part 1, JM-010 component Group A | - | - | - | - | 1件: 6 6 💬 |
2062 | Part 1, JM-010 component Group B | - | - | - | - | 1件: 6 6 💬 |
2063 | Part 1, JM-010 component Group C | - | - | - | - | 1件: 6 6 💬 |
2064 | Part 2, JM-010 combination Group A | - | - | - | - | 1件: 6 6 💬 |
2065 | Part 2, JM-010 combination Group B | - | - | - | - | 1件: 6 6 💬 |
2066 | Part 2, JM-010 component Group C | - | - | - | - | 1件: 6 6 💬 |
2067 | Pasireotida 300 | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
2068 | Pasireotide 0.3mg | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
2069 | Pasireotide 0.6 MG/ML | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
2070 | Pasireotide 0.6mg | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
2071 | Pasireotide 0.9 mg | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
2072 | PAT-001, 0.1% | - | - | - | - | 1件: 160 160 💬 |
2073 | PAT-001, 0.2% | - | - | - | - | 1件: 160 160 💬 |
2074 | PBF-509 | - | - | - | - | 1件: 6 6 💬 |
2075 | PBF-999 / 320 mg | - | - | - | - | 1件: 8 8 💬 |
2076 | PD 0299685 | - | - | - | - | 1件: 226 226 💬 |
2077 | PD 0299685 at 15mg BID | - | - | - | - | 1件: 226 226 💬 |
2078 | PD 0299685 at 30mg BID | - | - | - | - | 1件: 226 226 💬 |
2079 | PD 0360324 | - | - | - | - | 2件: 46 46, 84 💬 |
2080 | PD patients H&Y=1.5-2 Medications OFF | - | - | - | - | 1件: 6 6 💬 |
2081 | PD patients H&Y=1.5-2 Medications ON | - | - | - | - | 1件: 6 6 💬 |
2082 | PD patients H&Y=3 Medications OFF | - | - | - | - | 1件: 6 6 💬 |
2083 | PD patients H&Y=3 Medications ON | - | - | - | - | 1件: 6 6 💬 |
2084 | PD-0299685 | 1件: PD-0299685 PD-0299685 | - | - | - | 1件: 226 226 💬 |
2085 | PD-0325901 | 1件: Mirdametinib Mirdametinib | 1件: Mirdametinib
Mirdametinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
2086 | Pelubiprofen 30 mg | 1件: Pelubiprofen Pelubiprofen | 1件: Pelubiprofen
Pelubiprofen
💬 | - | - | 1件: 46 46 💬 |
2087 | PEMINE - 150 MG CAPSULE RIGIDE 50 CAPSULE | - | - | - | - | 1件: 171 171 💬 |
2088 | PEN+usual care | - | - | - | - | 1件: 96 96 💬 |
2089 | Pentasa 500 mg Retardtabletten | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2090 | Pentosan Polysulfat SP 54® injection solution | - | - | - | - | 1件: 19 19 💬 |
2091 | Peptide-conjugated phosphorodiamidate morpholino oligomer for exon 51 skipping | - | - | - | - | 1件: 113 113 💬 |
2092 | PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714 | - | - | - | - | 1件: 85 85 💬 |
2093 | PF 06687234 | - | - | - | - | 2件: 96 96, 97 💬 |
2094 | PF-00489791 | 1件: PF-00489791 PF-00489791 | - | - | - | 1件: 86 86 💬 |
2095 | PF-00547659 | - | - | - | - | 2件: 96 96, 97 💬 |
2096 | PF-00547659 SC injection | - | - | - | - | 2件: 96 96, 97 💬 |
2097 | PF-02545920 | - | - | - | - | 1件: 8 8 💬 |
2098 | PF-04171327 | - | - | - | - | 1件: 46 46 💬 |
2099 | PF-04171327 10 mg | - | - | - | - | 1件: 46 46 💬 |
2100 | PF-04171327 25 mg | - | - | - | - | 1件: 46 46 💬 |
2101 | PF-04236921 | - | - | - | - | 2件: 49 49, 96 💬 |
2102 | PF-04236921 SC injection | - | - | - | - | 1件: 96 96 💬 |
2103 | PF-04383119 | - | - | - | - | 1件: 226 226 💬 |
2104 | PF-05208763 | - | - | - | - | 1件: 67 67 💬 |
2105 | PF-05230917 | - | - | - | - | 1件: 97 97 💬 |
2106 | PF-05280586 | - | - | - | - | 1件: 46 46 💬 |
2107 | PF-05285401 | - | - | - | - | 1件: 97 97 💬 |
2108 | PF-06252616 | 1件: Domagrozumab Domagrozumab | 1件: Domagrozumab
Domagrozumab
💬 | 1件: MSTN MSTN 💬 | 1件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction 💬 | 1件: 113 113 💬 |
2109 | PF-06291826-83/Fx-1006A | 1件: Fx-1006A Fx-1006A | - | - | - | 1件: 28 28 💬 |
2110 | PF-06342674 0.25 mg/kg | - | - | - | - | 1件: 13 13 💬 |
2111 | PF-06342674 1.5 mg/kg | - | - | - | - | 1件: 13 13 💬 |
2112 | PF-06342674 6.0 mg/kg | - | - | - | - | 1件: 13 13 💬 |
2113 | PF-06410293 | - | - | - | - | 1件: 46 46 💬 |
2114 | PF-06412562 | - | - | - | - | 1件: 6 6 💬 |
2115 | PF-06438179 | - | - | - | - | 1件: 46 46 💬 |
2116 | PF-06462700 | - | - | - | - | 1件: 60 60 💬 |
2117 | PF-06480605 | - | - | - | - | 1件: 97 97 💬 |
2118 | PF-06480605 100 mg/ml | - | - | - | - | 1件: 97 97 💬 |
2119 | PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2120 | PF-06649751 - 15mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2121 | PF-06649751 - 1mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2122 | PF-06649751 - 5mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2123 | PF-06649751 high dose (15 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2124 | PF-06649751 low dose (1 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2125 | PF-06649751 middle dose 1 (3 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2126 | PF-06649751 middle dose 2 (7 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2127 | PF-06650833 | 1件: PF-06650833 PF-06650833 | - | - | - | 1件: 46 46 💬 |
2128 | PF-06650833 100 mg | 1件: PF-06650833 PF-06650833 | - | - | - | 1件: 46 46 💬 |
2129 | PF-06650833 20 mg | 1件: PF-06650833 PF-06650833 | - | - | - | 1件: 46 46 💬 |
2130 | PF-06651600 | 1件: PF-06651600 PF-06651600 | - | - | - | 3件: 46 46, 96, 97 💬 |
2131 | PF-06651600 10 mg | 1件: PF-06651600 PF-06651600 | - | - | - | 1件: 97 97 💬 |
2132 | PF-06651600 50 mg | 1件: PF-06651600 PF-06651600 | - | - | - | 2件: 96 96, 97 💬 |
2133 | PF-06651600 50mg | 1件: PF-06651600 PF-06651600 | - | - | - | 1件: 96 96 💬 |
2134 | PF-06651600-15 | 1件: PF-06651600 PF-06651600 | - | - | - | 2件: 96 96, 97 💬 |
2135 | PF-06669571 | - | - | - | - | 1件: 6 6 💬 |
2136 | PF-06687234 | - | - | - | - | 1件: 97 97 💬 |
2137 | PF-06700841 | 1件: PF-06700841 PF-06700841 | - | - | - | 3件: 49 49, 96, 97 💬 |
2138 | PF-06700841 15 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
2139 | PF-06700841 25 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 2件: 96 96, 97 💬 |
2140 | PF-06700841 25mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
2141 | PF-06700841 30 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
2142 | PF-06700841 45 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
2143 | PF-06700841 5 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 3件: 49 49, 96, 97 💬 |
2144 | PF-06700841 5mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
2145 | PF-06700841-15 | 1件: PF-06700841 PF-06700841 | - | - | - | 3件: 49 49, 96, 97 💬 |
2146 | PF-06730512 | - | - | - | - | 1件: 222 222 💬 |
2147 | PF-06755347 intravenous healthy participant | - | - | - | - | 1件: 63 63 💬 |
2148 | PF-06755347 subcutaneous healthy participant | - | - | - | - | 1件: 63 63 💬 |
2149 | PF-06755347 subcutaneous ITP | - | - | - | - | 1件: 63 63 💬 |
2150 | PF-06823859 | - | - | - | - | 1件: 50 50 💬 |
2151 | PF-06823859 high | - | - | - | - | 1件: 50 50 💬 |
2152 | PF-06823859 low | - | - | - | - | 1件: 50 50 💬 |
2153 | PF-06826647 | - | - | - | - | 1件: 97 97 💬 |
2154 | PF-06826647 100 mg QD | - | - | - | - | 1件: 97 97 💬 |
2155 | PF-06826647 300 mg QD | - | - | - | - | 1件: 97 97 💬 |
2156 | PF-06826647 600 mg QD | - | - | - | - | 1件: 97 97 💬 |
2157 | PF-06835375 | - | - | - | - | 3件: 46 46, 49, 63 💬 |
2158 | PF-06836922 | - | - | - | - | 1件: 78 78 💬 |
2159 | PF-06939926 | - | - | - | - | 1件: 113 113 💬 |
2160 | PF-07054894 | - | - | - | - | 1件: 97 97 💬 |
2161 | PF-07256472 | - | - | - | - | 1件: 276 276 💬 |
2162 | Ph. Eur.: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid | 1件: Propanoic acid Propanoic acid | - | - | - | 1件: 6 6 💬 |
2163 | Ph. Eur.: (2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylprop acid | - | - | - | - | 1件: 6 6 💬 |
2164 | PHA-022121 | - | - | - | - | 1件: 65 65 💬 |
2165 | PHA-022121 high dose | - | - | - | - | 1件: 65 65 💬 |
2166 | PHA-022121 low dose | - | - | - | - | 1件: 65 65 💬 |
2167 | PHA-022121 medium dose | - | - | - | - | 1件: 65 65 💬 |
2168 | PHA-022121 selected dose | - | - | - | - | 1件: 65 65 💬 |
2169 | Phase 2a, SQY51 (cohort 3) | - | - | - | - | 1件: 113 113 💬 |
2170 | Phase 3 | - | - | - | - | 1件: 13 13 💬 |
2171 | Phase2 and 3 : | - | - | - | - | 1件: 96 96 💬 |
2172 | Phenylalanine-free protein substitute in tablet form (XPhe minis) | 1件: Phenylalanine Phenylalanine | 1件: Phenylalanine
Phenylalanine
💬 | - | - | 1件: 240 240 💬 |
2173 | PhEur.: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid | 1件: Propanoic acid Propanoic acid | - | - | - | 1件: 6 6 💬 |
2174 | PhEur.: (2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylpropanoic acid | - | - | - | - | 1件: 6 6 💬 |
2175 | Phosphorodiamidate morpholino oligomer for exon 53 skipping | - | - | - | - | 1件: 113 113 💬 |
2176 | PHP-303 | - | - | - | - | 1件: 231 231 💬 |
2177 | PI-0824 | 1件: PI-0824 PI-0824 | - | - | - | 1件: 35 35 💬 |
2178 | Pilocarpine Nitrate 5% | 2件: Nitrate Nitrate, Pilocarpine | 2件: Pilocarpine
Pilocarpine
,
Nitric acid
💬 | 2件: CHRM2 CHRM2, CHRM3 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2179 | PIPE-307 | - | - | - | - | 1件: 13 13 💬 |
2180 | Piperacilline/Tazobactam Fresenius Kabi 2 g/0,25 g poeder voor oplossing voor infusie | 1件: Tazobactam Tazobactam | 1件: Tazobactam
Tazobactam
💬 | - | - | 1件: 299 299 💬 |
2181 | Piperacilline/Tazobactam Fresenius Kabi 4 g/0,5 g poeder voor oplossing voor infusie | 1件: Tazobactam Tazobactam | 1件: Tazobactam
Tazobactam
💬 | - | - | 1件: 299 299 💬 |
2182 | Pirepemat x fumarate | - | - | - | - | 1件: 6 6 💬 |
2183 | Pirepemat, 50 mg | - | - | - | - | 1件: 6 6 💬 |
2184 | PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj | 1件: Amantadine Amantadine | 1件: Amantadine
Amantadine
💬 | 5件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 20件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2185 | PL 00095/5079R | - | - | - | - | 1件: 46 46 💬 |
2186 | PL 0010/0211 | - | - | - | - | 1件: 299 299 💬 |
2187 | PL 00512/0150 | - | - | - | - | 1件: 298 298 💬 |
2188 | PL 04515/0127 | - | - | - | - | 1件: 13 13 💬 |
2189 | PL 12185/0002 & PL 12185/0005(WATER FOR INJECTION) | 1件: Water Water | 1件: Water
Water
💬 | - | - | 1件: 57 57 💬 |
2190 | PL 12762/0049 | - | - | - | - | 1件: 13 13 💬 |
2191 | PL 17901/0122 | - | - | - | - | 1件: 96 96 💬 |
2192 | PL 20532/0012 | - | - | - | - | 1件: 96 96 💬 |
2193 | PLACENTEX ¿ Polydeoxyribonucleotide 5.625 mg/3 ml | - | - | - | - | 1件: 51 51 💬 |
2194 | PLACENTEX ¿5.625 mg/3 ml soluzione iniettabile¿ | - | - | - | - | 1件: 51 51 💬 |
2195 | PLEGRIDY - 125 MCG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - PENNA PRERIEMPITA - 0,5 ML - 6 PENNE PRERIEMPITE | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: Peginterferon beta-1a
Peginterferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2196 | Plenadren 5 mg modified-release tablets | 2件: Hydrocortisone Hydrocortisone, Manganese citrate | 1件: Hydrocortisone
Hydrocortisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 78 78 💬 |
2197 | Pleneva TM BGC20-0134 | - | - | - | - | 1件: 13 13 💬 |
2198 | PLN-74809-000 | 1件: PLN-74809 PLN-74809 | - | - | - | 1件: 85 85 💬 |
2199 | PLN-74809-020 | 1件: PLN-74809 PLN-74809 | - | - | - | 1件: 85 85 💬 |
2200 | Plovamer acetate 0.5 milligram (mg) | 1件: Acetate Acetate | - | - | - | 1件: 13 13 💬 |
2201 | Plovamer acetate 3 mg | 1件: Acetate Acetate | - | - | - | 1件: 13 13 💬 |
2202 | PMG1015 Dose 3 | - | - | - | - | 1件: 85 85 💬 |
2203 | PMG1015 Dose 5 | - | - | - | - | 1件: 85 85 💬 |
2204 | PN 200 tablets (500 mg naproxen and 20 mg omeprazole) | 2件: Naproxen Naproxen, Omeprazole | 2件: Naproxen
Naproxen
,
Omeprazole
💬 | 4件: ATP4A ATP4A, ATP4B, PTGS1, PTGS2 💬 | 26件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Collecting duct acid secretion, Gastric acid secretion, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxidative phosphorylation, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 2件: 46 46, 271 💬 |
2205 | Pneumococcal polysaccharide serotype 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F | - | - | - | - | 1件: 46 46 💬 |
2206 | Pneumococcal polysaccharide serotype 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F | - | - | - | - | 1件: 46 46 💬 |
2207 | Pneumococcal polysaccharide serotype 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F | - | - | - | - | 1件: 222 222 💬 |
2208 | PNEUMOVAX – Soluzione iniettabile in siringa preriempita da 0,5 ml | - | - | - | - | 2件: 62 62, 66 💬 |
2209 | POLY(OXY-1,2-ETHANEDIYL), ALPHA-HYDRO-OMEGA-METHOXY, ETHER WITH N-[[[2-[[6-[[1-[3-[[3-(2,3-DIHYDROXYPROPOXY)PROPYL]AMINO]-3-OXOPROPYL]-2,5-DI | 1件: Diethyl ether Diethyl ether | 1件: Ether
Ether
💬 | - | - | 1件: 235 235 💬 |
2210 | POLY(OXY-1,2-ETHANEDIYL), ALPHA-HYDRO-OMEGA-METHOXY, ETHER WITH N-[[[2-[[6-[[1-[3-[[3-(2,3-DIHYDROXYPROPOXY)PROPYL]AMINO]-3-OXOPROPYL]-2,5-DIOXO-3-PYRROLIDINYL]THIO]HEXYL]AMINO]ETHYL]AMINO]CARBONYL]-2-METHYLALANYL-TERIPARATIDE (2:1) | 2件: Diethyl ether Diethyl ether, Teriparatide | 2件: Ether
Ether
,
Teriparatide
💬 | 1件: PTH1R PTH1R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
2211 | Polyethylene Glycol 3350 | 1件: Polyethylene glycol Polyethylene glycol | 1件: Polyethylene glycol 3350
Polyethylene glycol 3350
💬 | - | - | 2件: 96 96, 299 💬 |
2212 | Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin) | 1件: Activated charcoal Activated charcoal | - | - | - | 1件: 6 6 💬 |
2213 | Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin) | - | - | - | - | 1件: 6 6 💬 |
2214 | Postoperative 3-month exclusive enteral nutrition | - | - | - | - | 1件: 96 96 💬 |
2215 | PR-06410293 | - | - | - | - | 1件: 46 46 💬 |
2216 | Pramipexole 0.125 mg tablets | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2217 | Pramipexole 0.5 mg tablets | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2218 | Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole) | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2219 | Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride) | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2220 | PredniHEXAL® 5mg Tabletten | - | - | - | - | 1件: 46 46 💬 |
2221 | PredniHEXAL® 5mg Tabletten, PredniHEXAL® 10mg Tabletten | - | - | - | - | 1件: 46 46 💬 |
2222 | PredniHEXAL® 5mg Tabletten, PredniHEXAL® 20mg Tabletten | - | - | - | - | 1件: 46 46 💬 |
2223 | Prednisolon 5 mg JENAPHARM | - | - | - | - | 1件: 41 41 💬 |
2224 | Prednisolone 2,5 mg Tablets | 1件: Prednisolone Prednisolone | 1件: Prednisolone
Prednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
2225 | Prednisolone 5 mg | 1件: Prednisolone Prednisolone | 1件: Prednisolone
Prednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 46 46, 51 💬 |
2226 | Prednisolone 5 mg JENAPHARM | 1件: Prednisolone Prednisolone | 1件: Prednisolone
Prednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 💬 |
2227 | Prednisolone 5 mg Tablets | 1件: Prednisolone Prednisolone | 1件: Prednisolone
Prednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
2228 | Prednisolone 5mg Gastro-resistant Tablets | 1件: Prednisolone Prednisolone | 1件: Prednisolone
Prednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 51 51 💬 |
2229 | Prednisolone 5mg Tablet | 1件: Prednisolone Prednisolone | 1件: Prednisolone
Prednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
2230 | Prednisolone Tablets B.P. 5mg | 1件: Prednisolone Prednisolone | 1件: Prednisolone
Prednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
2231 | Prednisolone Tablets USP 5 mg | 1件: Prednisolone Prednisolone | 1件: Prednisolone
Prednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
2232 | Prednison 5 mg GALEN | - | - | - | - | 1件: 35 35 💬 |
2233 | PREDNISON 5, 20 Léciva por. tablet nob | - | - | - | - | 1件: 50 50 💬 |
2234 | Prednison 5, 20 Léciva por. tablet nob. | - | - | - | - | 1件: 50 50 💬 |
2235 | Prednison 50 mg GALEN | - | - | - | - | 1件: 35 35 💬 |
2236 | Prednison acis® 5 mg | - | - | - | - | 2件: 43 43, 44 💬 |
2237 | Prednison acis¿ 5 mg | - | - | - | - | 2件: 43 43, 44 💬 |
2238 | Prednisone 0,5 mg/kg orally on alternate days | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 222 222 💬 |
2239 | Prednisone 3 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
2240 | Prednisone 5 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 46 46, 66 💬 |
2241 | Prednisone 5 mg tablets | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2242 | Prednisone 7.5 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
2243 | Prednisone and ustekinumab treatment | 2件: Prednisone Prednisone, Ustekinumab | 2件: Prednisone
Prednisone
,
Ustekinumab
💬 | 4件: IL12A IL12A, IL12B, IL23A, NR3C1 💬 | 29件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Neuroactive ligand-receptor interaction, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 41 41 💬 |
2244 | PREDNISONE ARROW 5 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 66 66 💬 |
2245 | PREDNISONE DOC GENERICI - 5 MG COMPRESSE 10 COMPRESSE IN BLISTER PVC-PVDC/ALU | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 19 19 💬 |
2246 | PREDNISONE DOC GENERICI - 5 MG COMPRESSE 30 COMPRESSE IN BLISTER PVC-PVDC/ALU | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 300 300 💬 |
2247 | PredniSONE Tablets USP, 1 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 41 41, 46 💬 |
2248 | PredniSONE Tablets USP, 10 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 💬 |
2249 | PredniSONE Tablets USP, 1mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 💬 |
2250 | PredniSONE Tablets USP, 2.5 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 💬 |
2251 | PredniSONE Tablets USP, 2.5mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 💬 |
2252 | PredniSONE Tablets USP, 20mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 💬 |
2253 | PredniSONE Tablets USP, 5 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 41 41, 46 💬 |
2254 | PredniSONE Tablets USP, 5mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 💬 |
2255 | PredniSONE Tablets, USP | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 3件: 41 41, 43, 44 💬 |
2256 | PredniSONE Tablets, USP 10 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 💬 |
2257 | PredniSONE Tablets, USP 2.5 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 💬 |
2258 | PredniSONE Tablets, USP 5 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 💬 |
2259 | PredniSONE Tablets, USP, 1 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 💬 |
2260 | PREFOLIC 15*30CPR GASTROR 15MG | - | - | - | - | 1件: 337 337 💬 |
2261 | PREFOLIC*30CPR GASTROR 15MG | - | - | - | - | 1件: 299 299 💬 |
2262 | Preladenant 5 mg tablet | 1件: Preladenant Preladenant | 1件: Preladenant
Preladenant
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2263 | PREVENAR 13 - 0.5 ML SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - FLACONCINO MONODOSE (0,5 ML VETRO TIPO I) - 1 FLACONCINO MONODOSE | 12件: Streptococcus pneumoniae type 1 capsular polysaccharide antigen Streptococcus pneumoniae type 1 capsular polysaccharide antigen, Streptococcus pneumoniae type 14 capsular polysaccharide antigen, Streptococcus pneumoniae type 18c capsular polysaccharide antigen, Streptococcus pneumoniae type 19a capsular polysaccharide antigen, Streptococcus pneumoniae type 19f capsular polysaccharide antigen, Streptococcus pneumoniae type 23f capsular polysaccharide antigen, Streptococcus pneumoniae type 3 capsular polysaccharide antigen, Streptococcus pneumoniae type 4 capsular polysaccharide antigen, Streptococcus pneumoniae type 5 capsular polysaccharide antigen, Streptococcus pneumoniae type 6b capsular polysaccharide antigen, Streptococcus pneumoniae type 7f capsular polysaccharide antigen, Streptococcus pneumoniae type 9v capsular polysaccharide antigen | - | - | - | 1件: 222 222 💬 |
2264 | Previously referred to as MEDI2070 and AMG 139, AGN-151-598 | - | - | - | - | 1件: 96 96 💬 |
2265 | Pridia (Donepezil Hydrochloride) 5mg | 1件: Donepezil Donepezil | 1件: Donepezil
Donepezil
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 6 6 💬 |
2266 | Pridia 5mg | - | - | - | - | 1件: 6 6 💬 |
2267 | Prior Donepezil 5mg | 1件: Donepezil Donepezil | 1件: Donepezil
Donepezil
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 6 6 💬 |
2268 | PRIVIGEN - 100 MG/ML - SOLUZIONE PER INFUSIONE USO ENDOVENOSO FLACONCINO(VETRO) 1 FLACONCINO DA 100 ML | - | - | - | - | 1件: 51 51 💬 |
2269 | PRO045, 0.15 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
2270 | PRO045, 1.0 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
2271 | PRO045, 3.0 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
2272 | PRO045, 6.0 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
2273 | PRO045, 9.0 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
2274 | Probiotic - VSL#3 | - | - | - | - | 1件: 96 96 💬 |
2275 | PROCAPTAN - 5 MG COMPRESSE RIVESTITE CON FILM 10 COMPRESSE IN CONTENITORE PER COMPRESSE PP | - | - | - | - | 1件: 58 58 💬 |
2276 | Promixin 1 million International Units (IU) Powder for Nebuliser Solution | - | - | - | - | 1件: 299 299 💬 |
2277 | PROMIXIN*NEBUL 30MONOD 1MUI | - | - | - | - | 1件: 299 299 💬 |
2278 | Promixin, 1 million International Units (IU) Powder for Nebuliser Solution | - | - | - | - | 1件: 299 299 💬 |
2279 | Promixin,1 millón de Unidades Internacionales,polvo para solución para inhalación por nebulizador | - | - | - | - | 1件: 299 299 💬 |
2280 | PROSCAR*30CPR RIV 5MG | 1件: Finasteride Finasteride | 1件: Finasteride
Finasteride
💬 | 1件: SRD5A2 SRD5A2 💬 | 3件: Metabolic pathways Metabolic pathways, Prostate cancer, Steroid hormone biosynthesis 💬 | 1件: 6 6 💬 |
2281 | Prototype capsule GDC-0134 | 1件: GDC-0134 GDC-0134 | - | - | - | 1件: 2 2 💬 |
2282 | PROVIGIL - 100 MG COMPRESSE 30 COMPRESSE | 1件: Modafinil Modafinil | 1件: Modafinil
Modafinil
💬 | - | - | 1件: 113 113 💬 |
2283 | PRTX-100 at 1.5 mcg/kg | - | - | - | - | 1件: 46 46 💬 |
2284 | PRTX-100 at 12.0 mcg/kg | - | - | - | - | 1件: 46 46 💬 |
2285 | PRTX-100 at 3.0 mcg/kg | - | - | - | - | 1件: 46 46 💬 |
2286 | PRTX-100 at 6.0 mcg/kg | - | - | - | - | 1件: 46 46 💬 |
2287 | PRV-300 | - | - | - | - | 1件: 97 97 💬 |
2288 | Pseudoephedrine + 50 ml water | 2件: Pseudoephedrine Pseudoephedrine, Water | 2件: Water
Water
,
Pseudoephedrine
💬 | 9件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 | 14件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 17 17 💬 |
2289 | PT320 2.0 mg | - | - | - | - | 1件: 6 6 💬 |
2290 | PT320 2.5 mg | - | - | - | - | 1件: 6 6 💬 |
2291 | PTC-0161480 | - | - | - | - | 2件: 246 246, 299 💬 |
2292 | PTC518 tablet 5 mg | - | - | - | - | 1件: 8 8 💬 |
2293 | PTH 1-34 | 1件: Teriparatide Teriparatide | 1件: Teriparatide
Teriparatide
💬 | 1件: PTH1R PTH1R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 2件: 65 65, 235 💬 |
2294 | PTR-01 | - | - | - | - | 1件: 36 36 💬 |
2295 | PTW-002 10 mg/g gel | - | - | - | - | 1件: 36 36 💬 |
2296 | Puerarin tablet 50 mg | 1件: Puerarin Puerarin | - | - | - | 1件: 46 46 💬 |
2297 | Pulmozyme single use ampule | 1件: Dornase alfa Dornase alfa | 1件: Dornase alfa
Dornase alfa
💬 | - | - | 1件: 299 299 💬 |
2298 | PUR 0110 | - | - | - | - | 1件: 97 97 💬 |
2299 | PUR 0110 Rectal Enema | - | - | - | - | 1件: 97 97 💬 |
2300 | PUR 0110 Rectal Enema 1000 mg | - | - | - | - | 1件: 97 97 💬 |
2301 | PUR 0110 Rectal Enema 250 mg | - | - | - | - | 1件: 97 97 💬 |
2302 | PUR 0110 Rectal Enema 500 mg | - | - | - | - | 1件: 97 97 💬 |
2303 | Puri-Nethol 50 mg | - | - | - | - | 1件: 96 96 💬 |
2304 | PURINETHOL - 50 MG COMPRESSE25 COMPRESSE | 1件: Mercaptopurine Mercaptopurine | 2件: Mercaptopurine
Mercaptopurine
,
Mercaptopurine
💬 | 1件: HPRT1 HPRT1 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 96 96 💬 |
2305 | Q4W GMA301 IV injections (300 mg) | - | - | - | - | 1件: 86 86 💬 |
2306 | QBW276 300mcg | - | - | - | - | 1件: 299 299 💬 |
2307 | QCC374 0.015 mg | - | - | - | - | 1件: 86 86 💬 |
2308 | QCC374 0.06 mg | - | - | - | - | 1件: 86 86 💬 |
2309 | Qing Re Huo Xue (QRHX) | - | - | - | - | 1件: 46 46 💬 |
2310 | QLS-101 ophthalmic solution, 2.0 % | - | - | - | - | 1件: 157 157 💬 |
2311 | QR-010 | - | - | - | - | 1件: 299 299 💬 |
2312 | QR-313 | - | - | - | - | 1件: 36 36 💬 |
2313 | QR-313 Gel for Topical (Cutaneous) Administration | - | - | - | - | 1件: 36 36 💬 |
2314 | QRL-201 - Dose 3 | - | - | - | - | 1件: 2 2 💬 |
2315 | QRL-201 - Dose 5 | - | - | - | - | 1件: 2 2 💬 |
2316 | QTXEW2-04-AF, EW2, GC-1, QRX-431 | - | - | - | - | 1件: 20 20 💬 |
2317 | R-021 | - | - | - | - | 1件: 222 222 💬 |
2318 | R-3750 | - | - | - | - | 1件: 97 97 💬 |
2319 | R788 sodium hexahydrate, RIG2-01, RIG-G | - | - | - | - | 1件: 46 46 💬 |
2320 | R788, fostamatinib disodium hexahydrate (in USPI/FPI) | 1件: Fostamatinib Fostamatinib | 1件: Fostamatinib
Fostamatinib
💬 | 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 1件: 61 61 💬 |
2321 | RAAV2.5-CMV-minidystrophin (d3990) | - | - | - | - | 1件: 113 113 💬 |
2322 | RAAV2/5-hNAGLU | - | - | - | - | 1件: 19 19 💬 |
2323 | RAAV2/5-PBGD vector dosage 1 | - | - | - | - | 1件: 254 254 💬 |
2324 | RAAV2/5-PBGD vector dosage 2 | - | - | - | - | 1件: 254 254 💬 |
2325 | RAAV2/5-PBGD vector dosage 3 | - | - | - | - | 1件: 254 254 💬 |
2326 | RAAV2/5-PBGD vector dosage 4 | - | - | - | - | 1件: 254 254 💬 |
2327 | RAD001 2,5 mg | - | - | - | - | 1件: 158 158 💬 |
2328 | RAD001 5mg | - | - | - | - | 2件: 89 89, 158 💬 |
2329 | Radiolabelled OligoG CF-5/20 6% Solution | - | - | - | - | 1件: 299 299 💬 |
2330 | Radiolabelled OligoG CF-5/20 6% Solution for Nebulisation | - | - | - | - | 1件: 299 299 💬 |
2331 | Radiolabelled OligoG CF-5/20 DPI | - | - | - | - | 1件: 299 299 💬 |
2332 | Radiolabelled OligoG CF-5/20 Dry Powder for Inhalation (DPI) | - | - | - | - | 1件: 299 299 💬 |
2333 | Radotinib HCl 50 mg | 1件: Radotinib Radotinib | - | - | - | 1件: 6 6 💬 |
2334 | RANEXA - 750 MG - COMPRESSA A RILASCIO PROLUNGATO- USO ORALE - BLISTER (PVC/PVDC/ALLUMINIO) 60 COMPRESSE | 1件: Ranolazine Ranolazine | 1件: Ranolazine
Ranolazine
💬 | - | - | 1件: 58 58 💬 |
2335 | RANEXA*60CPR 500MG R.P. | 1件: Ranolazine Ranolazine | 1件: Ranolazine
Ranolazine
💬 | - | - | 1件: 58 58 💬 |
2336 | Ranibizumab injection (0.5 mg) | 1件: Ranibizumab Ranibizumab | 1件: Ranibizumab
Ranibizumab
💬 | 1件: VEGFA VEGFA 💬 | 24件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬 | 2件: 166 166, 301 💬 |
2337 | Ranolazine 500 MG | 1件: Ranolazine Ranolazine | 1件: Ranolazine
Ranolazine
💬 | - | - | 1件: 2 2 💬 |
2338 | Ranolazine 500 mg PR tablets | 1件: Ranolazine Ranolazine | 1件: Ranolazine
Ranolazine
💬 | - | - | 1件: 58 58 💬 |
2339 | Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die | 1件: Ranolazine Ranolazine | 1件: Ranolazine
Ranolazine
💬 | - | - | 1件: 58 58 💬 |
2340 | RAPA-501 Autologous T cells | - | - | - | - | 1件: 2 2 💬 |
2341 | RAPAMUNE - 1 MG 100 COMPRESSE RIVESTITE IN BLISTER USO ORALE | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 2 2 💬 |
2342 | RAPAMUNE*30CPR RIV 1MG | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 67 67 💬 |
2343 | RAPAMUNE*30CPR RIV 2MG | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 67 67 💬 |
2344 | Rapamycin cream, topical, 0.5%, 1.0% w/w | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
2345 | Rasagiline mesylate 1.0 mg | 1件: Rasagiline Rasagiline | 2件: Rasagiline
Rasagiline
,
Rasagiline tartrate
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
2346 | RAvPAL-PEG 0.001 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
2347 | RAvPAL-PEG 0.003 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
2348 | RAvPAL-PEG 0.01 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
2349 | RAvPAL-PEG 0.03 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
2350 | RAvPAL-PEG 0.1 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
2351 | RAXONE - 150 MG- COMPRESSE RIVESTITE CON FILM- USO ORALE- FLACONE (HDPE)- 180 COMPRESSE | 1件: Idebenone Idebenone | 1件: Idebenone
Idebenone
💬 | - | - | 1件: 113 113 💬 |
2352 | RE-021 | - | - | - | - | 3件: 66 66, 218, 222 💬 |
2353 | RE-021 (Sparsentan) | 1件: Sparsentan Sparsentan | 1件: Sparsentan
Sparsentan
💬 | 2件: AGTR1 AGTR1, EDNRA 💬 | 17件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
2354 | RE-024 | - | - | - | - | 1件: 120 120 💬 |
2355 | REBIF - 44 MCG(12 MILIONI UI) -SOLUZ INIETTABILE- USO SOTTOCUTANEO-PENNA PRERIEMPITA 0.5 ML (24 MILIONI UI/ML)12 PENNE PRERIEMPITE | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2356 | Rebif 44 microgrammi/0.5ml soluzione iniettabile in cartuccia | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2357 | Rebif® (clone 484-39) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2358 | Rebif® New Formulation (RNF) using RebiSmartTM | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2359 | Recombinant coagulation FVIII Fc – von Willebrand factor – XTEN fusion protein | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
2360 | Recombinant coagulation FVIII Fc –von Willebrand factor – XTEN fusion protein | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
2361 | Recombinant Factor XIII | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 1件: 288 288 💬 |
2362 | Recombinant Factor XIII (rFXIII) | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 2件: 97 97, 288 💬 |
2363 | RECOMBINANT HUMAN COAGULATION FACTOR VIII FC - VON WILLEBRAND FACTOR - XTEN FUSION PROTEIN | 3件: Antihemophilic factor human Antihemophilic factor human, Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
2364 | RECOMBINANT HUMAN COAGULATION FACTOR VIII FC - VON WILLEBRAND FACTOR -XTEN FUSION PROTEIN | 3件: Antihemophilic factor human Antihemophilic factor human, Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
2365 | Recombinant humanized monoclonal antibody specific for human IL-5 | - | - | - | - | 1件: 44 44 💬 |
2366 | REF CRUZADA PEI Nº 12-088 | - | - | - | - | 1件: 274 274 💬 |
2367 | Reference capsule GDC-0134 | 1件: GDC-0134 GDC-0134 | - | - | - | 1件: 2 2 💬 |
2368 | Regimen Selection Phase Group 3 | - | - | - | - | 1件: 113 113 💬 |
2369 | REMICADE - 100 MG POLVERE PER CONCENTRATO PER INFUSIONE ENDOVENOSA 1 FLACONE VETRO 20 ML USO EV | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
2370 | Remodulin 2.5mg/ml 20ml | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 88 88 💬 |
2371 | Remodulin 5mg/ml 20ml | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 88 88 💬 |
2372 | Remodulin® (treprostinil) 2.5 mg/ml solution for infusion | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
2373 | Remodulin® (treprostinil) 5 mg/ml solution for infusion | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
2374 | REMSIMA - 100 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLANCONCINO (VETRO) - 1 FLACONCINO | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 4件: 46 46, 96, 97, 271 💬 |
2375 | REQUIP 21 CPR 0,25 MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2376 | REQUIP 21 CPR 0,5 MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2377 | Requip XL prolonged-release | 2件: Manganese citrate Manganese citrate, Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2378 | REQUIP*21CPR 0,25MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2379 | REQUIP*21CPR 0,5MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2380 | REQUIP*21CPR 5MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2381 | REVATIO - 0.8 MG/ML - SOLUZIONE INIETTABILE - USO ENDOVENOSO - FLACONCINO(VETRO) 1 FLACONCINO DA 20 ML | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 294 294 💬 |
2382 | Revatio 0.8mg/ml solution for injection | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 294 294 💬 |
2383 | REVOLADE - 25 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER(PA/ALU/PVC/ALU) 28 COMPRESSE | 1件: Eltrombopag Eltrombopag | - | - | - | 1件: 60 60 💬 |
2384 | REVOLADE - 50 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER(PA/ALU/PVC/ALU | 1件: Eltrombopag Eltrombopag | - | - | - | 1件: 60 60 💬 |
2385 | Revolade 50 mg film-coated tablets | 1件: Eltrombopag Eltrombopag | - | - | - | 1件: 63 63 💬 |
2386 | RG-012 | - | - | - | - | 1件: 218 218 💬 |
2387 | RG2133 (2',3',5'-tri-O-acetyluridine) | 1件: Uridine triacetate Uridine triacetate | 1件: Uridine triacetate
Uridine triacetate
💬 | - | - | 1件: 21 21 💬 |
2388 | RGB-03 | - | - | - | - | 1件: 46 46 💬 |
2389 | RhASA - Dose Level 3 | - | - | - | - | 1件: 19 19 💬 |
2390 | RhGH Norditropin® pen (34 µg/kg) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2391 | RhIGF-1/rhIGFBP-3 | 1件: rhIGFBP-3 rhIGFBP-3 | - | - | - | 1件: 195 195 💬 |
2392 | RhIGF-I/rhIGFBP-3 | 1件: rhIGFBP-3 rhIGFBP-3 | - | - | - | 1件: 113 113 💬 |
2393 | RhIGFBP-3 | 1件: rhIGFBP-3 rhIGFBP-3 | - | - | - | 2件: 113 113, 195 💬 |
2394 | RhPTH (1-34) | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 70 70 💬 |
2395 | RhuDex 25 mg (31.75 mg RhuDex choline salt) granules | 1件: Choline Choline | 1件: Choline
Choline
💬 | - | - | 1件: 93 93 💬 |
2396 | RhuDex 50 mg (63.5 mg RhuDex choline salt) granules | 1件: Choline Choline | 1件: Choline
Choline
💬 | - | - | 1件: 93 93 💬 |
2397 | Rhustoxicodendron 30 | - | - | - | - | 1件: 46 46 💬 |
2398 | RI-002 | - | - | - | - | 1件: 65 65 💬 |
2399 | Rifampin 300mg BID + istradefylline 40mg Day 8 only | 2件: Istradefylline Istradefylline, Rifampicin | 2件: Rifampin
Rifampin
,
Istradefylline
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2400 | Rifaximin 550 MG | 1件: Rifaximin Rifaximin | 1件: Rifaximin
Rifaximin
💬 | - | - | 1件: 6 6 💬 |
2401 | Rifaximin 550 MG Oral Tablet [XIFAXAN] | 1件: Rifaximin Rifaximin | 1件: Rifaximin
Rifaximin
💬 | - | - | 1件: 299 299 💬 |
2402 | Rilutek 50 mg film-coated tablets | 1件: Riluzole Riluzole | 1件: Riluzole
Riluzole
💬 | 14件: GRIA1 GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 23件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway 💬 | 1件: 2 2 💬 |
2403 | RILUTEK 50 mg, film-coated tablets | 1件: Riluzole Riluzole | 1件: Riluzole
Riluzole
💬 | 14件: GRIA1 GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 23件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway 💬 | 1件: 2 2 💬 |
2404 | Riluzole 50 MG | 1件: Riluzole Riluzole | 1件: Riluzole
Riluzole
💬 | 14件: GRIA1 GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 23件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway 💬 | 1件: 2 2 💬 |
2405 | Riluzole 50 MG (Part B) | 1件: Riluzole Riluzole | 1件: Riluzole
Riluzole
💬 | 14件: GRIA1 GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 23件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway 💬 | 1件: 2 2 💬 |
2406 | Riluzole Oral Soluble film (ROSF) 50 mg | 1件: Riluzole Riluzole | 1件: Riluzole
Riluzole
💬 | 14件: GRIA1 GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 23件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway 💬 | 1件: 2 2 💬 |
2407 | RILUZOLO TEVA - 50 MG COMPRESSE RIVESTITE CON FILM 90 COMPRESSE IN BLISTER AL/PVC | - | - | - | - | 1件: 114 114 💬 |
2408 | RIMSO 50 | - | - | - | - | 1件: 226 226 💬 |
2409 | Riociguat coated tablet 0.5 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
2410 | Riociguat coated tablet 1.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
2411 | Riociguat coated tablet 1.5 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
2412 | Riociguat coated tablet 2.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
2413 | Riociguat coated tablet 2.5 m | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
2414 | Riociguat coated tablet 2.5 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
2415 | Riociguat granules 0.3% for oral application | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
2416 | Risedronate sodium 2.5mg | 1件: Risedronic acid Risedronic acid | 1件: Risedronic acid
Risedronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 274 274 💬 |
2417 | Risedronate sodium 5mg | 1件: Risedronic acid Risedronic acid | 1件: Risedronic acid
Risedronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 274 274 💬 |
2418 | Risedronato sódico 2.5mg | - | - | - | - | 1件: 274 274 💬 |
2419 | Risedronato sódico 5mg | - | - | - | - | 1件: 274 274 💬 |
2420 | Ritalin LA 30mg capsules | 1件: Methylphenidate Methylphenidate | 1件: Methylphenidate
Methylphenidate
💬 | 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
2421 | Ritlecitinib 5 mg | - | - | - | - | 1件: 97 97 💬 |
2422 | Ritlecitinib 50 mg | - | - | - | - | 2件: 96 96, 97 💬 |
2423 | Ritlecitinib 50mg | - | - | - | - | 1件: 96 96 💬 |
2424 | Ritlecitinib/JAK 3 | - | - | - | - | 1件: 46 46 💬 |
2425 | Rituxan (INN: Rituximab), brand name in the United States | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
2426 | Rituxan (INN: Rituximab), brand name in the US | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
2427 | Rituxan (US, Canada, Japan), MabThera (rest of the world) | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
2428 | Rituxan (US, Canada, Japan), MabThera (rest of world) | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 53 53 💬 |
2429 | Rituximab (US) | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
2430 | Rituximab-EU+ Rituximab-Pfizer x 2 Courses | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
2431 | Rituximab-Pfizer (PF-05280586) x 3 courses | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
2432 | Rituximab-US + Rituximab-Pfizer x 2 Courses | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
2433 | RIV-TDS 13.3 mg/24 h | - | - | - | - | 1件: 6 6 💬 |
2434 | Rivastigmine Luye Transdermal Patch- 9.5mg/24h | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 6 6 💬 |
2435 | Rivastigmine Patch 9.5 cm2 | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 6 6 💬 |
2436 | Rivastigmine transdermal system 13.3 mg/24 h | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 6 6 💬 |
2437 | RIXATHON 500 mg | - | - | - | - | 1件: 85 85 💬 |
2438 | RIXATHON 500mg | - | - | - | - | 1件: 43 43 💬 |
2439 | Ro 001-9265 | - | - | - | - | 1件: 41 41 💬 |
2440 | Ro 001-9265/F02 | - | - | - | - | 1件: 41 41 💬 |
2441 | RO 001-9265/F02-01 | - | - | - | - | 1件: 46 46 💬 |
2442 | Ro 001-9265/F03 | - | - | - | - | 1件: 41 41 💬 |
2443 | Ro 001-9265/F04 | - | - | - | - | 1件: 41 41 💬 |
2444 | Ro 002-9893/F02 | - | - | - | - | 1件: 46 46 💬 |
2445 | Ro 47-0203 | - | - | - | - | 4件: 51 51, 85, 86, 88 💬 |
2446 | Ro 47-0203 / ACT-050088 | - | - | - | - | 1件: 86 86 💬 |
2447 | Ro 487-533/F01 | - | - | - | - | 1件: 271 271 💬 |
2448 | Ro 487-5733/F01 | - | - | - | - | 1件: 271 271 💬 |
2449 | Ro 487-7533/F10-02 | - | - | - | - | 1件: 46 46 💬 |
2450 | Ro 487-7533/F10-04 | - | - | - | - | 4件: 41 41, 46, 51, 107 💬 |
2451 | Ro 533-3787/F01- 06 | - | - | - | - | 1件: 13 13 💬 |
2452 | Ro 533-3787/F01-06 | - | - | - | - | 1件: 11 11 💬 |
2453 | Ro 549-0261/F04 | - | - | - | - | 1件: 97 97 💬 |
2454 | Ro 549-0261/F04-02 | - | - | - | - | 1件: 96 96 💬 |
2455 | Ro 549-0261/F08-02 | - | - | - | - | 1件: 96 96 💬 |
2456 | RO 551-6922 | - | - | - | - | 1件: 46 46 💬 |
2457 | Ro-47-0203 | - | - | - | - | 1件: 86 86 💬 |
2458 | Ro-47-0203/029 | - | - | - | - | 1件: 86 86 💬 |
2459 | Ro47-0203 | - | - | - | - | 1件: 86 86 💬 |
2460 | Ro47-0203 / ACT-050088 | - | - | - | - | 2件: 51 51, 86 💬 |
2461 | RO487-7533/F10-04 | - | - | - | - | 2件: 46 46, 51 💬 |
2462 | RO4917523 0.5 mg | - | - | - | - | 1件: 206 206 💬 |
2463 | RO4917523 1.5 mg | - | - | - | - | 1件: 206 206 💬 |
2464 | RO4964913/F07-01 | - | - | - | - | 1件: 13 13 💬 |
2465 | Ro549-0261/F04-02 | - | - | - | - | 1件: 96 96 💬 |
2466 | RO5490255/F01-02 | - | - | - | - | 1件: 85 85 💬 |
2467 | RO5490261/F04-02 | - | - | - | - | 1件: 97 97 💬 |
2468 | RO7112689/F03-01 | - | - | - | - | 2件: 62 62, 109 💬 |
2469 | RO7123520/F03-01 | - | - | - | - | 1件: 46 46 💬 |
2470 | RO7204239/F01-01 | - | - | - | - | 1件: 3 3 💬 |
2471 | RO7239361 Injections, 35 mg/Syringe (50 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
2472 | RO7239361 Injections, 50 mg/Syringe (71.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
2473 | RO7239361 Injections, 7.5 mg/Syringe (10.7 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
2474 | RO7248824/F02-01 | - | - | - | - | 1件: 201 201 💬 |
2475 | RO7248824/F03-01 (Diluent for RO7248824/F02-01 | - | - | - | - | 1件: 201 201 💬 |
2476 | RO7490677 320 mg/16 ml (2nd generation) | - | - | - | - | 1件: 85 85 💬 |
2477 | RO7490677 320mg/16mL (1st generation) | - | - | - | - | 1件: 85 85 💬 |
2478 | RO7490677 320mg/16mL (2nd generation) | - | - | - | - | 1件: 85 85 💬 |
2479 | RO7490677/ F01-02 | - | - | - | - | 1件: 85 85 💬 |
2480 | RO7490677/F01-01 | - | - | - | - | 1件: 85 85 💬 |
2481 | RO7490677/F01-02 | - | - | - | - | 1件: 85 85 💬 |
2482 | RO7490677/F01-03 | - | - | - | - | 1件: 85 85 💬 |
2483 | ROACTEMRA - 162 MG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - SIRINGA PRERIEMPITA 0,9ML (VETRO) - 4 SIRINGHE PRERIEMPITE | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 51 💬 |
2484 | ROACTEMRA - 20 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 4ML 1 FLACONCINO | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
2485 | Rob 803 (9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo[2,3-b] quinoxali | - | - | - | - | 1件: 46 46 💬 |
2486 | Rob 803 (capsules 12.5 mg) | - | - | - | - | 1件: 46 46 💬 |
2487 | Rob 803 12.5mg capsule | - | - | - | - | 1件: 46 46 💬 |
2488 | Rob 803 6.5mg capsule | - | - | - | - | 1件: 46 46 💬 |
2489 | Rodatristat ethyl 300 mg tablet BID | - | - | - | - | 1件: 86 86 💬 |
2490 | Roferon-A 3miu | 1件: Interferon alfa-2a Interferon alfa-2a | 1件: Interferon alfa-2a
Interferon alfa-2a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 56 56 💬 |
2491 | Roferon-A, 3miu | 1件: Interferon alfa-2a Interferon alfa-2a | 1件: Interferon alfa-2a
Interferon alfa-2a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 56 56 💬 |
2492 | Roferon-A, 4.5miu | 1件: Interferon alfa-2a Interferon alfa-2a | 1件: Interferon alfa-2a
Interferon alfa-2a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 56 56 💬 |
2493 | Roflumilast 500 Ug ORAL TABLET [Daliresp] | 1件: Roflumilast Roflumilast | 1件: Roflumilast
Roflumilast
💬 | 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 1件: 97 97 💬 |
2494 | Ropinirole PR/XR | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2495 | Ropinirole PR/XR Tablets | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2496 | Ropinirole prolonged release/extended release(PR/XR) | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2497 | Ropinirole XL | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2498 | Ropinirole XL (formerly CR) | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2499 | Rosiglitazone XR | 1件: Rosiglitazone Rosiglitazone | 1件: Rosiglitazone
Rosiglitazone
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 46 46 💬 |
2500 | Rotigotine (Test product PR 2.3.1) | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2501 | Rotigotine transdermal patch 6mg/24h (30cm2) | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2502 | RQ-00000010 | - | - | - | - | 1件: 6 6 💬 |
2503 | RST-001 | - | - | - | - | 1件: 90 90 💬 |
2504 | RVG 03820 | - | - | - | - | 1件: 3 3 💬 |
2505 | RVG 05565 | - | - | - | - | 1件: 96 96 💬 |
2506 | RVG 07151 | - | - | - | - | 1件: 96 96 💬 |
2507 | RVG 08740 | - | - | - | - | 1件: 6 6 💬 |
2508 | RVG 08938 | - | - | - | - | 1件: 75 75 💬 |
2509 | RVG 33865 | - | - | - | - | 1件: 86 86 💬 |
2510 | RVG 51680 | - | - | - | - | 1件: 14 14 💬 |
2511 | RVG 55618 | - | - | - | - | 1件: 6 6 💬 |
2512 | RVG 56083 | - | - | - | - | 1件: 14 14 💬 |
2513 | RVT-101 35 mg | - | - | - | - | 1件: 6 6 💬 |
2514 | RWJ-445380 300 mg | - | - | - | - | 1件: 46 46 💬 |
2515 | RWJ-445380 Capsules 50 mg | - | - | - | - | 1件: 46 46 💬 |
2516 | RWJ-445380-002 | - | - | - | - | 1件: 46 46 💬 |
2517 | S(-)-3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1(2H)-yl]-N,4-dimethylbenzamide | - | - | - | - | 1件: 46 46 💬 |
2518 | SA-001 | - | - | - | - | 1件: 298 298 💬 |
2519 | SABRIL 500 mg, granules for oral solution | 1件: Vigabatrin Vigabatrin | 1件: Vigabatrin
Vigabatrin
💬 | 1件: ABAT ABAT 💬 | 7件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | 1件: 158 158 💬 |
2520 | Sabril granules for oral use | 1件: Vigabatrin Vigabatrin | 1件: Vigabatrin
Vigabatrin
💬 | 1件: ABAT ABAT 💬 | 7件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | 1件: 145 145 💬 |
2521 | SAF-301 | - | - | - | - | 1件: 19 19 💬 |
2522 | Saffron 50 | - | - | - | - | 1件: 97 97 💬 |
2523 | Safinimide 50-100 mg/day | - | - | - | - | 1件: 6 6 💬 |
2524 | SAIZEN - 1 FLACONCINO POLV. 8 MG + 1 CARTUCCIA. SOLV. INSERITI IN UN DISPOSITIVO PER LA RICOSTITUZIONE | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2525 | Salazopyrin EN 500 mg enterotabletter | - | - | - | - | 1件: 46 46 💬 |
2526 | Saline 0.9% inhalation solution | - | - | - | - | 1件: 299 299 💬 |
2527 | Saline 0.9% NaCl | - | - | - | - | 1件: 235 235 💬 |
2528 | Salofalk 3g gastro-resistant prolonged-release granules | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2529 | Salofalk 500 mg | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 96 96 💬 |
2530 | Salofalk Granu-Stix 500 mg | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2531 | Salofalk® 500 mg gastro-resistant tablet | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2532 | Salofalk® 500 mg tablets | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2533 | Salofalk® 500mg | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2534 | Salofalk® 500mg Granu-Stix® | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2535 | Samsca 30 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2536 | SAMSCA 7.5 mg oral tablet | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2537 | SAN-300 0.5 mg/kg QW | - | - | - | - | 1件: 46 46 💬 |
2538 | SAN-300 1.0 mg/kg QW | - | - | - | - | 1件: 46 46 💬 |
2539 | SAN-300 2.0 mg/kg QOW | - | - | - | - | 1件: 46 46 💬 |
2540 | SAN-300 4.0 mg/kg QOW | - | - | - | - | 1件: 46 46 💬 |
2541 | SAN-300 4.0 mg/kg QW | - | - | - | - | 1件: 46 46 💬 |
2542 | Sandimmun 50 mg/ml, infuusiokonsentraatti | - | - | - | - | 1件: 97 97 💬 |
2543 | SANDIMMUN NEORAL - 10 MG CAPSULE MOLLI 50 CAPSULE | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 60 60 💬 |
2544 | SANDIMMUN NEORAL - 100 MG CAPSULE MOLLI 30 CAPSULE | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 60 60 💬 |
2545 | SANDIMMUN NEORAL - 25 MG CAPSULE MOLLI 50 CAPSULE | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 60 60 💬 |
2546 | SANDIMMUN NEORAL - 50 MG CAPSULE MOLLI 50 CAPSULE | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 60 60 💬 |
2547 | SANDIMMUN NEORAL*30CPS 100MG | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 46 46 💬 |
2548 | SANDIMMUN NEORAL*50CPS 25MG | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 46 46 💬 |
2549 | SANDOSTATINA - LAR 20 MG/2.5 ML POLVERE E SOLVENTE PER SOSPENSIONE INIETTABILE FLACONE POLVERE + SIRINGA PRERIEMPITA 2.5 ML + 2 AGHI | - | - | - | - | 1件: 67 67 💬 |
2550 | Sativex 2,7mg/2,5 mg Solucion para pulverizacion bucal | 2件: Cannabidiol Cannabidiol, Dronabinol | 2件: Dronabinol
Dronabinol
,
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 💬 |
2551 | SB-318 | - | - | - | - | 1件: 19 19 💬 |
2552 | SB-497115-GR 12.5mg | - | - | - | - | 1件: 63 63 💬 |
2553 | SB-497115-GR 50 mg | - | - | - | - | 1件: 63 63 💬 |
2554 | SB-509 | - | - | - | - | 1件: 2 2 💬 |
2555 | SBI-087 | - | - | - | - | 2件: 46 46, 49 💬 |
2556 | SBT-020 | - | - | - | - | 1件: 8 8 💬 |
2557 | ScAAV9.U1A.hSGSH | - | - | - | - | 1件: 19 19 💬 |
2558 | ScAAV9.U1A.SGSH | - | - | - | - | 1件: 19 19 💬 |
2559 | ScAAV9.U7.ACCA | - | - | - | - | 1件: 113 113 💬 |
2560 | SCH-58235 | - | - | - | - | 1件: 260 260 💬 |
2561 | SCM-010 | - | - | - | - | 1件: 13 13 💬 |
2562 | SD-101 dermal cream (3%) | - | - | - | - | 1件: 36 36 💬 |
2563 | SD-101-6.0 cream | - | - | - | - | 1件: 36 36 💬 |
2564 | Search for exocrine pancreatic insufficiency at week 0 and 12 | - | - | - | - | 1件: 96 96 💬 |
2565 | Sebelipase alfa 0.35 mg/kg | 1件: Sebelipase alfa Sebelipase alfa | 1件: Sebelipase alfa
Sebelipase alfa
💬 | 1件: LIPA LIPA 💬 | 3件: Cholesterol metabolism Cholesterol metabolism, Lysosome, Steroid biosynthesis 💬 | 1件: 19 19 💬 |
2566 | Sebelipase alfa 3 mg/kg | 1件: Sebelipase alfa Sebelipase alfa | 1件: Sebelipase alfa
Sebelipase alfa
💬 | 1件: LIPA LIPA 💬 | 3件: Cholesterol metabolism Cholesterol metabolism, Lysosome, Steroid biosynthesis 💬 | 1件: 19 19 💬 |
2567 | Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection. | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬 |
2568 | Secukinumab 300 mg | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 41 41 💬 |
2569 | Secukinumab 300 mg, s.c. | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 41 41 💬 |
2570 | Secukinumab 300mg | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 37 37 💬 |
2571 | Secukinumab 75 mg/0.5 ml Solution for injection | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬 |
2572 | See D.3.9.3 'Other descriptive name' below | - | - | - | - | 1件: 46 46 💬 |
2573 | Seladelpar 5 mg | 1件: Seladelpar Seladelpar | 1件: Seladelpar
Seladelpar
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 93 93 💬 |
2574 | Seladelpar 5 mg Capsule | 1件: Seladelpar Seladelpar | 1件: Seladelpar
Seladelpar
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 93 93 💬 |
2575 | Seladelpar 5-10 mg | 1件: Seladelpar Seladelpar | 1件: Seladelpar
Seladelpar
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 93 93 💬 |
2576 | Selective Serotonin Uptake Inhibitors (SSRI) | 1件: Serotonin Serotonin | - | - | - | 1件: 2 2 💬 |
2577 | Selegiline HCl 5 PCH | 1件: Selegiline Selegiline | 1件: Selegiline
Selegiline
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
2578 | Selexipag (Uptravi) | 1件: Selexipag Selexipag | 1件: Selexipag
Selexipag
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
2579 | Selexipag, ACT-293987 (NS-304) | 1件: Selexipag Selexipag | 1件: Selexipag
Selexipag
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
2580 | Selumetinib (AZD6244 hyd sulfate) 50mg/dose | 2件: Selumetinib Selumetinib, Sulfate ion | 1件: Selumetinib
Selumetinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
2581 | Selumetinib granules in sprinkle capsules for opening 5 mg | 1件: Selumetinib Selumetinib | 1件: Selumetinib
Selumetinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
2582 | Selumetinib granules in sprinkle capsules for opening 7.5 mg | 1件: Selumetinib Selumetinib | 1件: Selumetinib
Selumetinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
2583 | SEP-363856 | 1件: SEP-363856 SEP-363856 | - | - | - | 1件: 6 6 💬 |
2584 | SERUM ALBUMINE 5% | - | - | - | - | 1件: 96 96 💬 |
2585 | Serum physiologique 0.9 % | - | - | - | - | 1件: 96 96 💬 |
2586 | Sezione * D.3.6.2.1 - valore: 400mg alla settimana 0, in seguito 200mg ogni due settimane | - | - | - | - | 1件: 96 96 💬 |
2587 | SGT-001 | - | - | - | - | 1件: 113 113 💬 |
2588 | SH U 555 C | - | - | - | - | 1件: 13 13 💬 |
2589 | Sifrol 0,088 | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2590 | Sifrol 0,18 | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2591 | Sifrol 0,35 | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2592 | Sifrol 0,7 | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2593 | Sifrol, 0,35 mg Tablette | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2594 | Sifrol, 0,70 mg Tablette | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2595 | Sildenafil (50 mg) | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 85 85 💬 |
2596 | Sildenafil 20mg and Bosentan 62.5mg | 2件: Bosentan Bosentan, Sildenafil | 3件: Bosentan
Bosentan
,
Bosentan
,
Sildenafil
💬 | 3件: EDNRA EDNRA, EDNRB, PDE5A 💬 | 11件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 💬 |
2597 | Sildenafil citrate (UK-92,480) | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
2598 | Silikis 3µg/g Salbe | - | - | - | - | 1件: 37 37 💬 |
2599 | SIMPONI - 50 MG-SOLUZIONE PER INIEZIONE IN PENNA PRERIEMPITA-USO SOTTOCUTANEO-PENNA PRERIEMPITA(VETRO) -0.5 ML 3 (3X1) PENNE PRERIEMPITE | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
2600 | Simponi 50 mg injeksjonsvæske, oppløsning i ferdigfylt sprøyte. | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
2601 | SIMPONI 50 mg solución inyectable en pluma precargada | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
2602 | Simvastatin 20mg/5ml Oral Suspension | 1件: Simvastatin Simvastatin | 1件: Simvastatin
Simvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 34 34 💬 |
2603 | SINEMET - 100 MG + 25 MG COMPRESSE 50 COMPRESSE DIVISIBILI | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2604 | Sinemet 200mg/50mg | 1件: Carbidopa Carbidopa | 1件: Carbidopa
Carbidopa
💬 | 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
2605 | SINEMET*50CPR 100MG+25MG | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2606 | Siponimod 0,25 mg | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
2607 | Siponimod 0.25 mg tablet | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 50 💬 |
2608 | Siponimod 0.5 mg tablet | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 50 💬 |
2609 | SIRIO*30CPR EFF 25MG+100MG | - | - | - | - | 1件: 6 6 💬 |
2610 | Sirolimus 0,1% crème | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 2件: 278 278, 280 💬 |
2611 | Sirolimus 0.2% | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
2612 | Sirolimus 0.4% | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
2613 | Sirukumab 50 mg | 1件: Sirukumab Sirukumab | 1件: Sirukumab
Sirukumab
💬 | 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 💬 |
2614 | SLS-005 | - | - | - | - | 1件: 2 2 💬 |
2615 | SLS-005 Trehalose | 1件: Trehalose Trehalose | - | - | - | 1件: 2 2 💬 |
2616 | SM101 5mg/mL | - | - | - | - | 1件: 63 63 💬 |
2617 | Sodium (R)-8-methyl-2-(3-methylbenzofuran-2-yl)-5-(1-(tetrahydro-2H-pyran-4-yl)ethoxy)quinoline-4-ca | - | - | - | - | 1件: 299 299 💬 |
2618 | Sodium (S)-3-(4-hydroxyphenyl)-2-(2-((S)-1-((S)-1-palmitoylpyrrolidine-2-carbonyl)pyrrolidine-2-carboxamido)acetamido)propanoate | 1件: Pyrrolidine Pyrrolidine | - | - | - | 1件: 97 97 💬 |
2619 | Sodium chloride 0,9% | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
2620 | Sodium Chloride 0.9% | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 2件: 14 14, 227 💬 |
2621 | SODIUM CHLORIDE SOLUTION 0.9% | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 4件: 51 51, 60, 288, 299 💬 |
2622 | Sodium Pyruvate in 0.9% Sodium Chloride Solution | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
2623 | Sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth | 2件: Dextrose, unspecified form Dextrose, unspecified form, Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
2624 | Sogroya 10 mg/1.5 mL solution for injection in pre-filled pen | 1件: Somapacitan Somapacitan | 1件: Somapacitan
Somapacitan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 195 195 💬 |
2625 | Sogroya 5 mg/1.5 mL solution for injection in pre-filled pen | 1件: Somapacitan Somapacitan | 1件: Somapacitan
Somapacitan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 195 195 💬 |
2626 | SOLIRIS - 300 MG CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO 1 FLACONCINO (VETRO) 30 ML (10 MG/ML) | 1件: Eculizumab Eculizumab | 1件: Eculizumab
Eculizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 3件: 13 13, 62, 109 💬 |
2627 | Soliris 300 | 1件: Eculizumab Eculizumab | 1件: Eculizumab
Eculizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 62 62 💬 |
2628 | SOLIRIS 300 mg concentrado para solución para perfusión | 1件: Eculizumab Eculizumab | 1件: Eculizumab
Eculizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 109 109 💬 |
2629 | Soliris 300 mg concentrate for solution for infusion | 1件: Eculizumab Eculizumab | 1件: Eculizumab
Eculizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 62 62 💬 |
2630 | Soliris 300mg/30ml | 1件: Eculizumab Eculizumab | 1件: Eculizumab
Eculizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 62 62 💬 |
2631 | SOLIRIS® (eculizumab) injection, for intravenous use | 1件: Eculizumab Eculizumab | 1件: Eculizumab
Eculizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 62 62 💬 |
2632 | SOLU MEDROL - 500 MG/8 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE DI POLVERE DA 500 MG+ FIALA SOLVENTE DA 8 ML | - | - | - | - | 1件: 56 56 💬 |
2633 | SOM230 300µg | - | - | - | - | 1件: 75 75 💬 |
2634 | SOM230 LAR 30 mg | - | - | - | - | 1件: 75 75 💬 |
2635 | SOM230, 300micrograms | - | - | - | - | 1件: 75 75 💬 |
2636 | Somapacitan 10 mg/1.5ml PDS290 | 1件: Somapacitan Somapacitan | 1件: Somapacitan
Somapacitan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 💬 |
2637 | Somapacitan 10 mg/1.5ml PDS290S | 1件: Somapacitan Somapacitan | 1件: Somapacitan
Somapacitan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 💬 |
2638 | Somapacitan 15 mg/1.5 mL PDS290 | 1件: Somapacitan Somapacitan | 1件: Somapacitan
Somapacitan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 195 195 💬 |
2639 | Somapacitan 15 mg/1.5ml PDS290 | 1件: Somapacitan Somapacitan | 1件: Somapacitan
Somapacitan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 💬 |
2640 | Somapacitan 5 mg/1.5 mL PDS290 | 1件: Somapacitan Somapacitan | 1件: Somapacitan
Somapacitan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 195 195 💬 |
2641 | Somapacitan 5 mg/1.5ml PDS290 | 1件: Somapacitan Somapacitan | 1件: Somapacitan
Somapacitan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 💬 |
2642 | Somatic gene-therapy by X-CGD | - | - | - | - | 1件: 65 65 💬 |
2643 | Somavaratan (VRS-317) | 1件: Somavaratan Somavaratan | 1件: Somavaratan
Somavaratan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 💬 |
2644 | Spheramine (BAY86-5280) | 1件: Spheramine Spheramine | - | - | - | 1件: 6 6 💬 |
2645 | SPI-1005 Ebselen 200mg Capsule x1 | 1件: Ebselen Ebselen | - | - | - | 1件: 299 299 💬 |
2646 | SPI-1005 Ebselen 200mg Capsule x2 | 1件: Ebselen Ebselen | - | - | - | 1件: 299 299 💬 |
2647 | SPI-1005 Ebselen 200mg Capsule x3 | 1件: Ebselen Ebselen | - | - | - | 1件: 299 299 💬 |
2648 | SPI-62 dose 3 | - | - | - | - | 1件: 75 75 💬 |
2649 | Spiriva Respimat 2.5 mcg | 1件: Tiotropium Tiotropium | - | - | - | 1件: 299 299 💬 |
2650 | Spiriva Respimat 2.5 microgram | 1件: Tiotropium Tiotropium | - | - | - | 1件: 299 299 💬 |
2651 | Spiriva Respimat 2.5 microgram, solution for inhalation | 1件: Tiotropium Tiotropium | - | - | - | 1件: 299 299 💬 |
2652 | SPK-3006 | - | - | - | - | 1件: 256 256 💬 |
2653 | SPP-004 | - | - | - | - | 1件: 21 21 💬 |
2654 | SRK-015 | - | - | - | - | 1件: 3 3 💬 |
2655 | SRP-5051 | - | - | - | - | 1件: 113 113 💬 |
2656 | SSP-004184 100 mg | - | - | - | - | 1件: 284 284 💬 |
2657 | SSP-004184 100 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2658 | SSP-004184 250 mg | - | - | - | - | 1件: 284 284 💬 |
2659 | SSP-004184 250 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2660 | SSP-004184 375 mg | - | - | - | - | 1件: 284 284 💬 |
2661 | SSP-004184 375 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2662 | SSP-004184 50 mg | - | - | - | - | 1件: 284 284 💬 |
2663 | SSP-004184 50 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2664 | SSP-004184 500 mg | - | - | - | - | 1件: 284 284 💬 |
2665 | SSP-004184 500 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2666 | SSP-004184AQ 100 mg | - | - | - | - | 1件: 284 284 💬 |
2667 | SSP-004184AQ 100 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2668 | SSP-004184AQ 200 mg | - | - | - | - | 1件: 284 284 💬 |
2669 | SSP-004184AQ 200 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2670 | SSP-004184AQ 250 mg | - | - | - | - | 1件: 284 284 💬 |
2671 | SSP-004184AQ 250 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2672 | SSP-004184AQ 375 mg | - | - | - | - | 1件: 284 284 💬 |
2673 | SSP-004184AQ 375 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2674 | SSP-004184AQ 50 mg | - | - | - | - | 1件: 284 284 💬 |
2675 | SSP-004184AQ 50 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2676 | ST 36 | - | - | - | - | 1件: 49 49 💬 |
2677 | ST-0529 | - | - | - | - | 1件: 97 97 💬 |
2678 | ST10-021 | - | - | - | - | 2件: 96 96, 97 💬 |
2679 | STA 5326 mesylate | - | - | - | - | 1件: 46 46 💬 |
2680 | STA-5326 | - | - | - | - | 2件: 65 65, 96 💬 |
2681 | STA-5326 mesylate | - | - | - | - | 1件: 96 96 💬 |
2682 | STA-6838, STA-5326 m, S38 | - | - | - | - | 1件: 96 96 💬 |
2683 | Stalevo 150/37.5/200 mg | 3件: Carbidopa Carbidopa, Entacapone, Levodopa | 3件: Levodopa
Levodopa
,
Carbidopa
,
Entacapone
💬 | 7件: COMT COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 17件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2684 | STALEVO*100CPR 50/12,5/200MG | 2件: Entacapone Entacapone, Levodopa | 2件: Levodopa
Levodopa
,
Entacapone
💬 | 6件: COMT COMT, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Steroid hormone biosynthesis, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2685 | Standard analgesia use [Fentanyl] | 1件: Fentanyl Fentanyl | 1件: Fentanyl
Fentanyl
💬 | 1件: OPRM1 OPRM1 💬 | 3件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬 | 1件: 70 70 💬 |
2686 | Standard analgesia use [Hydromorphone] | 1件: Hydromorphone Hydromorphone | 1件: Hydromorphone
Hydromorphone
💬 | 1件: OPRM1 OPRM1 💬 | 3件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬 | 1件: 70 70 💬 |
2687 | Standard analgesia use [Oxygen] | 1件: Oxygen Oxygen | 1件: Oxygen
Oxygen
💬 | - | - | 1件: 70 70 💬 |
2688 | Standard analgesia use [Volatile Anesthesia] | - | - | - | - | 1件: 70 70 💬 |
2689 | Standard Dose YPT-01 | - | - | - | - | 1件: 299 299 💬 |
2690 | Standard of Care: UDCA | 1件: Ursodeoxycholic acid Ursodeoxycholic acid | 1件: Ursodiol
Ursodiol
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
2691 | Standard step-up care | - | - | - | - | 1件: 96 96 💬 |
2692 | Stelara (ustekinumab) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 65 65 💬 |
2693 | STELARA - 45 MG SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) 0.5 ML (90 MG/ML) 1 FLACONCINO | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2694 | STELARA - 90 MG - SOLUZIONE INIETTABILE IN SIRINGHE PRERIEMPITE - USO SOTTOCUTANEO - SIRINGA PRERIEMPITA(VETRO) 1 ML(90MG/ML) 1 SIRINGA PRERIEMPITA DA 1 ML | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2695 | STELARA - 90 MG SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) 1.0 ML (90 MG/ML) 1 FLACONCINO | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 2件: 96 96, 97 💬 |
2696 | Step-up | - | - | - | - | 1件: 96 96 💬 |
2697 | Sterile Normal Saline (0.9% NaCl) | - | - | - | - | 2件: 62 62, 254 💬 |
2698 | STERILE PYROGEN-FREE ISOTONIC NACL SOLUTE (0.9% W / V) | - | - | - | - | 1件: 299 299 💬 |
2699 | STG-001 | 1件: STG-001 STG-001 | - | - | - | 1件: 301 301 💬 |
2700 | STK-001 | 1件: Zorevunersen Zorevunersen | - | - | - | 1件: 140 140 💬 |
2701 | STK-001 - Multiple Ascending Doses | 1件: Zorevunersen Zorevunersen | - | - | - | 1件: 140 140 💬 |
2702 | STK-001 - Single Ascending Doses | 1件: Zorevunersen Zorevunersen | - | - | - | 1件: 140 140 💬 |
2703 | Subcutaneous Ustekinumab | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 56 56 💬 |
2704 | Subjects will undergo the 123-I IBVM imaging visit | - | - | - | - | 1件: 6 6 💬 |
2705 | Subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) | - | - | - | - | 1件: 90 90 💬 |
2706 | Sulindac (HLX-0201), dose strength 1 | 1件: Sulindac Sulindac | 1件: Sulindac
Sulindac
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 206 206 💬 |
2707 | Sulindac (HLX-0201), dose strength 2 | 1件: Sulindac Sulindac | 1件: Sulindac
Sulindac
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 206 206 💬 |
2708 | Sulphasalazine 500 mg En-Tabs | - | - | - | - | 1件: 271 271 💬 |
2709 | Suspension of human autologous MSC 3P in 1,5 ml | - | - | - | - | 1件: 2 2 💬 |
2710 | Suspension of human autologous MSC 3P in 1.5 ml | - | - | - | - | 1件: 2 2 💬 |
2711 | Synthetic Human Parathyroid Hormone 1-34 | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
2712 | Systane Ultra UD | - | - | - | - | 1件: 53 53 💬 |
2713 | T-326 | - | - | - | - | 1件: 299 299 💬 |
2714 | TA-650 3 mg/kg | - | - | - | - | 1件: 46 46 💬 |
2715 | TACHIPIRINA - 500 MG COMPRESSE20 COMPRESSE | - | - | - | - | 2件: 13 13, 53 💬 |
2716 | Tachipirina CPR 500mg | - | - | - | - | 1件: 13 13 💬 |
2717 | Tadalafil and ambrisentan upfront combination therapy | 2件: Ambrisentan Ambrisentan, Tadalafil | 2件: Tadalafil
Tadalafil
,
Ambrisentan
💬 | 2件: EDNRA EDNRA, PDE5A 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 💬 |
2718 | TAK-018 | - | - | - | - | 1件: 96 96 💬 |
2719 | TAK-071 | - | - | - | - | 1件: 6 6 💬 |
2720 | TAK-079 | - | - | - | - | 3件: 11 11, 49, 63 💬 |
2721 | TAK-079, TSF-021, TSF79 | - | - | - | - | 1件: 11 11 💬 |
2722 | TAK-341 | - | - | - | - | 1件: 17 17 💬 |
2723 | TAP-144-SR(3M) | - | - | - | - | 1件: 1 1 💬 |
2724 | Targinact 10 mg/5 mg prolonged-release tablets | 1件: Manganese citrate Manganese citrate | - | - | - | 2件: 6 6, 226 💬 |
2725 | Targinact 5 mg/2.5 mg prolonged-release tablets | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 6 6 💬 |
2726 | Targinact 5mg/2.5 mg prolonged-release tablets | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 226 226 💬 |
2727 | Tasigna 50 mg | 1件: Nilotinib Nilotinib | 1件: Nilotinib
Nilotinib
💬 | 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 34 34 💬 |
2728 | Tavapadon 0.25 mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2729 | Tavapadon 0.25mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2730 | Tavapadon 5 mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2731 | Tavapadon 5mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2732 | TD-3504 | - | - | - | - | 1件: 97 97 💬 |
2733 | TD-5108 hydrochloride | - | - | - | - | 1件: 99 99 💬 |
2734 | TECFIDERA - 240 MG - CAPSULA RIGIDA GASTRORESISTENTE - USO ORALE - BLISTER (PVC/PE/PVDC-PVC ALLUMINIO) - 56 CAPSULE | - | - | - | - | 1件: 13 13 💬 |
2735 | Teduglutide (ALX-0600) | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
2736 | Teduglutide 0.05 | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
2737 | Teduglutide 0.05 dose | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
2738 | Teduglutide 0.1 mg dose | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
2739 | Teduglutide 0.2 mg | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
2740 | Tehalose 30gr | - | - | - | - | 1件: 113 113 💬 |
2741 | Terazosin 5 MG | 1件: Terazosin Terazosin | 1件: Terazosin
Terazosin
💬 | 3件: ADRA1A ADRA1A, ADRA1B, ADRA1D 💬 | 7件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
2742 | Terguride 0,5mg tablet | 1件: Terguride Terguride | 1件: Terguride
Terguride
💬 | 2件: DRD2 DRD2, PRL 💬 | 12件: Alcoholism Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 86 86 💬 |
2743 | Terguride 0.5 mg tablet | 1件: Terguride Terguride | 1件: Terguride
Terguride
💬 | 2件: DRD2 DRD2, PRL 💬 | 12件: Alcoholism Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 86 86 💬 |
2744 | Teriparatide [rDNA origin] contains recombinant human parathyroid hormone (1-34) | 2件: Parathyroid hormone Parathyroid hormone, Teriparatide | 2件: Parathyroid hormone
Parathyroid hormone
,
Teriparatide
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 70 70 💬 |
2745 | Testosterone undecanoate | 3件: Testosterone Testosterone, Testosterone undecanoate, Undecanoic acid | 2件: Testosterone
Testosterone
,
Testosterone undecanoate
💬 | 1件: AR AR 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Oocyte meiosis, Pathways in cancer, Prostate cancer 💬 | 2件: 13 13, 60 💬 |
2746 | TETRACT-HIB - 1 SIRINGA PRECARICATA 0.5 ML | - | - | - | - | 1件: 222 222 💬 |
2747 | Tetrahydro-6,6,9-tri methyl-3-penthyl-6 H-dibenzo[ b,d ]pyran-1-ol | - | - | - | - | 1件: 298 298 💬 |
2748 | THALIDOMIDE CELGENE - 50 MG CAPSULA RIGIDA - USO ORALE - BLISTER (PVC/PE/ACLAR/ALU) 28 CAPSULE | 1件: Thalidomide Thalidomide | 1件: Thalidomide
Thalidomide
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
2749 | THALIDOMIDE CELGENE*28CPS 50MG | 1件: Thalidomide Thalidomide | 1件: Thalidomide
Thalidomide
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 227 227 💬 |
2750 | THC 5mg/ml and CBS 50mg/ml | - | - | - | - | 1件: 96 96 💬 |
2751 | The 0.5 mL dose of vaccine contains 25 micrograms of each of the following 23 pneumococcal polysaccharide | - | - | - | - | 1件: 222 222 💬 |
2752 | The effectiveness of Xeljanz in rheumatoid arthritis patients | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
2753 | The investigational medicinal product (IMP) may be labelled as either PF-04236921 106 mg/vial, Clonal SC lyophilized form” or PF-04236921 Powder for Injection, 106 mg/vial”. Supplies labelled with either nomenclature are equivalent. | - | - | - | - | 1件: 96 96 💬 |
2754 | The investigational medicinal product (IMP) will be labeled as PF-04236921 106 mg/vial, Clonal SC lyophilized form, which is equivalent to PF-04236921 Powder for Injection, 106 mg/vial as described in the enclosed CTA | - | - | - | - | 1件: 96 96 💬 |
2755 | The investigational medicinal product (IMP) will be labeled as PF-04236921 106 mg/vial, Clonal SC lyophilized form, which is equivalent to PF-04236921 Powder for Injection, 106 mg/vial as described in the enclosed CTA. | - | - | - | - | 1件: 96 96 💬 |
2756 | Timolol Alcon 0.5% collyre | 1件: Timolol Timolol | 2件: Timolol
Timolol
,
Timolol
💬 | 2件: ADRB1 ADRB1, ADRB2 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 227 227 💬 |
2757 | Tiotropium bromide 5 mcg | 1件: Tiotropium Tiotropium | - | - | - | 1件: 299 299 💬 |
2758 | Tiotropium bromide-low dose-2.5mcg | 1件: Tiotropium Tiotropium | - | - | - | 1件: 299 299 💬 |
2759 | TJ301 300mg | - | - | - | - | 1件: 97 97 💬 |
2760 | TLL-018 | - | - | - | - | 1件: 46 46 💬 |
2761 | TLR7/8 Antagonist (2.5mg) | - | - | - | - | 1件: 49 49 💬 |
2762 | TMI-005 | - | - | - | - | 1件: 46 46 💬 |
2763 | TMI-005 (WAY-177005) | - | - | - | - | 1件: 46 46 💬 |
2764 | TMI-005 WAY-177005 | - | - | - | - | 1件: 46 46 💬 |
2765 | TNR-001 | - | - | - | - | 2件: 46 46, 271 💬 |
2766 | TNR-001, TNFR:FC | - | - | - | - | 1件: 271 271 💬 |
2767 | TOBI 300 mg / 5 mL nebuliser solution | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2768 | TOBI 300 mg/5 ml Lösung für einen | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2769 | TOBI 300 mg/5 ml Lösung für einen Vernebler | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2770 | TOBI 300 mg/5 ml Nebuliser Solution | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2771 | TOBI 300 mg/5 ml solución para inhalación por nebulizador | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2772 | TOBI 300 mg/5 ml, solution pour inhalation par nébuliseur | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2773 | TOBI 300mg/ 5ml solución para inhalación con nebulizador | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2774 | TOBI 300mg/5mL Nebuliser Solution | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2775 | Tobi 300mg/5ml Nebuliser solution. | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2776 | Tobi 300mg/5ml Solución para inhalación por nebulizador. | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2777 | TOBI PODHALER - 28 MG POLVERE PER INALAZIONE CAPSULA RIGIDA USO INALATORIO BLISTER(ALU/ALU) 56 CAPSULE + 1 INALATORE | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2778 | TOBI*NEBUL 56F 1D 300MG/5ML | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2779 | Tobramycin Inhalation Powder TIP delivered by the T-326 Inhaler | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2780 | Tobramycin inhalation solution using a PARI LC® Plus nebulizer. | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2781 | Tobramycin solution for inhalation 300 mg | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2782 | Tobramycin Steri-Neb 300 mg/5 ml, inhalation solution | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2783 | Tocilizumab 162Mg/0.9Ml Autoinjector | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 💬 |
2784 | Tocilizumab 162mg/0.9ml jeringa SC | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
2785 | Tocilizumab 162mg/0.9ml SC PFS SC | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
2786 | Tocilizumab 162mg/0.9ml syringe SC | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
2787 | Tocilizumab SC 162 mg/0.9 ml disposable auto-injector (AI) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
2788 | Tocilizumab SC 162 mg/0.9 ml pre-filled syringe with safety device (PFS) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
2789 | Tocilizumab SC 162 mg/0.9 ml prefilled syringe with safety device (PFS) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 51 51 💬 |
2790 | Tofacitinib (CP-690,550) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 96 96 💬 |
2791 | Tofacitinib (Xeljanz) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
2792 | Tofacitinib (Xeljanz®) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
2793 | Tofacitinib (Xeljanz®) 11mg Prolonged Release Tablet | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
2794 | Tofacitinib 10 MG [Xeljanz] | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 97 97 💬 |
2795 | Tofacitinib 5 MG | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 4件: 11 11, 40, 46, 271 💬 |
2796 | Tofacitinib 5 MG [Xeljanz] | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 50 💬 |
2797 | Tofacitinib 5 mg twice daily | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 84 84 💬 |
2798 | Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 84 84 💬 |
2799 | Tofacitinib 5mg po bid | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
2800 | Tofacitinib XR | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 271 💬 |
2801 | TOLVAPTAN 30 | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2802 | Tolvaptan 30 mg Tablet | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2803 | Tolvaptan 30 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2804 | Tolvaptan 30mg | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2805 | Tolvaptan 50mg Granules | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2806 | TOLVAPTAN 60/30 | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2807 | Tolvaptan 7.5 mg Tablet | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2808 | Topical 0.1% Sirolimus | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 278 278 💬 |
2809 | Topical AmphiMatrix with nitroglycerin (MQX-503) | 1件: Nitroglycerin Nitroglycerin | 1件: Nitroglycerin
Nitroglycerin
💬 | - | - | 1件: 51 51 💬 |
2810 | Topical BPM31510 3.0% Cream | - | - | - | - | 1件: 36 36 💬 |
2811 | Topical calcipotriene 0.005% ointment | 1件: Calcipotriol Calcipotriol | 1件: Calcipotriene
Calcipotriene
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 51 51 💬 |
2812 | TOTTIZIM - 1 G/10 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO ENDOVENOSO 1 FLACONCINO POLVERE + 1 FIALA SOLVENTE 10 ML | - | - | - | - | 1件: 299 299 💬 |
2813 | TPI-287 6.3 mg/m2 | 1件: TPI-287 TPI-287 | - | - | - | 2件: 5 5, 7 💬 |
2814 | TRACLEER 125MG 56CPR RIV. | 1件: Bosentan Bosentan | 2件: Bosentan
Bosentan
,
Bosentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 88 88 💬 |
2815 | TRACLEER 62,5 mg comprimidos recubiertos con película | 1件: Bosentan Bosentan | 2件: Bosentan
Bosentan
,
Bosentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
2816 | TRACLEER 62,5MG 56CPR RIV. | 1件: Bosentan Bosentan | 2件: Bosentan
Bosentan
,
Bosentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
2817 | TRACLEER*125MG 56CPR RIV. | 1件: Bosentan Bosentan | 2件: Bosentan
Bosentan
,
Bosentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 💬 |
2818 | TRACLEER*56CPR RIV 125MG | 1件: Bosentan Bosentan | 2件: Bosentan
Bosentan
,
Bosentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 3件: 51 51, 86, 88 💬 |
2819 | Trade Name Xarelto | 1件: Rivaroxaban Rivaroxaban | 1件: Rivaroxaban
Rivaroxaban
💬 | 1件: F10 F10 💬 | 1件: Complement and coagulation cascades Complement and coagulation cascades 💬 | 1件: 49 49 💬 |
2820 | Trametinib (0.5 mg) | 1件: Trametinib Trametinib | 1件: Trametinib
Trametinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 2 2 💬 |
2821 | TransCon CNP 3.9 mg CNP-38/vial | - | - | - | - | 1件: 276 276 💬 |
2822 | TransCon hGH (ACP-011) | - | - | - | - | 1件: 78 78 💬 |
2823 | TransCon hGH (ACP-011) - 12,1mg | - | - | - | - | 1件: 78 78 💬 |
2824 | TransCon hGH (ACP-011) - 12.1mg | - | - | - | - | 1件: 78 78 💬 |
2825 | TransCon hGH (ACP-011) - 24.2mg | - | - | - | - | 1件: 78 78 💬 |
2826 | TransCon hGH CT-301 (ACP-011) - 12,1mg | - | - | - | - | 1件: 78 78 💬 |
2827 | Transvamix (100mg/mL THC, 50mg/mL CBD) | - | - | - | - | 1件: 36 36 💬 |
2828 | Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms | 1件: Lansoprazole Lansoprazole | 1件: Lansoprazole
Lansoprazole
💬 | 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 98 98 💬 |
2829 | Treatment as Usual (TAU) | - | - | - | - | 1件: 85 85 💬 |
2830 | TREPROSTINIL SODIUM, UT-15 | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
2831 | Treprostinil, UT-15, LRX-15, 15AU81, BW A15AU, U-62, 840 | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
2832 | Trientine dihydrochloride 300mg capsules | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 💬 |
2833 | TRIMETON - 10 MG/1 ML SOLUZIONE INIETTABILE 5 FIALE 1 ML | - | - | - | - | 1件: 14 14 💬 |
2834 | Triomar™ (omega-3 fatty acids) | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 1件: 13 13 💬 |
2835 | TRU-015 | 1件: TRU-015 TRU-015 | - | - | - | 3件: 46 46, 49, 222 💬 |
2836 | Trulicity 0,75 mg injekcný roztok naplnený v injekcnom pere | 1件: Dulaglutide Dulaglutide | 1件: Dulaglutide
Dulaglutide
💬 | 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
2837 | Trulicity 0,75 mg injekcný roztok naplnený v injekcnom pere. | 1件: Dulaglutide Dulaglutide | 1件: Dulaglutide
Dulaglutide
💬 | 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
2838 | TV-5010 | - | - | - | - | 1件: 13 13 💬 |
2839 | TV-5600 | - | - | - | - | 3件: 8 8, 13, 96 💬 |
2840 | TVP-1012 0.5mg | - | - | - | - | 1件: 6 6 💬 |
2841 | Twice-daily dosage with 0.5% cyclosporine-A eyedrops | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 90 90 💬 |
2842 | TY-0305 | - | - | - | - | 1件: 58 58 💬 |
2843 | TYSABRI 300 mg concentrado para solución para perfusión | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
2844 | TYSABRI 300 mg concentrate for solution for infusion | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
2845 | TYSABRI 300 mg solution à diluer pour perfusion | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
2846 | TYSABRI*IV 1FL 300MG 15ML | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
2847 | TYVASO® (treprostinil) inhalation solution, for oral inhalation use | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 85 85 💬 |
2848 | UB-312 | - | - | - | - | 1件: 6 6 💬 |
2849 | UB-312 Injection | - | - | - | - | 2件: 6 6, 17 💬 |
2850 | Ucb 34714 | - | - | - | - | 2件: 149 149, 309 💬 |
2851 | UDCA (Ursodeoxycholic acid) | 1件: Ursodeoxycholic acid Ursodeoxycholic acid | 1件: Ursodiol
Ursodiol
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
2852 | UF-021 | - | - | - | - | 1件: 90 90 💬 |
2853 | UF-021 (isopropyl unoprostone) | 1件: Unoprostone Unoprostone | 1件: Unoprostone
Unoprostone
💬 | 1件: PTGFR PTGFR 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway 💬 | 1件: 90 90 💬 |
2854 | UF-021(isopropyl unoprostone) | 1件: Unoprostone Unoprostone | 1件: Unoprostone
Unoprostone
💬 | 1件: PTGFR PTGFR 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway 💬 | 1件: 90 90 💬 |
2855 | UK 092480 | - | - | - | - | 1件: 86 86 💬 |
2856 | ULTOMIRIS - 300 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 3 ML (100 MG / ML) - 1 FLACONCINO | 1件: Ravulizumab Ravulizumab | 1件: Ravulizumab
Ravulizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 62 62 💬 |
2857 | Ultomiris 300 mg/30 ml | 1件: Ravulizumab Ravulizumab | 1件: Ravulizumab
Ravulizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 66 66 💬 |
2858 | Ultomiris 300mg/30ml | 1件: Ravulizumab Ravulizumab | 1件: Ravulizumab
Ravulizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 62 62 💬 |
2859 | Ultra small particles of iron oxide (USPIO) | 1件: Ferric oxide Ferric oxide | 1件: Ferric oxide
Ferric oxide
💬 | - | - | 1件: 13 13 💬 |
2860 | Umbilical cord blood (UCB) | - | - | - | - | 1件: 60 60 💬 |
2861 | Umbilical Cord Blood Unit | - | - | - | - | 1件: 333 333 💬 |
2862 | Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation | - | - | - | - | 2件: 93 93, 296 💬 |
2863 | Umbilical Cord Mesenchymal Stem Cell (UC-MSC) | - | - | - | - | 1件: 90 90 💬 |
2864 | Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs) | 1件: Human Umbilical Cord Mesenchymal Stem Cells Human Umbilical Cord Mesenchymal Stem Cells | - | - | - | 1件: 46 46 💬 |
2865 | UN-ALPHA-R 0.25µg | - | - | - | - | 1件: 235 235 💬 |
2866 | Unrelated Umbilical Cord Blood Transplant | - | - | - | - | 1件: 19 19 💬 |
2867 | Upadacitinib 30mg | 1件: Upadacitinib Upadacitinib | 1件: Upadacitinib
Upadacitinib
💬 | 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
2868 | Upadacitinib 3mg | 1件: Upadacitinib Upadacitinib | 1件: Upadacitinib
Upadacitinib
💬 | 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
2869 | URBASON*IM EV 1F 250MG+1F 5ML | - | - | - | - | 1件: 222 222 💬 |
2870 | URSOCHOL 300 | - | - | - | - | 1件: 67 67 💬 |
2871 | Ursodeoxycholic acid (UDCA) | 1件: Ursodeoxycholic acid Ursodeoxycholic acid | 1件: Ursodiol
Ursodiol
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 94 94 💬 |
2872 | Ursodeoxycholic acid (UDCA) 500 mg | 1件: Ursodeoxycholic acid Ursodeoxycholic acid | 1件: Ursodiol
Ursodiol
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 46 46 💬 |
2873 | Ursodeoxycholic Acid (URSO) | 1件: Ursodeoxycholic acid Ursodeoxycholic acid | 1件: Ursodiol
Ursodiol
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
2874 | Ursodeoxycholic Acid 300mg capsule | 1件: Ursodeoxycholic acid Ursodeoxycholic acid | 1件: Ursodiol
Ursodiol
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
2875 | Ursodeoxycholic Acid 300mg tablet | 1件: Ursodeoxycholic acid Ursodeoxycholic acid | 1件: Ursodiol
Ursodiol
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
2876 | Ursodeoxycholsäure | - | - | - | - | 1件: 93 93 💬 |
2877 | Ursodiol (ursodeoxycholic acid, UDCA) | 1件: Ursodeoxycholic acid Ursodeoxycholic acid | 1件: Ursodiol
Ursodiol
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 97 97 💬 |
2878 | Ursofalk® 500 mg film-coated tablets | 1件: Ursodeoxycholic acid Ursodeoxycholic acid | 1件: Ursodiol
Ursodiol
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
2879 | Ursofalk® 500 mg Filmtabletten | 1件: Ursodeoxycholic acid Ursodeoxycholic acid | 1件: Ursodiol
Ursodiol
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
2880 | Ustekinumab + MTX (Group 3) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 46 46 💬 |
2881 | Ustekinumab 3 mg/kg (IP) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2882 | Ustekinumab 4.5 mg/kg | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2883 | Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2884 | Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2885 | UT-15C 0.25 mg | - | - | - | - | 1件: 86 86 💬 |
2886 | UT-15C 5 mg | - | - | - | - | 1件: 86 86 💬 |
2887 | UVADEX and UVAR XTS Photopheresis System | 1件: Methoxsalen Methoxsalen | 1件: Methoxsalen
Methoxsalen
💬 | - | - | 1件: 96 96 💬 |
2888 | UVEDOSE 100 000 UI | - | - | - | - | 1件: 13 13 💬 |
2889 | UVEDOSE 100 000 UI, solution buvable en ampoule | - | - | - | - | 1件: 13 13 💬 |
2890 | UX701 (1.0 × 10^13 genome copies/kg) | - | - | - | - | 1件: 171 171 💬 |
2891 | UX701 (2.0 × 10^13 genome copies/kg) | - | - | - | - | 1件: 171 171 💬 |
2892 | UX701 (5.0 × 10^12 genome copies/kg) | - | - | - | - | 1件: 171 171 💬 |
2893 | Vamorolone 0.25 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2894 | Vamorolone 0.25 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2895 | Vamorolone 0.75 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2896 | Vamorolone 0.75 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2897 | Vamorolone 2.0 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2898 | Vamorolone 2.0 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2899 | Vamorolone 6.0 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2900 | Vamorolone 6.0 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2901 | Vedolizumab 300 mg | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 💬 |
2902 | Vedolizumab 300 MG Injection [Entyvio] | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 96 96 💬 |
2903 | Vedolizumab 300 mg IV | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 💬 |
2904 | Vedolizumab IV 300 mg | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 96 96 💬 |
2905 | Vedolizumab, Ustekinumab, or Tofacitinib | 3件: Tofacitinib Tofacitinib, Ustekinumab, Vedolizumab | 3件: Vedolizumab
Vedolizumab
,
Ustekinumab
,
Tofacitinib
💬 | 9件: IL12A IL12A, IL12B, IL23A, ITGA4, ITGB7, JAK1, JAK2, JAK3, TYK2 💬 | 65件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, Arrhythmogenic right ventricular cardiomyopathy, C-type lectin receptor signaling pathway, Cell adhesion molecules, Chagas disease, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, ECM-receptor interaction, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Focal adhesion, Growth hormone synthesis, secretion and action, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Leukocyte transendothelial migration, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pertussis, Primary immunodeficiency, Prolactin signaling pathway, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Yersinia infection 💬 | 1件: 97 97 💬 |
2906 | Vehicle (SD-101 0%) | - | - | - | - | 1件: 36 36 💬 |
2907 | VELCADE*1FL 3,5MG | 2件: Bortezomib Bortezomib, Bortezomib D-mannitol | 1件: Bortezomib
Bortezomib
💬 | 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 28 28 💬 |
2908 | VELCADE*EV 1FL 3,5MG 1MG/ML | 2件: Bortezomib Bortezomib, Bortezomib D-mannitol | 1件: Bortezomib
Bortezomib
💬 | 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 61 61 💬 |
2909 | Ventoline oral solution 0,4mg/ml | - | - | - | - | 1件: 111 111 💬 |
2910 | Viaskin Milk 500 mcg | 1件: Cow milk Cow milk | - | - | - | 1件: 98 98 💬 |
2911 | Vigantol® Öl 20.000 I.E./ml | - | - | - | - | 1件: 13 13 💬 |
2912 | VIMOVO 375/20 | - | - | - | - | 1件: 107 107 💬 |
2913 | VIMOVO 500/20 | - | - | - | - | 1件: 107 107 💬 |
2914 | VIREAD - 245 MG 30 COMPRESSE RIVESTITE CON FILM IN FLACONE USO ORALE | - | - | - | - | 1件: 46 46 💬 |
2915 | VIREAD 30 CPR 245 MG | - | - | - | - | 1件: 46 46 💬 |
2916 | Vitamin D3 3000 UI daily | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
2917 | Vitamin D3 4000 UI daily | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
2918 | Vitamin D3 800 UI/day then 800 UI/day | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
2919 | Vitamin D3: 3000 or 4000 UI/day then 2,000 UI/day | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
2920 | VOLIBRIS 5 mg comprimidos recubiertos con película | 1件: Ambrisentan Ambrisentan | 1件: Ambrisentan
Ambrisentan
💬 | 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
2921 | VOLMAX*30CPR 4MG R.P. | - | - | - | - | 1件: 3 3 💬 |
2922 | VPRIV - 400 U - POLVERE PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO(VETRO) 1 FLACONCINO | 1件: Velaglucerase alfa Velaglucerase alfa | 1件: Velaglucerase alfa
Velaglucerase alfa
💬 | 1件: GBA1 GBA1 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
2923 | VPRIV 400 Units powder for solution of infusion | 1件: Velaglucerase alfa Velaglucerase alfa | 1件: Velaglucerase alfa
Velaglucerase alfa
💬 | 1件: GBA1 GBA1 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
2924 | VRS-317 | - | - | - | - | 1件: 78 78 💬 |
2925 | VRT-893661 VRT-0893661 | - | - | - | - | 1件: 299 299 💬 |
2926 | VSL#3 | - | - | - | - | 4件: 96 96, 97, 107, 291 💬 |
2927 | VSL#3® | - | - | - | - | 2件: 96 96, 97 💬 |
2928 | VT-001 | - | - | - | - | 1件: 66 66 💬 |
2929 | VWF SD-35-DH | - | - | - | - | 1件: 288 288 💬 |
2930 | VX-371 | - | - | - | - | 1件: 299 299 💬 |
2931 | VX-371 in hypertonic saline | - | - | - | - | 1件: 299 299 💬 |
2932 | VX-371 in saline | - | - | - | - | 1件: 299 299 💬 |
2933 | VX-509 | - | - | - | - | 1件: 46 46 💬 |
2934 | VX-522 mRNA therapy | - | - | - | - | 1件: 299 299 💬 |
2935 | VX-561 | - | - | - | - | 1件: 299 299 💬 |
2936 | VX-561 (CTP-656) | - | - | - | - | 1件: 299 299 💬 |
2937 | VX-661/ivacaftor 50 mg/ 75 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2938 | VYNT-0126 | - | - | - | - | 1件: 156 156 💬 |
2939 | Vyondys 53 | 1件: Golodirsen Golodirsen | 1件: Golodirsen
Golodirsen
💬 | 1件: DMD DMD 💬 | 4件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Viral myocarditis 💬 | 1件: 113 113 💬 |
2940 | White chocolate (0% cocoa) | 1件: Cocoa Cocoa | - | - | - | 1件: 6 6 💬 |
2941 | WILATE 1000 I.U. | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
2942 | Wilate 500 | 2件: Antihemophilic factor human Antihemophilic factor human, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
2943 | WILATE 500 I.U. | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
2944 | With U-VANCO (vancomycin hydrochloride) | 1件: Vancomycin Vancomycin | 1件: Vancomycin
Vancomycin
💬 | - | - | 1件: 70 70 💬 |
2945 | Without U-VANCO (vancomycin hydrochloride) | 1件: Vancomycin Vancomycin | 1件: Vancomycin
Vancomycin
💬 | - | - | 1件: 70 70 💬 |
2946 | Wound topically irrigated with 500mg TXA | - | - | - | - | 1件: 70 70 💬 |
2947 | WVE-003 | - | - | - | - | 1件: 8 8 💬 |
2948 | WVE-004 | - | - | - | - | 2件: 2 2, 127 💬 |
2949 | X4P-001 | - | - | - | - | 1件: 65 65 💬 |
2950 | XADAGO - 100 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (PVC/PVDC/ALLUMINIO)- 30 COMPRESSE | 1件: Safinamide Safinamide | 1件: Safinamide
Safinamide
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
2951 | XADAGO - 50 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (PVC/PVDC/ALLUMINIO)- 30 COMPRESSE | 1件: Safinamide Safinamide | 1件: Safinamide
Safinamide
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
2952 | XELJANZ 5 mg film-coated tablets | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 97 💬 |
2953 | Xeljanz 5mg | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
2954 | Xeljanz 5mg film-coated tablets | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 97 97 💬 |
2955 | XELJANZ 5Mg Tablet | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
2956 | Xeljanz XR | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
2957 | XGEVA - 120 MG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) - 1.7 ML 4 FLACONCINI | 1件: Denosumab Denosumab | 1件: Denosumab
Denosumab
💬 | 1件: TNFSF11 TNFSF11 💬 | 8件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬 | 1件: 274 274 💬 |
2958 | XmAb5871_0.3MG | - | - | - | - | 1件: 46 46 💬 |
2959 | XmAb5871_1.0MG | - | - | - | - | 1件: 46 46 💬 |
2960 | XmAb5871_10.0MG | - | - | - | - | 1件: 46 46 💬 |
2961 | XmAb5871_3.0MG | - | - | - | - | 1件: 46 46 💬 |
2962 | XmAb®5871 | - | - | - | - | 1件: 46 46 💬 |
2963 | Xolair 150 mg Pulver und Injektionslösung zur Herstellung einer Injektionslösung | 1件: Omalizumab Omalizumab | 1件: Omalizumab
Omalizumab
💬 | 1件: FCER1A FCER1A 💬 | 4件: Asthma Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬 | 1件: 299 299 💬 |
2964 | XOMA 052 | - | - | - | - | 5件: 41 41, 46, 50, 56, 106 💬 |
2965 | YONDELIS 0,25 mg polvo para concentrado para solución para perfusión | 1件: Trabectedin Trabectedin | 1件: Trabectedin
Trabectedin
💬 | - | - | 1件: 159 159 💬 |
2966 | Yondelis 0.25 mg powder for concentrate for solution for infusion. | 1件: Trabectedin Trabectedin | 1件: Trabectedin
Trabectedin
💬 | - | - | 1件: 159 159 💬 |
2967 | Z-521 | - | - | - | - | 1件: 238 238 💬 |
2968 | ZIBREN*20BUST 500MG | - | - | - | - | 1件: 2 2 💬 |
2969 | Zoledronic Acid 5Mg/Bag 100Ml Inj | 1件: Zoledronic acid Zoledronic acid | 2件: Zoledronic acid
Zoledronic acid
,
Zoledronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 3件: 5 5, 6, 17 💬 |
2970 | Zolgensma 2 x 1013 vector genomes/mL solution for infusion | 1件: Onasemnogene abeparvovec Onasemnogene abeparvovec | 1件: Onasemnogene abeparvovec
Onasemnogene abeparvovec
💬 | 1件: SMN1 SMN1 💬 | - | 1件: 3 3 💬 |
2971 | Zolgensma 2 x 1013 vg (vector genomes)/mL solution for infusion | 1件: Onasemnogene abeparvovec Onasemnogene abeparvovec | 1件: Onasemnogene abeparvovec
Onasemnogene abeparvovec
💬 | 1件: SMN1 SMN1 💬 | - | 1件: 3 3 💬 |
2972 | Zoloft 50Mg Tablet | - | - | - | - | 1件: 8 8 💬 |
2973 | ZSP1603 12.5 mg | - | - | - | - | 1件: 85 85 💬 |
2974 | ZSP1603 50 mg | - | - | - | - | 1件: 85 85 💬 |
2975 | ZSP1603 7.5 mg | - | - | - | - | 1件: 85 85 💬 |
2976 | ZUGLIMET - 500 MG COMPRESSE RIVESTITE CON FILM 30 COMPRESSE IN BLISTER PVC/AL | - | - | - | - | 1件: 67 67 💬 |
2977 | ZX008 - 0.2 mg/kg/day | - | - | - | - | 1件: 140 140 💬 |
2978 | ZX008 - 0.8 mg/kg/day | - | - | - | - | 1件: 140 140 💬 |
2979 | ZX008 0.2 or 0.8 mg/kg/day | - | - | - | - | 1件: 144 144 💬 |
2980 | ZX008 0.2 to 0.8 mg/kg/day | - | - | - | - | 2件: 140 140, 144 💬 |
2981 | ZYTIGA - 250 MG - COMPRESSA - USO ORALE - FLACONE 120 COMPRESSE | 1件: Abiraterone Abiraterone | - | - | - | 1件: 75 75 💬 |